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Abstract 
 
Introduction: Basal-like (BL) breast cancer is an aggressive sub-type of breast 
cancer for which there is no targeted systemic therapy. C-Met is a receptor tyrosine 
kinase implicated in breast cancer. Clinical trials assessing the efficacy of anti-c-Met 
therapy are underway, yet few studies have analysed the clinical significance of c-
Met expression and/or activation in breast cancer, in particular whether there is a 
correlation with molecular sub-type. The aims of this study are: 1) to establish the 
clinical significance of c-Met expression in invasive breast cancer, 2) evaluate the 
novel proximity ligation assay (PLA) as a method of measuring c-Met activation and 
3) address the effect of hepatocyte growth factor (HGF)-mediated c-Met 
phosphorylation on migration and protein expression in cell lines representative of 
the BL sub-type. 
Methods: Immunohistochemistry for c-Met was performed on 1455 cases of breast 
cancer using tissue microarray (TMA) technology. The PLA was performed on 
TMAs constructed from 181 breast cancers. C-Met expression and the PLA product 
were correlated with clinico-pathological parameters and survival. The effects of 
HGF on cell migration and protein expression were assessed using migration assays, 
western blots and immunofluorescent studies. 
Results: C-Met expression was independently associated with BL breast cancer 
(odds ratio = 6.44, 95% confidence interval (CI) = 1.74-23.78, p = 0.005) and 
reduced overall survival (hazard ratio = 1.81, 95% CI = 1.07-3.06), p = 0.026). The 
PLA signal was not associated with molecular sub-type or survival. HGF stimulation 
was associated with a significant increase in BL cell migration (p < 0.01) but no 
evidence of epithelial-mesenchymal transition was observed. 
6 
 
 
Conclusion: My findings suggest BL breast cancer patients should be included in 
future trials of anti-c-Met therapy. Further work is necessary to establish the 
prognostic utility of the PLA as a measure of c-Met activation and the mechanisms 
driving HGF-mediated cell migration.         
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1.0 Introduction 
 
1.1 The normal breast 
 
1.1.1 Anatomy and histology 
 
The breast is bordered anteriorly by the skin (from where it originates) and 
posteriorly by pectoralis major, serratus anterior and by the superior rectus sheath 
(Going, 2006). The normal breast is composed of a variable number of major ducts 
that emerge from the nipple and branch to form the terminal duct lobular unit 
(TDLU, Figure 1.1) (Lester, 2005). The keratinising squamous epithelium of the 
nipple undergoes transition into the specialised breast epithelium that lines the ducts 
and TDLU. This bilayered epithelium is formed of an inner layer of milk-producing 
epithelial cells and an outer discontinuous layer of contractile myoepithelial cells 
that assist in structural maintenance and milk expression (Lester, 2005). The 
glandular component of breast tissue is surrounded by mixed connective tissue; the 
lobules are invested by specialised myxoid tissue that lacks elastic fibres (Rosai, 
2004). This intralobular stroma merges with the interlobular stroma comprised of a 
variable proportion of dense fibrous and adipose tissue (Lester, 2005).  
Both the epithelial and stromal components of the breast undergo pregnancy and 
age-related changes. Young women’s breasts are characterised by mostly fibrous 
stroma and a relative lack of adipose tissue. During pregnancy, there is proliferation 
of the TDLUs and the epithelium undergoes lactational changes. With increasing age 
there is involution, characterised by lobular atrophy and a greater proportion of 
adipose tissue in the interlobular stroma (Lester, 2005). 
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Figure 1.1: The normal breast. The photograph shows a haematoxylin and eosin-
stained section of normal breast tissue. The terminal duct feeds into the lobule. 
Together, the terminal duct and lobule form the terminal duct lobular unit (TDLU) 
(x10 objective, scale bar represents 40µm). 
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1.1.2 Cell lineage and stem cells 
 
The two layers of epithelium that line the TDLU can be differentiated by 
immunohistochemistry. The inner layer of luminal epithelial cells generally 
expresses the cytokeratins CK7, CK8/18 and CK19 whereas the outer 
basal/myoepithelial cells show CK5, CK17 and CK14 reactivity (Haupt et al, 2010; 
Going, 2006). Other markers of the basal/myoepithelial cells include smooth muscle 
actin (SMA), p63, common acute lymphoblastic leukaemia antigen (CALLA, CD10) 
and S100 (Haupt et al, 2010; Going, 2006). The luminal cells also show steroid 
receptor (oestrogen (ER) and progesterone (PR)) positivity along with epithelial 
membrane antigen (EMA) expression (Haupt, 2010 et al; Going, 2006). 
Interestingly, the luminal epithelium does not show diffuse positivity for ER/PR; in 
particular, antibodies against these receptors rarely label proliferating cells (Going, 
2006). This suggests that the steroid hormones stimulate proliferation in the normal 
breast via an indirect paracrine or juxtacrine pathway (Going, 2006). 
While the cytokeratin profiles of the luminal and basal compartments appear distinct, 
certain cytokeratins do not appear particularly specific (Gusterson, 2009). Antibodies 
to CK5 and CK14 can label luminal cells in ducts and lobules (Figure 1.2); this is in 
contrast to murine mammary glands where CK14 is specific for basal cells 
(Gusterson, 2009). Moreover, intensity of CK5 and CK14 expression varies greatly, 
even within the same breast (Gusterson, 2009).  
Work on murine models of mammary biology, including the discovery that an entire 
mammary gland can be generated from a single cell (Kordon and Smith, 1998) has 
stimulated considerable interest in the concept of progenitor or stem cells within 
adult breast epithelium (Boecker and Buerger, 2003). Using double-staining  
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Figure 1.2: Cytokeratin immunohistochemical staining in the normal breast. The 
cytokeratins CK5 and CK14 are generally regarded as basal/myoepithelial markers 
however, both may also stain the luminal cells in normal ducts and lobules. Staining 
may also vary markedly within duct/lobules and in different parts of the same breast 
(Gusterson, 2009; reproduced with permission. Copyright (2009), Nature Publishing 
Group). 
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technology, Boecker and Buerger identified five sub-sets of normal breast epithelial 
cells: 1) only CK5 positive, 2) CK5 and CK8/18 positive, 3) only CK8/18 positive, 
4) CK5/SMA positive and 5) only SMA positive (Boecker and Buerger, 2003). The 
authors suggested that the cells positive for CK5 only represented progenitor cells 
and that the additional presence of luminal (CK8/18) or myoepithelial (SMA) 
markers was indicative of intermediary luminal and myoepithelial cells respectively. 
Only the differentiated luminal (only CK8/18) and myoepithelial (only SMA 
expression) cells lacked CK5 reactivity (Boecker and Buerger, 2003). This 
progenitor cell concept would help explain the presence of CK5 positive cells in both 
the basal and luminal compartments.    
1.2 Breast cancer 
 
1.2.1 Incidence 
 
According to the Surveillance Epidemiology and End Results (SEER) database, an 
estimated 232,670 American women will be diagnosed with breast cancer in 2014 
and 39,620 will die from the disease (SEER, 2014). It is thought that 1 in 8 
American women born today will be diagnosed with breast cancer over their lifetime 
(SEER, 2014). On a worldwide view, nearly 1.4 million women were diagnosed with 
breast cancer in 2008 and there were 459,000 deaths (Youlden et al, 2012). Here in 
the UK, there were 50,285 new diagnoses of breast cancer in 2011 and 11,762 breast 
cancer deaths in 2011 (Cancer Research UK, 2014).  
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1.2.2 Risk factors 
 
Numerous parameters have been identified as being influential in a woman’s 
likelihood of developing breast cancer. 
1.2.2.1 Age and family history 
 
Increasing age is a risk factor: the majority of tumours occur over the age of 50 
(Lester, 2005). Women with a family history of breast cancer have approximately 
twice the risk compared to those without (Da Silva and Lakhani, 2010) and up to 5-
10% of breast cancers may be due to germ-line mutations in one of several breast 
cancer susceptibility genes. These include the high risk BRCA1, BRCA2, PTEN, 
TP53, LKB1/STK11, CDH1 genes and the low to moderate risk CHEK2, TGFβ1, 
CASP8 and ATM (Mangia et al, 2011).  
Breast cancers associated with BRCA1/2 mutations have received considerable 
attention in both the media and scientific literature. Women harbouring germline 
mutations in either BRCA1 or BRCA2 are thought to have an 85% chance of 
developing breast cancer during their lifetime (Toft and Cryns, 2011). BRCA1 has 
diverse cellular functions that include cell-cycle regulation, chromatin re-modelling 
and regulation of transcriptional processes (Da Silva and Lakhani, 2010). Perhaps 
the most interesting property of BRCA1/2 is their role in DNA repair, more 
specifically, the repair of double-stranded breaks (DSBs) (Turner et al, 2004).  
The process of homologous recombination (HR) utilises identical sister chromatids 
to repair damaged DNA in a conservative and error-free mechanism in which the 
BRCA1/2 proteins play a pivotal role (Da Silva and Lakhani, 2010). In the absence 
of functioning BRCA1/2, cells become dependent on alternative repair pathways 
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such as non-homologous end joining and single-strand annealing (Turner et al, 
2004). Both of these processes are error-prone, resulting in DNA loss and 
chromosomal instability (Turner et al, 2004). Loss of BRCA1 may be particularly 
important in oestrogen-driven tumours because BRCA1 regulates oestrogen 
metabolism through enzymes such as CYP1A1 (Savage et al, 2014). In BRCA1-
deficient cells, deregulated oestrogen metabolism generates increased numbers of 
toxic oestrogen metabolites resulting in DNA damage that cannot be effectively 
repaired, ultimately leading to genomic instability (Savage et al, 2014).   
1.2.2.2 Reproductive and hormonal factors 
 
A long duration of endogenous oestrogen exposure, due to late onset of the 
menopause is associated with an increased risk of breast cancer (Collaborative 
Group on Hormonal Factors in Breast Cancer, 1997). Oral contraceptives are thought 
not to increase a woman’s chances of breast cancer - in a study involving over 9000 
women, Marchbanks et al reported a relative risk of 1.0 for developing breast cancer 
in women currently using oral contraceptives (95% confidence interval (CI): 0.8-1.3) 
and 0.9 (95% CI: 0.8-1.0) in previous users (Marchbanks et al, 2002). Moreover, the 
risk did not increase with increasing dose, longer duration of treatment, younger age 
at initiation or in women with a family history of breast cancer (Marchbanks et al, 
2002). In contrast, hormone replacement therapy (HRT) is a risk factor, particularly 
in current users (Collaborative Group on Hormonal Factors in Breast Cancer, 1997). 
Pregnancy is believed to convert breast epithelial cells into a more stable state and 
hence, a younger age at first pregnancy is linked with a reduction in breast cancer 
risk (Amir et al, 2010). Breast feeding also has a protective effect, possibly due to 
ovulatory delay, loss of oestrogens in breast milk, removal of carcinogenic agents, 
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changes in the pH of the mammary microenvironment and stimulation of terminal 
differentiation (Amir et al, 2010; Millikan et al, 2008; Lipworth et al, 2000).  
1.2.2.3 Mammographic density 
 
Mammographic density – the proportion of breast tissue that shows a dense 
appearance at mammography – is another recognised risk factor (Amir et al, 2010). 
In one study, women with mammographic density involving more than three-
quarters of the breast tissue had five times the risk of those with dense areas 
occupying less than a tenth (Boyd et al, 2007). The increased risk of breast cancer 
persisted for at least eight years after study entry and was more pronounced in 
younger women (Boyd et al, 2007). Indeed, the authors calculated that in women 
below the median age of 56 years, 26% of all breast cancers and 50% of tumours 
detected within a year following a negative screening test, were due to density in 
50% or more of the mammogram (Boyd et al, 2007). 
1.2.2.4 Proliferative breast disease 
 
Epithelial hyperplasia of usual type can be defined as the presence of three or more 
cell layers above the basement membrane (the normal number is two) and in the 
absence of atypical cytological features, increases the chances of future breast cancer 
by almost two-fold (Carter et al, 2006). However, when atypia is also present 
(referred to atypical ductal hyperplasia (ADH) where a proliferative lesion has some 
but not all the features of DCIS or is limited in extent) the risk increases to four to 
five-fold in the ensuing 10-15 years (Carter et al, 2006). In-situ lobular neoplasia is 
associated with 10 times increased risk of breast cancer (Dupont et al, 1993). 
 
33 
 
1.2.2.5 Obesity 
 
Obesity has a conflicting influence on breast cancer risk: in younger women it results 
in a decrease in risk due in part to its association with anovulatory cycles whereas 
the production of oestrogen from adipose tissue renders obese women more prone to 
breast cancer in the post-menopausal group (Lester, 2005). 
1.2.2.6 Ethnicity 
 
Women from different ethnic groups have differing risks of breast cancer and breast 
cancer mortality: the SEER database shows that white women have the highest 
incidence at 127.9/100000 women versus just 79.3/100000 for American 
Indian/Alaskan native women (SEER, 2014). Black women also have a lower 
incidence of breast cancer than white women (122.8/100000) but, strikingly have a 
much higher incidence of breast cancer-related death than all the other ethnic groups 
at 30.8/100000 women. The next highest mortality rate is 22.1/100000 and this 
applies to white women (SEER, 2014). Similarly, British black women have been 
found to have a higher rate of mortality for tumours measuring 2cm or less, as well 
as presenting some 21 years earlier than their white counterparts (Bowen et al, 
2008).  
Although breast cancer incidence in Western Africa is lower compared to western 
countries at around 20/100000 (Fregene and Newman, 2005), studies observing 
indigenous African women show many parallels with western domiciled black 
women, including high mortality rates, early-onset disease and  tumours presenting 
at a higher stage (Fregene and Newman, 2005; Huo et al, 2009; Adesunkanmi et al, 
2006). 
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The aetiology of this racial disparity appears multifactorial, with features such as 
tumour biology, socioeconomic status and treatment factors all thought to influence 
the poorer outlook for black women (Ademuyiwa et al, 2011). 
1.2.3 Ductal carcinoma in-situ (DCIS) 
 
In contrast to the above risk factors, ductal carcinoma in-situ (DCIS) is regarded as a 
precursor to invasive breast cancer and is defined as a proliferation of neoplastic 
cells within the breast ducts and lobules, that has not yet invaded through the 
myoepithelium/basement membrane (Jones, 2006). As most patients with DCIS 
undergo surgery following diagnosis, there is little data on the natural history of 
DCIS. Nevertheless, small retrospective and follow-up studies have shown that 40-
46% of patients with untreated DCIS go on to develop invasive breast cancer 
(Sanders et al, 2005; Collins et al, 2005). 
1.2.4 Prognostic factors in breast cancer 
 
Several factors exert an influence on the outlook for breast cancer patients. 
1.2.4.1 Metastasis 
 
Probably the most important prognostic factor is the presence or absence of 
metastasis, since a full recovery in unlikely when there is distant spread. The most 
common sites of breast cancer metastasis are: the lungs, bones, liver, adrenal glands, 
brain and meninges (Lester, 2005). 
1.2.4.2 Lymph node status, tumour size and pathological grade 
 
Both axillary lymph node involvement by tumour and increasing primary tumour 
size are independent but additive poor prognostic factors (Carter et al, 1989). 
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Pathological grading of tumours has in the past been problematic, mostly due to poor 
reproducibility (Elston and Ellis, 1991). Over the years, modification and refinement 
of the grading system has resulted in an objective technique that takes into account 
tubule formation, mitotic activity and nuclear pleomorphism to give an overall grade 
between 1 and 3 (Elston and Ellis, 1991). This grading system has been shown to be 
both robust and prognostic, with grade 1 tumours showing a markedly better 
prognosis compared to grade 2/3 cancers (Elston and Ellis, 1991; Pereira et al, 
1995). 
These three prognostic factors: lymph node status, grade and tumour size together 
form the Nottingham Prognostic Index (NPI) for primary breast cancer (Galea et al, 
1992). The index divides patients into good, moderate and poor prognostic groups 
based on the chances of survival over a 15 year period (Galea et al, 1992) and it is 
widely used to stratify patients and guide therapy. 
1.2.4.3 Histological sub-type 
 
Histological tumour classification is fundamental to the assessment of breast 
tumours since many have a characteristic morphology that also has prognostic 
significance. A key limitation however, is that most breast cancers (approximately 
70%) fall into a single category: invasive ductal carcinoma, not otherwise specified 
(IDC-NOS) or no special type (IDC-NST)(Harris et al, 2006; Berg and Hutter, 
1995). Patients with these tumours have a very variable prognosis and it is these 
women who stand to gain most from new methods of tumour classification (Harris et 
al, 2006). Of the so-called ‘special types’ of breast cancer, the bulk are associated 
with a more favourable outlook compared to IDC-NST and include the well-
differentiated tubular carcinoma, the related cribriform carcinoma, mucinous (or 
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colloid) carcinoma, medullary carcinoma, papillary carcinoma and adenoid cystic 
carcinoma (Harris et al, 2006; Berg and Hutter, 1995). It should be noted that even 
within special types, behaviour is variable, so sub-typing should be combined with 
grading to more accurately gauge prognosis (Pereira et al, 1995). 
1.2.4.4 Other factors 
 
The presence of tumour cells within vascular spaces (lymphovascular invasion) 
correlates with reduced survival and an increased chance of recurrence (Pinder et al, 
1994; Mohammed et al, 2013). Tumours that express oestrogen receptor (ER) and/or 
progesterone receptor (PR) have a better prognosis than those that do not (Cheang et 
al, 2008). In contrast, cancers that over-express the receptor tyrosine kinase Her2 
have a worse outcome (Cheang et al, 2008). Perhaps more importantly though, 
patients whose tumours express/over-express any of these three receptors can be 
treated with targeted endocrine therapy or trastuzumab (Payne et al, 2008).     
1.2.5 Treatment and outcome 
 
The key elements of breast cancer treatment are surgery, radiotherapy, 
chemotherapy, endocrine therapy and anti-Her2 treatment (reviewed in Wolters et al, 
2012). Surgical options include breast conserving surgery (BCS) or mastectomy. 
BCS is recommended if the primary tumour can be resected without involvement of 
the margins and when the tumour size to breast volume ratio is not excessive 
(Wolters et al, 2012). Mastectomy is the procedure of choice when there is tumour 
multifocality, widespread malignant calcifications, inflammatory carcinoma or if 
radiotherapy (normally advised after BCS by most guidelines) is contra-indicated. 
Patient preference may also influence the surgical decision (Wolters et al, 2012).  
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Axillary surgery should be performed to stage invasive breast cancers when no 
morphological abnormalities are identified at axillary ultrasound scanning (NICE, 
2009). The National Institute for Health and Clinical Excellence (NICE) guidelines 
recommend biopsy of the sentinel node (the first node to receive lymphatic drainage 
from a defined anatomical site) in preference to lymph node clearance, which is 
associated with significant morbidity (NICE, 2009).  
In addition to the post-BCS scenario, radiotherapy is recommended in situations 
when the risk of relapse is high, these include: positive resection margins, large 
tumour size (greater than five cm) and the presence of more than three involved 
lymph nodes (Wolters et al, 2012). 
Chemotherapy, like radiotherapy, is indicated for the treatment of tumours at high 
risk of recurrence, including lymph node positive tumours (Wolters et al, 2012). The 
taxane-containing chemotherapeutic agents (such as docetaxel) are recommended in 
the adjuvant treatment of cancers with nodal metastasis (Wolters et al, 2012; NICE, 
2009).  
According to the consensus of opinion from the St Gallen conference, any positive 
expression of ER is sufficient justification for the use of endocrine therapy 
(tamoxifen in pre-menopausal patients and aromatase inhibitors in post-menopausal 
women) in most cases (Goldhirsch et al, 2009). Elsewhere, the American Society of 
Clinical Oncology/College of American Pathologists advise treating patients with 
anti-oestrogen therapy if the tumour exhibits at least 1% reactivity (Hammond et al, 
2010). Regarding the use of the anti-Her2 agent trastuzumab, protein over-
expression or gene amplification is considered adequate for initiating treatment, 
except in those cases where the risk of progression is very low, for example in Her2 
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positive tumours less than 1cm in size with negative lymph nodes (Goldhirsch et al, 
2009). 
The outlook for breast cancer patients is highly variable and is dependent on many of 
the factors outlined above. Overall, 55-80% of breast cancer patients should survive 
to 10 years (Cheang et al, 2008).  
1.3 Molecular sub-typing in breast cancer 
 
The variation in natural history of breast cancer prompted a novel approach to breast 
cancer classification using gene expression microarrays (Perou et al, 2000; Sørlie et 
al, 2001; Sotiriou et al, 2003; Sørlie et al, 2003). By capturing the gene expression 
patterns of different breast cancers and relating this to patient outcome, these 
workers hoped to improve the taxonomy of breast cancer (Perou et al, 2000; Sørlie et 
al, 2003). These cDNA-based studies identified five main molecular sub-types: 
luminal A, luminal B, Erbb2 (Her2)-positive, normal-like and basal-like (BL)(Perou 
et al, 2000; Sørlie et al, 2003; Figure 1.3).  
Other less well characterised sub-groups include the molecular apocrine tumours 
(characterised by AR, FAS, ERBB2, XBP1 gene expression), claudin-low tumours 
(identified by low claudin protein expression and high CD44, SNA13 gene 
expression) and the interferon group (with over-expression of interferon-related 
genes such as STAT1)(Weigelt et al, 2010; Hu et al, 2006). A more recent study 
identified 10 different sub-types by gene expression/copy number analysis (Curtis et 
al, 2012).  
The potential of this new classification has stimulated a drive to generate 
immunohistochemical profiles of the main molecular sub-types that are more  
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Figure 1.3: Gene expression profiles and molecular sub-types of breast cancer. A 
shows a scaled-down image of the 534 genes and 122 tissue samples used to group 
tumours based on their gene expression profile. B is a dendrogram showing the 
arrangement of the tumour samples into one of five main sub-types; the grey 
branches identify those samples that do not show strong correlation with any sub-
type. C shows the ERBB2 (Her2 positive) sub-type and associated genes, D contains 
the luminal B cluster, E shows the BL cluster, F shows the genes associated with the 
normal-like sub-type and G contains the luminal A cluster, including the ER (ESR1) 
gene. The scale bar represents the fold change of a gene compared to the median 
level of expression for all samples, red is over-expression, green is under-expression 
(Sørlie et al, 2003; reproduced with permission. Copyright (2003) National 
Academy of Sciences, U.S.A).   
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applicable to the diagnostic setting. This process has not been straight-forward: the 
lack of commercially available antibodies to certain gene products, variations in the 
gene expression profiles used by different groups and different cut-points used to 
determine biomarker over-expression are some of the likely reasons. This is 
particularly true of the BL sub-type. 
1.3.1 Luminal A tumours 
 
The luminal A tumours account for approximately 71% of breast cancers (Blows et 
al, 2010) and have the best outcome of all the sub-types, with a 79-84% 10-year 
survival (Carey et al, 2006; Cheang et al, 2008). These tumours show high 
expression of ER, GATA binding protein 3, X-box binding protein 1, KRT8 and 
KRT18 (Sørlie et al, 2001; Weigelt et al, 2010). Luminal A tumours can be identified 
at immunohistochemistry (IHC) by positivity for ER and/or PR and negativity for 
Her2 (Carey et al, 2006; Cheang et al, 2008; Blows et al, 2010). 
1.3.2 Luminal B tumours 
 
Luminal B tumours make up about six percent of breast cancers (Blows et al, 2010) 
and have an intermediate prognosis – 10-year survival is between 60 and 87% 
(Carey et al, 2006; Cheang et al, 2008). The gene expression profile is one of low-to-
moderate expression of luminal-related genes, but a higher amount of proliferation-
associated genes compared with luminal A tumours (Sørlie et al, 2001; Weigelt et al, 
2010). There is over-expression of Her2, hence the immunoprofile is: positivity for 
ER and/or PR together with Her2 reactivity (Carey et al, 2006; Cheang et al, 2008; 
Blows et al, 2010). 
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1.3.3 Her2 positive tumours 
 
Some six percent of breast cancers (Blows et al, 2010) show high expression of 
ERBB2 and GRB7 (Sørlie et al, 2001; Weigelt et al, 2010). At IHC, these tumours 
show Her2 positivity and are ER and PR negative (Carey et al, 2006; Cheang et al, 
2008; Blows et al, 2010). Patients with Her2 positive tumours have a poor prognosis, 
with a 10-year survival rate of 52-55% (Carey et al, 2006; Cheang et al, 2008). 
However, it is important to remember that this survival data pre-dates the widespread 
use of trastuzumab for the treatment of early breast cancer in the UK, which was 
recommended by NICE in 2006 (NICE, 2006). Hence one would expect these 
survival rates to be more favourable under current treatment regimes. 
1.3.4 Normal breast-like tumours 
 
Cancers that cluster in the normal breast-like category show high expression of genes 
associated with adipose tissue and cell types other than those of epithelial origin, 
such as CD36, PTN, FABP4 and ITGA7 (Sørlie et al, 2001; Weigelt et al, 2010). 
While this sub-type remains poorly understood, some feel that this category is an 
artefact due to tumour samples being contaminated with too much normal breast 
tissue (Hu et al, 2006). 
1.3.5 BL tumours 
 
Basal-like (BL) breast cancers make up 10-25% of breast cancers, depending on the 
characteristics of the underlying study population (Perou, 2011). BL cancer has been 
recognised for more than 20 years when a proportion of invasive carcinomas were 
found to express basal cytokeratins (Nagle et al, 1986). The BL sub-group is of 
particular interest because they have a poor outcome (10-year survival is 62-75% 
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with a particularly steep survival curve in the first five years) and, since they 
generally lack expression of ER and Her2, they have limited treatment options. 
Chemotherapy remains the only form of systemic therapy available (Ray et al, 
2010).  
Triple negative (TN) cancers account for 12-17% of breast cancers and lack 
expression of ER, PR and Her2 (Foulkes et al, 2010). The BL and TN tumours are 
defined differently: BL like tumours are normally identified at gene expression 
profiling (although surrogate IHC markers are now available) whereas TN tumours 
are identified using IHC for ER, PR and Her2 (FISH is also used for cases with 
borderline Her2 IHC positivity) (Foulkes et al, 2010). TN tumours have much in 
common with BL tumours but are not synonymous – 29% of TN tumours have been 
shown to have a non-basal expression signature following cDNA microarray analysis 
(Bertucci et al, 2008). A recent genomic study of TN breast cancers found 
considerable variation in the number of mutations in this sub-group, with some 
tumours showing only a few mutations in selected pathways and others showing 
more extensive clonal evolution (Shah et al, 2012). Interestingly, the BL TN cancers 
were found to have higher clonality than the non-BL TN cancers (Shah et al, 2012). 
Other molecular sub-types postulated to make up the non-BL TN tumours are the 
claudin-low and interferon-rich groups (Hu et al, 2006; Perou et al, 2011).  
1.3.5.1 Clinical and epidemiological features of BL tumours  
 
Compared with other sub-types BL tumours are associated with younger patient age, 
with a higher proportion of patients presenting under 40 years of age (Cheang et al, 
2008) and are more likely to present as interval cancers i.e present between regular 
mammograms (Collett et al, 2005). BL cancer is more common in women in the 
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African-American (AA) ethnic group (Millikan et al, 2008). Risk factors for this 
sub-type include earlier menarche, increased waist-to-hip ratio and a lack of breast-
feeding combined with high parity; unlike the more common luminal A subtype, in 
which having multiple children and a younger age at first full-term pregnancy are 
protective, these factors increase the risk of BL cancer (Millikan et al, 2008). The 
vast majority (80-90%) of breast cancers arising in BRCA1 germ-line mutation 
carriers are BL tumours (Foulkes et al, 2003). BL tumours are an aggressive form of 
breast cancer, linked with a lower disease-specific survival (Nielsen et al, 2004; 
Cheang et al, 2008) and a higher risk of local and regional relapse (Voduc et al, 
2010).  
1.3.5.2 Pathological features 
 
At presentation BL tumours tend to be larger than other breast cancers (Foulkes et al, 
2004), with a median size of 2 cm in one series (Rakha et al, 2006). Microscopically, 
the majority of BL cancers fall into the histological category of invasive ductal 
carcinoma, NOS/NST (Fulford et al, 2006; Rakha et al, 2006; Carey et al, 2006) 
however, mixed tumours, lobular, tubular, medullary, mucinous, papillary, adenoid 
cystic and metaplastic tumours can show a basal phenotype (Rakha et al, 2006). In 
particular, most metaplastic carcinomas have been shown to have a basal phenotype 
(Reis-Filho et al, 2006) and one study demonstrated that 17% of BL cancers showed 
medullary-like features, based on a simplified definition of prominent inflammation 
coupled with anastomosing sheets in at least 30% of the tumour (Marginean et al, 
2010). Other architectural features of BL tumours include: a pushing border, a 
ribbon-like appearance and areas of geographic necrosis (Livasy et al, 2006) (Figure 
1.4). Central scarring within the tumour is also more common than in non-BL lesions  
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Figure 1.4: Histological features of BL breast cancer. The photographs are of 
haematoxylin and eosin-stained breast cancers showing some of the distinctive 
features more often seen in BL cancer. A shows a ‘pushing’, circumscribed invasive 
tumour front on the left side, with an associated chronic inflammatory cell infiltrate. 
B shows a band of tumour cells creating a ‘ribbon-like’ appearance along with some 
adjacent tumour necrosis. In C there is a prominent area of tumour-associated 
fibrosis and D shows poor tumour differentiation with a lack of tubule formation and 
frequent mitosis (see arrows; Ho-Yen et al, 2012; reproduced with permission. 
Copyright (2012), Elsevier). 
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(Fulford et al, 2006). Cytologically, the tumour cells tend to have minimal 
cytoplasm, with a high nuclear/cytoplasmic ratio and round/oval nuclei containing 
variable vesicular to coarse chromatin; nucleoli are a common finding (Livasy et al, 
2006). Another useful feature is the presence of spindle-cell, clear cell or squamous 
differentiation (Fulford et al, 2006). Apoptotic cells may be numerous (particularly 
when associated with geographic necrosis) and the mitotic count is high – average or 
median counts of 45-48 per 10 high power fields (Livasy et al, 2006; Fulford et al, 
2006) have been recorded.  
A basal sub-type of in-situ carcinoma has been described (Dabbs et al, 2006; Clark 
et al, 2011). Foci of DCIS are usually small, in one series the in-situ component 
accounted for no more than 10% of the total tumour volume (Dabbs et al, 2006). In 
fact, in many cases of BL carcinoma no in-situ component is seen, perhaps as a 
result of rapid progression to invasive carcinoma or obliteration of the precursor 
lesion (Badve et al, 2011). 
1.3.5.3 Molecular profile 
The BL tumours show a gene expression profile characteristic of the basal epithelial 
layer at cDNA microarray analysis, these highly expressed genes include KRT5, 
KRT17, integrin β4 (ITGB4) and laminin (LAM)(Perou et al, 2000; Sørlie et al, 
2001). The epidermal growth factor receptor (EGFR)(Sørlie et al, 2003; Nielsen et 
al, 2004) together with c-Kit (KIT), FOXC1 and P-cadherin (CDH3)(Hu et al, 2006) 
also forms part of the gene expression cluster. Conversely, these tumours show 
absent or reduced expression of ER and transcription factors that characterise the 
luminal sub-type or ER positive cluster (Sørlie et al, 2001). Similar studies have 
found an increase in cell growth and cell cycle associated genes such as 
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topoisomerase IIa (TOP2A), mitotic feedback control protein Madp2 homolog 
(MAD2L1), cell division control protein 2 homolog (CDC2) and proliferating cell 
nuclear antigen (PCNA)(Sotiriou et al, 2003). The epithelial to mesenchymal 
transition (EMT) related gene SLUG has also been linked to BL tumours (Storci et 
al, 2008). 
Following the identification of tumourigenic stem cell-like cells with high 
expression of the cell surface protein CD44 and low expression of CD24 (Al-Hajj et 
al, 2003), Honeth et al found a positive association between CD44
+
/CD24
-
 cells and 
the BL sub-type (Honeth et al, 2008). The authors concluded that BL cancers were 
enriched with tumour-initiating cells (Honeth et al, 2008) suggesting that the 
presence of these cells contributes to the natural history of BL cancer. 
The high proportion of BRCA1 mutated tumours that have a BL gene expression 
profile (Foulkes et al, 2003) has prompted some to examine the role of BRCA1 
dysfunction in sporadic BL cancer. Aside from BRCA1 mutation, other mechanisms 
may contribute to BRCA1 dysfunction, such as promoter methylation and negative 
regulation of the gene (Turner et al, 2007). In a study of sporadic breast cancers, 
Matros et al found promoter methylation in 21% of tumours, and this was associated 
with lower expression of the BRCA1 protein (Matros et al, 2005). These workers 
found that most BL cancers in fact had no BRCA1 methylation and high BRCA1 
protein expression, most likely due to the higher rate of proliferation in these 
tumours (indicative of normal BRCA1 cell regulation)(Matros et al, 2005). A later 
study by Turner et al confirmed the absence of increased BRCA1 methylation in BL 
cancers but, found significantly lower BRCA1 mRNA expression compared to 
controls (Turner et al, 2007). Furthermore, ID4, a negative regulator of BRCA1 was 
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found at levels over nine times higher than controls, implicating ID4 in BRCA1 
dysregulation in BL cancer (Turner et al, 2007).  
The connection between BRCA1 and BL cancer is supported by a more recent study 
showing that BRCA1 and c-Myc (MYC) form a transcriptional repressor complex on 
the promoters of three genes associated with the BL phenotype: KRT5 (cytokeratin 
5), KRT17 (cytokeratin 17) and CDH3 (P-Cadherin). This may explain the increased 
expression of these genes and proteins in BRCA1 mutated tumours (Gorski et al, 
2010).     
Mutations in the TP53 tumour suppressor gene are common in the BL phenotype 
with frequencies of 82-92% (Sørlie et al, 2001; Manié et al, 2009) and this compares 
with a mutation rate of just 13% in luminal A tumours (Sørlie et al, 2001). Other 
molecular features described in this sub-type are: chromosome 3q gains and 5q 
losses (Holstege et al, 2010) and abnormalities of the X chromosome resulting in an 
increase in the expression of a subset of X chromosome genes (Richardson et al, 
2006). 
1.3.5.4 Immunohistochemical profile 
 
Currently, there is no consensus on the ideal IHC signature for BL tumours and 
different definitions have been utilised or proposed in the literature (Nielsen et al, 
2004; Livasy et al, 2006; Carey et al, 2006; Fulford et al, 2006; Rakha et al, 2007; 
Ihemelandu et al, 2007; Cheang et al, 2008; Rakha et al, 2009; Table 1.1). 
Nevertheless, most of the larger clinical studies find the profile of ER/PR/Her2 
negative, CK5/6 (Figure 1.5) and/or EGFR positive to be robust and specific in 
identifying BL tumours (Cheang et al, 2008; Blows et al, 2010). Importantly, 
negativity for ER, PR and Her2 alone is not regarded as a good proxy for the BL  
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Figure 1.5: Immunohistochemical staining for cytokeratins in BL breast cancer. A 
shows strong and diffuse staining of the tumour cells by CK5, whereas staining for 
CK14 (B) is more often patchy in nature (Ho-Yen et al, 2012; reproduced with 
permission. Copyright (2012), Elsevier). 
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sub-type since BL tumours have a worse outcome and appear distinct from TN 
tumours that lack basal cytokeratin/EGFR expression (Cheang et al, 2008; Blows et 
al, 2010). Other immunohistochemical markers may also be relevant to the BL 
category; these include p53, Ki67 and E-Cadherin. 
 
 
 
 
Table 1.1: Range of immunohistochemical profiles used by different studies to 
identify BL cancer. The lack of a broad consensus has resulted in considerable 
variation in what researchers regard as a BL tumour. The table shows a selection of 
studies and the markers used, ranging from a single cytokeratin to a cocktail of seven 
markers (* = positive for at least one of these markers; modified from Ho-Yen et al, 
2012). 
 
1.3.5.4.1 p53 
 
The tumour suppressor protein p53 (encoded by the TP53 gene), also known as the 
‘guardian of the genome’, has several roles in cell biology, such as apoptosis, cell-
cycle arrest and senescence (Inoue et al, 2012; Turner et al, 2013). A key function of 
p53 is the induction of cell-cycle arrest via the G1S checkpoint mechanism to allow 
DNA repair or apoptosis in response to cellular stress (Inoue et al, 2012). TP53 
mutations are common in human cancer, most of which lead to the accumulation of 
non-functioning protein in the nucleus (Allred et al, 1993), possibly because these 
mutations disrupt the process of ubiquitin-mediated degradation (Inoue et al, 2012).  
Journal article ER PR Her2 CK5/6 CK14 CK17 CK8/18 EGFR Vimentin
Ihemelandu et al , 
2007
Neg Neg Neg - - - - - -
Livasy et al , 2006 Neg - Neg Pos - - Pos Pos Pos
Carey et al , 2006; 
Cheang et al , 2008
Neg Neg Neg Pos/Neg* - - - Pos/Neg* -
Nielsen et al , 2004 Neg - Neg Pos/Neg* - - - Pos/Neg* -
Rakha et al , 2007 - - - Pos/Neg* Pos/Neg* - - - -
Rakha et al, 2009 Neg Neg Neg Pos/Neg* Pos/Neg* Pos/Neg* - Pos/Neg* -
Fulford et al, 2006 - - - - Pos - - - -
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Unlike wild-type p53, mutant p53 can be detected by IHC (Allred et al, 1993; 
Biganzoli et al, 2011) where expression has been associated with high tumour 
proliferation, early recurrence and early death in lymph node negative breast cancer 
(Allred et al, 1993). In keeping with the high frequency of TP53 mutations detected 
in BL cancer (Sørlie et al, 2001), p53 immunopositivity has been found in 81% of 
sporadic BL cancers (Manié et al, 2009). 
1.3.5.4.2 Ki67 
 
The nuclear antigen Ki67 is expressed at all stages of the cell cycle except the resting 
phase (G0) and is considered by some to be a better prognostic marker than mitotic 
count in breast cancer (Yerushalmi et al, 2010). The prognostic significance of Ki67 
expression has been confirmed in two large meta-analyses, where a high Ki67 index 
correlated with worse disease-free and overall survival (de Azambuja et al, 2007; 
Stuart-Harris et al, 2008).  
Some groups use Ki67 positivity (in more than 14% of tumour cells) to define 
luminal B tumours as an alternative to Her2 positivity in ER and/or PR positive 
cancers, based on the importance of the ‘proliferation cluster’ in identifying luminal 
B tumours at gene expression analysis (Cheang et al, 2009; Hu et al, 2006). 
Similarly, consistent with the high expression of cell-cycle associated genes in BL 
tumours (Sotiriou et al, 2003), 79.6% of BL tumours were found to express high 
levels of Ki67 by IHC compared to just 29.1% of non-BL tumours (Kuroda et al, 
2008). 
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1.3.5.4.3 E-Cadherin 
 
The transmembrane glycoprotein E-Cadherin (endoded by the CDH1 gene) is 
regarded by some as an inhibitor of tumour progression (Mahler-Araujo et al, 2008). 
IHC for E-Cadherin is widely used in diagnostic pathology as a marker of in-situ and 
invasive lobular carcinoma, where there is loss of membranous expression of the 
protein (Mahler-Araujo et al, 2008). 
In non-lobular invasive breast carcinoma, loss of membranous E-Cadherin has been 
associated with poor prognostic factors and reduced survival (Rakha et al, 2005). 
While many BL tumours show normal IHC expression of E-Cadherin, studies have 
shown that down-regulation of the protein is more common in BL tumours (Mahler-
Araujo et al, 2008; Sarrió et al, 2008), consistent with the EMT-like characteristics 
of BL cancer and suggesting that loss of E-Cadherin may have a role in promoting 
metastasis.      
1.3.5.5 Treatment in BL cancer 
 
Due to the absence of ER and Her2 expression in BL cancer, chemotherapy remains 
the only established form of systemic therapy (Ray et al, 2010). While anthracycline-
based adjuvant chemotherapy appears to be less effective (Banerjee et al, 2006), 
most data suggests that the taxane class of chemotherapeutic agents (such as 
paclitaxel) is the current treatment of choice in BL cancer patients (De Laurentiis et 
al, 2010; Rouzier et al, 2005). 
In recent years, there has been considerable interest in the development of novel 
therapies that specifically target BL cancer. Amongst these, inhibitors of EGFR, poly 
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(ADP-ribose) polymerase (PARP) inhibitors and anti-angiogenic agents have shown 
some promise (De Laurentiis et al, 2010). 
1.3.5.5.1 PARP inhibitors 
 
The possible involvement of BRCA1 dysfunction in BL breast cancer, and 
particularly BRCA1 mutated (hereditary) BL breast cancer has drawn attention to a 
novel class of drugs known as poly (ADP-ribose) polymerase (PARP) inhibitors. 
The enzyme PARP is a key component of base excision repair (Rehman et al, 2010). 
Inhibition of the enzyme normally results in single-strand breaks that are repaired by 
homologous recombination (HR) in the presence of functioning BRCA1/2 (Farmer et 
al, 2005). In BRCA1/2 deficient cells however, HR is severely impaired, resulting in 
permanent cell arrest or apoptosis (Farmer et al, 2005). This concept of ‘synthetic 
lethality’, whereby loss of either of two related genes is compensated by the other 
gene in normal cells, but loss of both results in cell death in tumour cells, has been 
demonstrated in in-vitro and in-vivo models using BRCA1/2 deficient cells (Farmer 
et al, 2005; Rehman et al, 2010; Figure 1.6). 
PARP inhibitors are now being evaluated in the clinical setting; it is not yet clear if 
patients with sporadic (non-BRCA1 mutated) BL cancer will also derive benefit from 
these drugs. 
1.3.5.5.2 Anti-angiogenics 
 
The angiogenic protein – vascular endothelial growth factor (VEGF) is associated 
with a poor outcome in breast cancer (Linderholm et al, 2001). Furthermore, high 
expression of a 13-gene signature that contains several angiogenic factors (VEGF 
included) distinguishes distant metastatic breast cancer deposits from primary  
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Figure 1.6: The principle of synthetic lethality. Targeting one of two related genes 
does not affect cell survival in normal cells, since each gene compensates for the loss 
of the other. However, cancer cells harbouring a mutation in one gene are susceptible 
to pharmacological intervention targeting the related gene, resulting in cell death 
with sparing of the adjacent normal tissue (Rehman et al, 2010; figure reproduced 
with permission. Copyright (2010), Nature Publishing Group).     
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tumours and regional metastasis (Hu et al, 2009). This ‘VEGF-profile’ was also 
linked to poor prognosis and the authors hypothesised that metastatic tumour cells 
had the ability to form new blood vessels, thus favouring survival in hypoxic 
conditions (Hu et al, 2009).  
While these data implicate VEGF in breast cancer progression, the anti-angiogenic 
compound, sunitinib, which targets the VEGF receptor, has shown limited benefit in 
unselected breast cancer patients (De Laurentiis et al, 2010). Appropriate patient 
selection may in fact be crucial in the assessment of anti-angiogenics, as studies have 
shown a positive correlation between VEGF expression and ER negative status and 
BL breast cancer (Linderholm et al, 2001; Perou, 2011). Sunitinib and another agent 
with inhibitory effects on VEGF (bevacizumab) now form part of separate clinical 
trials focusing on TN breast cancer (Linderholm et al, 2001; Perou, 2011).  
1.3.5.5.3 Anti-EGFR agents 
 
The role of EGFR as an oncogenic factor has been established in several human 
cancers including glioblastoma, lung cancer and head and neck cancers where it is 
regarded as an attractive therapeutic target (Burness et al, 2010). Although less well 
studied in breast cancer, numerous studies have found an association between EGFR 
and the BL phenotype (Cheang et al, 2008; Blows et al, 2010). Dysregulation of 
EGFR signalling promotes tumour proliferation, reduced apoptosis, increased 
survival, angiogenesis and metastasis (Burness et al, 2010).  
In BL breast cancer, the importance of EGFR is endorsed by evidence that signalling 
pathways downstream of EGFR – the Ras/Raf/mitogen-activated protein kinase 
kinase (MEK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways – are 
activated in BL cancer (López-Knowles et al, 2010; Hoeflich et al, 2009). BL breast 
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cancer cell lines are highly sensitive to MEK inhibition compared to breast cancer 
cell lines from the other molecular sub-types and the combination of a MEK 
inhibitor and PI3K inhibitor is synergistic, impairing the growth of BL cells/tumours 
in in-vitro and in-vivo models (Hoeflich et al, 2009). Furthermore, inositol 
polyphosphate 4-phosphatase type II (INPP4B), a regulator of PI3K/Akt signalling 
has been noted to be absent in over 80% of BL cancers (Fedele et al, 2010).  
Despite the rationale for targeting EGFR in breast cancer, the results of clinical trials 
have so far proven disappointing (Burness et al, 2010). Various factors may 
contribute to this discrepancy. Clearly, EGFR dysregulation is a complex process, 
and it may be necessary to tailor strategies towards specific abnormalities, such as 
protein over-expression or activating mutations (Burness et al, 2010). However, this 
approach is itself not without complications, since abnormal EGFR activation for 
example can occur in the absence of protein over-expression (Burness et al, 2010). It 
is also apparent that there is a wide variation in the definitions used to quantify IHC 
EGFR staining, and there is at present no international criterion for evaluating EGFR 
in breast cancer (Arnes et al, 2009). Of course, the down-stream signalling pathways 
activated by EGFR (the MEK pathway for instance) are not exclusive to the receptor 
(Burness et al, 2010) and it very possible that other RTKs make a significant 
contribution to BL cancer cell activation.    
One possible candidate is c-Met, an RTK associated with a poor outlook in breast 
cancer (Camp et al, 1999; Tolgay Ocal et al, 2003; Ghoussoub et al, 1998) and 
implicated in the BL phenotype (Charafe-Jauffret et al, 2006; Garcia et al, 2007a; 
Graveel et al, 2009).  
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1.5 C-Met 
 
1.5.1 Structure and function 
 
C-Met was originally identified as the product of a transforming gene generated from 
a chemically transformed osteosarcoma cell line (Cooper et al, 1984). In 1991, c-Met 
was discovered to be the receptor for hepatocyte growth factor (HGF), a protein that 
had previously been shown to promote hepatocyte growth in culture (Nakamura et 
al, 1984; Bottaro et al, 1991). C-Met is a transmembrane RTK, produced first as a 
170kDa precursor that is subsequently cleaved to generate a 50kDa α subunit and a 
145kDa β subunit (Giordano et al, 1989; Hanna et al, 2009). The α subunit is 
extracellular and bound by a disulphide bond to the transmembrane β subunit 
(reviewed in Trusolino et al, 2010). The extracellular portion of the receptor is 
comprised of a Sema domain, PSI domain (so-called because it is found in plexins, 
semaphorins and integrins) and four immunoglobulin-like fold shared by plexins and 
transcription factors (IPT) domains (Trusolino et al, 2010). 
The intracellular portion contains three domains: the juxtamembrane region, which is 
important in the downregulation of signalling following Ser975 phosphorylation, the 
catalytic region that includes the Tyr1234 and 1235 residues and the multifunctional 
carboxy-terminal docking site (Trusolino et al, 2010; Figure 1.7).  
HGF, also known as scatter factor, is the only known mammalian agonistic ligand 
for c-Met (Goldoni et al, 2009). Like c-Met, HGF is first secreted as a single-chain 
precursor that undergoes proteolytic cleavage to form an α and β-chain heterodimer 
(Trusolino et al, 2010). Upon HGF binding, there is dimerisation of c-Met followed 
by autophosphorylation of the Tyr 1234 and 1235 residues in the kinase domain  
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Figure 1.7: Diagrammatic representation of the c-Met receptor. The key structural 
and functional components are illustrated and include the extracellular region 
containing the Sema domain (found in semaphorin receptors), the PSI domain 
(which is present in plexins, semaphorins and integrins) and four IPT domains 
(present in immunoglobulins, plexins and transcription factors). The intracellular 
region contains the juxtamembrane domain which is important in signalling down-
regulation, together with the catalytic tyrosine kinase domain and the multifunctional 
docking site at the C-terminus; transduction molecules such as Grb2 and Gab1 bind 
to the receptor in this region (Nakamura et al, 2011; reproduced with permission. 
Copyright (2011), John Wiley and Sons).     
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(Hanna et al, 2009). Subsequent to this, phosphorylation of the docking site tyrosines 
1349 and 1356 facilitates the binding of the downstream signal transduction 
molecules Growth-factor-receptor-bound protein 2 (Grb2), Grb2-associated binder 1 
(Gab1), Shc, Src and p85 (Hanna et al, 2009). These molecules promote downstream 
signalling through several c-Met regulated pathways, including : mitogen-activated 
protein kinase (MAPK)/extra-cellular signal regulated kinase (Erk) cascades,  
phosphoinositide 3-kinase (PI3K)/Akt cascades, signal transducer and activator of 
transcription 3 (STAT3) and the PI3K/nuclear factor-κB pathway (Trusolino et al, 
2010; Figure 1.8). Together, these pathways regulate cellular proliferation, 
differentiation, apoptosis, survival and tubulogenesis (Trusolino et al, 2010). In 
addition, signalling via the RAC1-CDC42 pathway can influence migration through 
the E-cadherin/β-catenin complex (Gherardi et al, 2012). 
After c-Met activation the receptor undergoes ubiquitinisation and downregulation, 
as is the case with several RTKs (Peschard and Park, 2007). The ubiquitin ligase Cbl 
binds to and ubiquitinates the receptor which is then internalised in a clathrin-coated 
vesicle and sorted into a multivesicular body, whereupon lysosome fusion results in 
degradation of the receptor (Peschard and Park, 2007). Although c-Met 
internalisation is part of the process of signal attenuation, trafficking of the receptor 
within endosomes under the control of protein kinase C (PKC) results in sustained 
phosphorylation and is necessary for HGF-mediated migration (Kermorgant et al, 
2004; Kermorgant and Parker, 2008). Moreover, in NIH3T3 cells harbouring the 
MET mutation originally indentified in human papillary renal cell carcinomas, 
blocking endocytosis inhibited in-vivo tumour growth and metastasis (Joffre et al, 
2011).  
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Figure 1.8: Diagram of c-Met with its associated downstream signalling pathways. 
HGF binding results in receptor homodimerisation and autophosphorylation of the 
tyrosine residues in the kinase domain (Tyr 1234/1235). Subsequent phosphorylation 
of the docking tyrosines (Tyr 1349/1356) recruits scaffolding and transducer proteins 
that activate downstream signalling via different pathways, including the Erk/MAPK 
and Akt/PI3K cascades, involved in the invasive process (Gastaldi et al, 2010; 
Figure reproduced in accordance with BioMed Central’s open access charter).   
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1.5.2 Cross-talk between c-Met and other membrane receptors 
 
C-Met has been shown to interact with other cell surface proteins including CD44, 
β4 integrin, Plexin β1, EGFR and RET (Trusolino et al, 2010; Lai et al, 2009; Figure 
1.9). The transmembrane protein CD44v6 is necessary for HGF-mediated signalling 
through the MAPK/Erk pathway (Orian-Rousseau et al, 2007). The MAPK/Erk 
pathway is also stimulated via interactions between c-Met and the integrin β4, during 
which c-Met promotes β4 phosphorylation and the recruitment of Gab1 and Grb2 
(Bertotti et al, 2006). The involvement of β4 in this pathway can sustain HGF-
mediated anchorage-independent growth (Bertotti et al, 2006). The Plexin β1 ligand 
Sema 4D can phosphorylate Plexin β1, Gab1 and c-Met and activation of the c-Met 
related RTK RET can phosphorylate Met by a Src-dependent process (Lai et al, 
2009).  
The RTK EGFR can transphosphorylate c-Met (and vice versa) and activation of 
EGFR has been shown to induce cleavage and ectodomain shedding of c-Met 
through the MAPK/Erk signalling cascade (Nath et al, 2001; Lai et al, 2009). 
Moreover, lung cancer cell lines that have EGFR mutations become resistant to 
EGFR inhibitors as a result of MET amplification (Engelman et al, 2007). Growth 
inhibition can then be restored with concurrent anti-c-Met and anti-EGFR treatment 
(Engelman et al, 2007; Bean et al, 2007), suggesting a close relationship between 
these two related receptors. 
Another cell surface protein thought to be linked to c-Met signalling is the adhesion 
molecule E-cadherin (Reshetnikova, 2007). It has been proposed that E-cadherin 
adhesion sites permit the accumulation of signalling proteins including RTKs 
(Reshetnikova, 2007). Work on pharyngeal carcinoma cell lines has shown that HGF  
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Figure 1.9: Cross-talk between c-Met and other proteins. A depicts c-Met and the 
α6β4 integrin which can associate with c-Met, increasing the number of docking 
sites for signal transducers such as Grb2. The hyaluronan receptor CD44 (B) can 
bind to c-Met, linking the receptor to actin microfilaments and facilitating Ras 
activation. Close association between c-Met and class B plexins (C) can result in c-
Met phosphorylation in the absence of HGF via Sema binding (Trusolino et al, 2010; 
figure reproduced with permission. Copyright (2010), Nature Publishing Group). 
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stimulates internalisation of E-cadherin along with enhanced invasion (Kim et al, 
2007; Xie et al, 2010). Cell treatment with anti-E-cadherin antibody was noted to 
result in a similar scattering effect to that seen following HGF administration (Kim 
et al, 2007). These authors postulated that HGF stimulation results in E-cadherin 
separating from β-catenin, with subsequent endocytosis and degradation of E-
cadherin (Kim et al, 2007). Elsewhere, a study comparing different breast cancer cell 
lines found that c-Met expression increased as E-cadherin expression diminished in 
more aggressive cell lines (Götte et al, 2007), raising the possibility that the 
relationship between these two proteins may vary between different tumour types. 
1.5.3 Role in development and repair 
 
C-Met is mainly expressed in epithelial and endothelial cells (Peschard and Park, 
2007; Hanna et al, 2009) whereas HGF is expressed in mesenchymal cells (Peschard 
and Park, 2007). HGF is necessary for normal embryological development and mice 
lacking the gene die in utero with impaired survival of liver hepatocytes and 
placental trophoblast (Schmidt et al, 1995; Uehara et al, 1995). The HGF-c-Met 
signalling axis is also important in tissue repair in a variety of different tissue types 
including liver, lung, spleen, kidney, nervous tissues, cutaneous and cardiovascular 
tissues (Nakamura et al, 2011). HGF may contribute to tissue regeneration by 
suppressing inflammation and promoting proliferation, 3-D morphogenesis and 
degradation of components of the extracellular matrix (Nakamura et al, 2011). 
1.5.4 Role in cancer 
 
The biological effects of the HGF-c-Met axis that are key in development and repair 
have also been implicated in cancer, where aberrant c-Met signalling may promote 
cancer progression and have a detrimental effect on prognosis (Lai et al, 2009). 
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Perturbations in the c-Met pathway may be due to a variety of mechanisms, these 
include: gene rearrangement, gene mutation, amplification, protein over-expression, 
increased paracrine stimulation, acquisition of autocrine signalling and cross-talk 
with other receptors (Cooper et al, 1984; Peschard and Park, 2007; Sierra and Tsao, 
2011). 
These mechanisms have been described in renal, breast, lung, gastric, bone and 
pharyngeal cancers (Cooper et al, 1984; Schmidt et al, 1997; Lengyel et al, 2005; 
Kim et al, 2007; Engelman et al, 2007; Li et al, 2012). MET mutations were first 
described in germline and sporadic papillary renal cell carcinomas (Schmidt et al, 
1997). Although MET mutations are in fact rare, one study identified mutations in 
30% of cancers of unknown primary origin (Stella et al, 2011). MET amplification 
appears to be particularly common in lung carcinomas treated with anti-EGFR 
therapy, where 21-22% of tumours show amplification of chromosome 7q, in which 
MET resides (Engelman et al, 2007; Bean et al, 2007). 
1.5.5 Role in breast cancer 
 
In the normal breast, c-Met is expressed in the mammary epithelium and stromal 
cells but not in the stroma itself (Jin et al, 1997; Lindemann et al, 2007). HGF, being 
a secreted protein has been identified by IHC in mammary epithelial cells, 
fibroblasts, blood vessel walls and in the acellular stroma (Jin et al, 1997; 
Lindemann et al, 2007). C-Met expression shows a spectrum of intensity in healthy 
and diseased breast tissue: low levels are seen in normal/hyperplastic breast tissue, 
moderate levels in DCIS and the highest expression is seen in invasive breast cancer 
(Jin et al, 1997).  
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Several studies have found increased c-Met expression in a sub-set of invasive breast 
cancers and associated this with a poor outcome. Camp et al and Tolgay Ocal et al, 
looked at samples from 113 and 324 patients respectively with lymph node negative 
breast cancer (Camp et al, 1999; Tolgay Ocal et al, 2003) and Ghoussoub et al 
studied 91 patients, composed of a mixture of lymph node positive and negative 
cases (Ghoussoub et al, 1998). The cause of c-Met over-expression is most likely 
transcriptional/post-translational regulation and hypoxia-induced, since amplification 
of the MET gene is not a common event (Carracedo et al, 2009). The transcription 
factor, hypoxia-inducible factor 1α (HIF1α) has been correlated with c-Met and a 
poor outcome in a series of 104 node-negative breast cancers and it has been put 
forward that tumour hypoxia increases c-Met expression via HIF1α (Chen et al, 
2007).        
In contrast to its role as a poor prognostic factor in breast cancer, evidence linking c-
Met to BL cancer is more limited. In 2009, two studies utilising different mouse 
models of activated c-Met found that MET gene expression in the resultant 
mammary tumours clustered with the BL sub-type (Graveel et al, 2009; Ponzo et al, 
2009). In human cancers, a gene expression signature that includes MET over-
expression has been shown to separate BL from luminal cancers (Charafe-Jauffret et 
al, 2006) and high protein expression of c-Met on IHC has been significantly 
associated with the BL sub-type (Graveel et al, 2009).  
1.5.6 Anti-c-Met therapy 
 
There are several different ways of targeting the c-Met signalling pathway: 1) kinase 
inhibitors (KIs), 2) antibodies directed against c-Met and 3) HGF inhibitors, such as 
anti-HGF antibodies (Gentile et al, 2008; Nakamura et al, 2011; Figure 1.10).  
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Figure 1.10: Strategies for targeting HGF/c-Met in anti-cancer treatment. There are 
several different methods of antagonising c-Met signalling. Amongst those under 
investigation are anti-HGF therapies (neutralising antibodies against HGF and 
antagonists of the ligand) as well as antibodies directed against the receptor itself. 
Many investigators have focused on the tyrosine kinase inhibitors such as 
Cabozantinib (XL184) and ARQ197, which are currently being investigated as 
possible breast cancer treatments (ClinicalTrials.gov, 2014) (figure reproduced with 
permission, Nakamura et al, 2011; Copyright (2011), John Wiley and Sons).    
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One of the first targeted small molecule inhibitors of c-Met to be developed was 
SU11274, an adenosine triphosphate (ATP)-competitive inhibitor of Met kinase 
(Sattler et al, 2003). SU11274 selectively inhibits c-Met without inhibition of 
PDGFβ and with only 2% inhibition of FGFR-1 at the IC50 for c-Met (Sattler et al, 
2003). Compared to c-Met, the inhibitory effect of SU11274 against Ron (the 
tyrosine kinase which c-Met is most closely related to) is 10 times less potent (Wang 
et al, 2003). In-vitro studies have demonstrated that the inhibitory effect of SU11274 
extends to several cellular processes regulated by the HGF/c-Met signalling axis, 
including HGF-dependant cell proliferation and motility (Sattler et al, 2003; Wang et 
al, 2003). Moreover, SU11274 reduces phosphorylation of key components of the 
PI3K signalling pathway, resulting in increased apoptosis and induction of G1 cell 
cycle arrest (Sattler et al, 2003). In addition, tubulogenesis assays have shown that 
HGF-mediated formation of invasive tubular structures by rat intestinal epithelial-1 
(RIE-1) cells is inhibited by SU11274 (Wang et al, 2003). Although SU11274 is not 
considered to be a candidate for in-vivo development (Wang et al, 2003), these in-
vitro studies demonstrated the potential for small molecule inhibitors of c-Met as a 
novel form of cancer treatment.  
Currently, numerous compounds are being evaluated in clinical trials 
(ClinicalTrials.gov, 2014), although many are still in their early phase. However, 
four agents that show particular promise are ARQ197 (also known as tivantinib), 
AMG 102 (rilotumumab), MetMab (onartuzumab) and PF-2341066 (crizotinib) (Yap 
and de Bono, 2010; Gordon et al, 2010; Yap et al, 2011; Sequist et al, 2011; Yano 
and Nakagawa, 2014).  
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Tivantinib belongs to the c-Met KIs class of anti-c-Met therapies (Cecchi et al, 
2010). Unlike most KIs which compete for the ATP binding site, thus preventing 
phosphorylation, tivantinib is a non-ATP competitive c-Met inhibitor (Cecchi et al, 
2010; Yap et al, 2011).  A phase I trial of tivantinib in 51 patients with solid tumours 
found the inhibitor to be well tolerated, with fatigue, nausea and vomiting being the 
most common adverse effects (Yap et al, 2011). Furthermore, when pre-treatment 
and ‘on-treatment’ tumour biopsies were compared, there was a reduction in total 
and phosphorylated c-Met expression in the ‘on-treatment’ samples suggesting 
tivantinib inhibited intra-tumoural c-Met signalling (Yap et al, 2011).  
Studies describing frequent MET amplification in non-small cell lung carcinomas 
(NSCLC) resistant to anti-EGFR therapy (Engelman et al, 2007; Bean et al, 2007) 
stimulated interest in combined anti-c-Met/anti-EGFR strategies (Sequist et al, 
2011). A phase II randomised trial in NSCLC patients, consisting of a combined 
tivantinib/anti-EGFR (erlotinib) arm and an erlotinib plus placebo arm found 
prolonged progression-free survival in the tivantinib/erlotinib (ET) arm (Sequist et 
al, 2011). Notably, the ET combination was particularly efficacious in patients with 
KRAS mutations (Sequist et al, 2011). Since KRAS mutations confer resistance to 
erlotinib (Massarelli et al, 2007), the authors proposed that tivantinib may increase 
the number of NSCLC patients who may benefit from erlotinib-based treatment 
(Sequist et al, 2011).  
AMG 102 is a fully humanised HGF/SF neutralising monoclonal antibody (Yap and 
de Bono, 2010; Gordon et al, 2010). In a phase I study looking at the safety, 
pharmacokinetics and pharmacodynamics of AMG 102 in 40 patients with advanced 
solid cancers (including four breast cancer patients), AMG 102 was found to be safe 
and well tolerated (Gordon et al, 2010). In this study, the maximum tolerated dose 
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was not reached and although anti-tumour activity was not a key study objective, at 
least half of the ovarian cancer patients showed a reduction in tumour size or in the 
serum marker CA-125 (Gordon et al, 2010). Phase II studies are now underway, 
assessing AMG 102 alone and in combination with other therapies (Yap and de 
Bono, 2010). One criticism of anti-HGF therapies is that they only antagonise HGF-
mediated c-Met activation (Gentile et al, 2008) so their efficacy would be limited in 
tumours where c-Met is activated by HGF-independent processes such as MET 
amplification or mutation. 
MetMab is an anti-c-Met monoclonal antibody (Yano and Nakagawa, 2014). Unlike 
many other anti-c-Met antibodies, MetMab is monovalent so it does not promote 
dimerisation when it binds to c-Met, thus avoiding agonistic effects associated with 
similar therapies. MetMab is currently being trialled in lung, colon and breast cancer 
(Yano and Nakagawa, 2014). Crizotinib is an anaplastic lymphoma kinase inhibitor 
which is also possesses anti-c-Met activity (Yano and Nakagawa, 2014). Crizotinib 
has been approved for the treatment of NSCLCs harbouring the EML4-ALK fusion 
gene but it has also been shown to be effective in a NSCLC patient with no ALK 
rearrangement but with de novo MET amplification (Yano and Nakagawa, 2014; Ou 
et al, 2011).     
Turning to breast cancer, tivantinib (ClinicalTrials.gov Identifier: NCT 01542996), 
another c-Met KI – cabozantinib (also known as XL184; ClinicalTrials.gov 
Identifier: NCT 01738438) and MetMab (ClinicalTrials.gov Identifier: NCT 
01186991) are currently being investigated for the treatment of metastatic TN breast 
cancer (ClinicalTrials.gov, 2014).  
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While the sheer number of anti-c-Met/HGF therapies currently being evaluated and 
the results of early clinical trials offer considerable promise, a key consideration is 
how to identify which patients are likely to gain from these specific treatments 
(Cecchi et al, 2010).  
Many of the challenges that have hindered the introduction of anti-EGFR therapy 
into breast cancer treatment regimens (Burness et al, 2010) may also apply to anti-c-
Met therapy, particularly the lack of studies validating methods of assessing 
expression and/or activity of c-Met (Gherardi et al, 2012). C-Met 
expression/activation is often ignored in clinical trial study design, but appropriate 
patient stratification is a necessary part of improving cancer therapy (Gherardi et al, 
2012).  
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2.0 Study Introduction 
 
The main objective of this study is to investigate the significance of c-Met 
expression and activation in invasive breast cancer, with particular reference to BL 
breast cancer in view of the poor prognosis and limited treatment modalities for 
patients with these tumours. 
Although several studies have linked c-Met over-expression with a poor outcome in 
breast cancer, the majority of these were based on a relatively small cohort of 
patients and few have looked at more than 200 subjects (Ghoussoub et al, 1998; 
Camp et al, 1999; Tolgay Ocal et al, 2003; Chen et al, 2007). Similarly, studies 
describing higher levels of c-Met in the BL sub-type have looked at limited numbers 
of patients and/or not fully taken into account the impact that relevant confounding 
factors may have had on their analyses (Ponzo et al, 2009; Graveel et al, 2009).  
Increasingly, tissue microarrays (TMAs) are being used by researchers for 
immunohistochemical analysis because of their many advantages in the evaluation of 
biomarkers. These include: the ability to analyse large numbers of samples in a 
rapid, efficient process that is cost-effective and results in less experimental bias 
because all samples are stained at the same time (Pinder et al, 2013). When 
accompanied by clinical, pathological and other biomarker data together with long-
term follow-up, TMAs represent a powerful resource in the assessment of prognostic 
and predictive markers in cancer research.  
A valid criticism of biomarker studies in general is that surprisingly few tumour 
markers progress through the clinical trial process, given the number of published 
studies describing promising new targets (McShane et al, 2005; Brennan et al, 
2007). In an effort to correct this anomaly, guidelines have been compiled with 
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specific reference to key elements of study design. These include recommendations 
on study methodology (describing the characteristics of the study population), 
statistical analysis (such as the handling of missing data and cut-point determination) 
and data analysis (relationship of the given marker to prognostic variables and 
multivariate analysis) (McShane et al, 2005). The aim of these guidelines is to 
promote transparency in the field of biomarker analysis, allowing the wider 
community to evaluate effectively the impact of such studies (McShane et al, 2005). 
Adherence to such guidelines is now a requirement of some journals (Hayes et al, 
2006).  
Taking these points on board, the current study will seek to clarify and confirm the 
significance of c-Met expression using TMAs constructed from two separate, well-
characterised breast cancer cohorts, comprising samples from over 2000 patients. 
The autophosphorylation of RTKs that follows ligand binding is pivotal in the 
subsequent activation of downstream signalling pathways that become hijacked in 
oncogenesis (Hunter, 2009). However, to date studies looking at RTK 
phosphorylation have struggled to demonstrate the prognostic and predictive utility 
of measuring protein phosphorylation and whether this is superior to measuring 
expression of the receptor (Blokzijl et al, 2010). This may be because the phospho-
antibodies used in conventional assays were limited by poor specificity (Blokzijl et 
al, 2010).  
The recent development of a novel proximity ligation assay (PLA) offers the 
opportunity to quantify protein phosphorylation with a high degree of sensitivity and 
specificity (Söderberg et al, 2008). Using this new technology, I will quantify c-Met 
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phosphorylation in our ‘in-house’ cohort of invasive breast cancers and discuss the 
relationship with prognostic and molecular parameters. 
With over 50 different breast cancer cell lines (BCLs) now available (Neve et al, 
2006), researchers are in a position to select specific BCLs that have similar 
molecular features to the primary tumours they are studying. Using models of BL 
breast cancer, the current study will appraise the functional and phenotypic influence 
of the HGF/c-Met pathway in this sub-type. 
To make interpretation easier, this thesis will be divided into 2 parts. In the first part 
I will outline the steps I have taken to validate the antibodies and techniques that will 
subsequently be applied to the study cohort of breast cancers. I will also explain my 
choice of BCLs, which will then be used to model HGF-mediated effects in-vitro.  
In the second part I will address the following study aims: 
1) Establish definitively whether c-Met expression is associated with the BL 
sub-type in a large series of breast cancers. 
 
2) Confirm whether c-Met expression is an independent poor prognostic factor 
in breast cancer and describe its relationship to established prognostic factors.   
 
3) Measure c-Met activity using the PLA in a cohort of breast cancers and 
determine the prognostic value of this assay in FFPE samples. 
 
4) Study the functional and phenotypic effects of HGF-mediated c-Met 
phosphorylation using in-vitro models of BL breast cancer.    
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It is hoped that the data produced from this study will be useful in the development 
of anti-c-Met therapy and in the design of future clinical trials. 
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3.0 Validation of the Methods: Immunohistochemistry 
 
3.1 Introduction 
 
The technique of immunohistochemistry (IHC), which amalgamates the two fields of 
immunochemistry and tissue morphology has developed greatly over the last decades 
and is now a key part of diagnostic pathology and research (Buchwalow and Böcker, 
2010). New approaches to antigen retrieval, signal amplification and reducing 
background staining, together with the proliferation in antibodies available have 
increased the complexity and applicability of IHC, resulting in many possibilities for 
each step in the technique.  
The choice of primary antibody is of course a crucial decision, not only in terms of 
the specific epitope recognised by the antibody, but also the clonality and species 
they are raised in: monoclonal antibodies are usually produced in mice and result in 
high specificity whereas the polyclonal rabbit antibodies generally demonstrate 
better antigen recognition (Buchwalow and Böcker, 2010).  
The widespread availability of formalin-fixed paraffin-embedded (FFPE) tissue from 
pathology laboratories and tissue banks makes FFPE sections a valuable resource for 
researchers. However, the process of formalin fixation may alter protein structure, 
rendering epitopes inaccessible to certain antibodies and resulting in a negative result 
on IHC (Montero, 2003; Buchwalow and Böcker, 2010). The ideal method of 
antigen retrieval depends on several factors including method of fixation, type of 
tissue and the epitope itself (Buchwalow and Böcker, 2010).  
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Numerous antibodies directed against c-Met are now commercially available (see 
Table 3.1 for the antibodies used in this study). Evidence from the literature suggests 
that different c-Met antibodies show a low level of reproducibility due to the features 
of the antibodies themselves or the effects of tissue fixation and paraffin embedding 
(Pozner-Moulis et al, 2007; Cecchi et al, 2010). Given this lack of reproducibility, 
every effort should be made to adequately validate c-Met antibodies (Pozner-Moulis 
et al, 2007; Gherardi et al, 2012) and this would seem particularly important in large 
clinical studies utilising archived material. 
The aim of this initial study was to select an anti-c-Met antibody that showed 
reproducible staining, confirm its specificity for the receptor and validate it for 
subsequent use on the main study cohort of invasive breast cancers.   
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3.2 Materials and Methods 
 
3.2.1 Tissue samples 
 
3.2.1.1 Formalin-fixed, paraffin-embedded sections (FFPE) 
 
3.2.1.1.1 Whole breast cancer sections 
 
Whole sections from 11 invasive breast cancers from the Barts Cancer Institute 
Breast Tissue Bank were used to validate c-Met antibodies. These FFPE sections 
were paired with snap-frozen sections (section 3.2.1.2).  
3.2.1.1.2 Tissue microarrays: invasive breast cancers 
 
In addition to whole breast cancer sections, sections of previously constructed tissue 
microarrays (TMAs) were also available. These TMAs represent part of the ‘in-
house’ Homerton cohort (section 6.0) and included cores from 181 patients. 
3.2.1.1.3 Tissue microarrays: renal cell carcinoma (RCC) 
 
FFPE tissue from patients (n=56) enrolled into 3 separate prospective phase II 
clinical trials investigating the effects of anti-VEGFR therapy in metastatic clear cell 
renal cell carcinoma (RCC) were included in this analysis. Patients in these trials 
received either sunitinib (50mg, 4 times in 2 weeks) or pazopanib (800mg once 
daily) (Boleti et al, 2012; Powles et al, 2011; Bex et al, 2011) before planned 
nephrectomy (institutional review board approval: EudraCT 2006-004511-21, 2006-
006491-38 and 2009-016675-29). 
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Paired tissue samples were available in the form of excess tissue from renal biopsies 
(pre-treatment samples) and post-treatment nephrectomies (post-treatment samples), 
arranged into TMAs.  
3.2.1.2 Frozen sections 
 
Tumour tissue snap-frozen in liquid nitrogen was available from a cohort of 11 
invasive breast carcinomas sampled in the fresh state. These samples also formed 
part of the Barts Cancer Institute Breast Tissue Bank and were paired with the FFPE 
tissue in section 3.2.1.1.1. 
3.2.2 Antibodies 
 
See Table 3.1 for details of the primary antibodies used in this study. The anti-c-Met 
antibodies targeted different parts of the receptor, including the intracellular and 
extracellular regions (Figure 3.1). 
 
 
 
 
Table 3.1: Primary antibodies utilised in this IHC validation study. Abbreviations: 
IF = immunofluoresence, IHC = immunohistochemistry, WB = western blot, n/a = 
not applicable. 
 
 
 
Antibody Target Supplier Species Dilution (IF, IHC) Dilution (WB)
CVD13 c-Met Invitrogen Rabbit 1:100 1:500
8F11 c-Met Novocastra Mouse 1:150 n/a
3D4 c-Met Invitrogen Mouse 1:100 n/a
AF276 c-Met R&D Systems Goat 1:50 n/a
B-6 HSC70 Santa Cruz Mouse n/a 1:10000
CD31 CD31 AstraZeneca Mouse 1:600 n/a
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Figure 3.1: Binding sites of commercially available anti-c-Met antibodies. The four 
anti-c-Met antibodies tested in this study targeted different parts of c-Met. The 8F11 
(Novocastra Laboratories, 2010) and AF276 (Dietz et al, 2013) bind somewhere in 
the extracellular domain. The 3D4 antibody binds to the region between amino acid 
(AA) 1200 and AA 1270 (personal communication with manufacturer) and CVD13 
binds to the C-terminus of the receptor, in the region of AA 1340 (personal 
communication with manufacturer). Figure modified from Nakamura et al, 2011.     
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3.2.3 Immunohistochemistry (IHC) 
3.2.3.1 Paraffin sections 
 
The chemicals used were from Fisher Scientific, Loughborough, UK unless 
otherwise stated. Unstained paraffin sections were de-waxed by first warming the 
slides to 60
o
C in an incubator for 10 minutes and placing them in xylene for 10 
minutes. The sections were re-hydrated through graded alcohol solutions and placed 
in 3% hydrogen peroxide solution for 10 minutes to block endogenous peroxidise 
activity. Antigen retrieval was performed by microwave treating the sections in 0.1M 
citrate buffer (CVD13, 8F11, 3D4, AF276, CD31) at pH 6 for 10 minutes. The slides 
were rinsed in water. 
3.2.3.2 Frozen sections 
 
Frozen sections were retrieved from the -80
o
C freezer and allowed to warm to room 
temperature. The sections were fixed in 4% paraformaldehyde (PFA; Cell Path, 
Newton Powys, UK) for 5 minutes in a fume hood. Endogenous peroxidise activity 
was blocked by placing the sections in 3% hydrogen peroxide solution for 10 
minutes. Slides were rinsed in water and then treated as in section 3.2.3.3. 
3.2.3.3 Blocking, antibody incubation and developing 
 
After washing in phosphate buffered saline (PBS), normal serum (horse for mouse 
primary antibodies and goat for rabbit primary antibodies) was deposited on the 
sections for 15 minutes at a dilution of 1:75 in 1% bovine serum albumin (BSA; 
Sigma-Aldrich, Dorset, UK)/PBS to block non-specific antibody binding. After 
draining the sections, the primary antibody was incubated for 1 hour at room 
temperature (see Table 3.1 for dilutions). Following PBS washes, the secondary 
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biotinylated antibody (Vector Laboratories, Peterborough, UK) was applied to the 
sections at a dilution of 1:200 for 40 minutes. The sections were washed in PBS then 
incubated with avidin-biotinylated peroxidase complex (Vectastain ABC kit, Vector 
Laboratories) for 30 minutes. The reaction was developed using a DAB kit 
(Vectastain, Vector Laboratories), after which sections were counterstained with 
haematoxylin (Sigma-Aldrich), rinsed and dehydrated through alcohol to xylene and 
mounted with coverslips. Negative controls consisted of a TMA containing 10 
invasive breast cancer samples in triplicate, with omission of the primary antibody. 
IHC on the renal tissue was performed by Mr Kevin Sharpe (KS). 
3.2.3.4 Scoring system 
 
C-Met IHC on breast tissue was scored using a semi-quantitative approach, 
combining numerical scores for intensity and area of reactivity in the cytoplasmic 
and membranous compartments. Intensity was scored on a scale of 0-3 (0 = negative, 
1 = weak, 2 = moderate, 3 = strong) and area on a scale of 0-4 (0 = <1%, 1 = 1-25%, 
2 = 26-50%, 3 = 51-75%, 4 = >75%), giving a total score between 0 and 14. All 
cores were scored twice by me, on two separate occasions to ensure reproducibility.  
C-Met IHC on renal carcinoma cells was scored using a similar approach: staining 
on the tumour cells was graded in intensity (0 = negative, 1 = weak, 2 = moderate, 3 
= strong) and this was multiplied the percentage area of tumour reactivity (0-100%) 
to give a combined score between 0 and 300.  
For quantification of c-Met on tumour-associated blood vessels, sequential sections 
were first stained for the endothelial marker CD31. The total number (identified by 
CD31 positivity in tubular structures) was then counted. Any blood vessel reactive 
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for c-Met (on the adjacent section) was regarded as positive and c-Met positive 
vessels were then expressed as a percentage of total vessels. IHC on renal tissue was 
scored by KS and me.   
3.2.4 Tissue culture 
3.2.4.1 Cell lines and media requirements 
 
The basal-like (BL) breast cancer cell line (MDA-MB-468) utilised in this study was 
previously established in the laboratory. Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma-Aldrich), supplemented with 10% fetal calf serum 
(FCS; PAA, Sommerset, UK).  
3.2.4.2 Propagation and sub-culture 
 
Cells were grown in T75 flasks (Fisher Scientific) and incubated at 37
o
C in 8% CO
2
. 
The cells were monitored using an inverted phase contrast microscope. Growth 
media was changed every 3-4 days unless the cells were confluent. At approximately 
80% confluence, cells were passaged by removing and discarding the media and 
adding 3 mls of 0.25% (w/v) Trypsin – 0.53 mM EDTA solution (PAA). The flask 
was placed at 37
o
C for 5-10 minutes until the cells had detached. The cells were then 
washed in 3 mls of media and spun down in a centrifuge for 3 minutes at 1200 rpm 
into a pellet form. The supernatant was discarded and the pellet re-suspended in 10 
mls of media prior to being transferred into a new T75 flask at a sub-cultivation ratio 
of 1:3.  
3.2.4.3 Preservation and de-frosting  
 
Cells were preserved in either a -80
o
C freezer (if going to be used within weeks of 
freezing) or in liquid nitrogen for longer-term storage. Freezing media was 
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formulated from 50% growth media, 40% FCS and 10% dimethyl sulphoxide 
(DMSO) and the pellet was re-suspended in 1ml of freezing media per cryovial. The 
cryovial was cooled slowly in a foil-wrapped polystyrene container. For re-
constitution, frozen cells were thawed rapidly by placing the cryovial in a water bath 
set at 37
o
C. The DMSO was washed off by gently mixing the vial contents with 1ml 
of media before adding the suspension to 9mls of media in a 15ml tube. The cells 
were centrifuged at 1200 rpm for 3 minutes, re-suspended in 10mls of media and 
added to a new T75 flask.  
3.2.4.4 Knock-down of c-Met  
 
MDA-MB-468 cells were trypsinised at approximately 80% confluence and re-
suspended in an equal volume of DMEM. Cells were counted using a 
haemocytometer; 10µl of cell suspension was pipetted into a well in the 
haemocytometer and the number of cells per 4x4 grid were counted under inverted 
phase contrast microscopy. An average cell count of 2 4x4 grids was taken and then 
multiplied by 10000 to give the number of cells per ml. Approximately 1.5 million 
cells were transferred into a 1.5ml eppindorf and centrifuged at 1200 rpm for 3 
minutes. The supernatant was discarded and the cell pellet was mixed with 100µl 
Nucleofector Solution V (Lonza, Berkshire, UK) and 2µg of Met siRNA 
(Dharmacon, Leicestershire, UK). Scrambled siRNA (Dharmacon) was used as a 
control. After homogenisaton, the solution was transferred to a cuvette and placed in 
the Nucleofector device (Lonza) and Nucleofector Programme X-005 was selected. 
Upon completion, 500µl of growth media was added to the cuvette and the solution 
was homogenised. The cell suspension was placed in a 6-well or 24-well plate at a 
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concentration of 200000 cells per well or 20-30000 cells per well respectively. The 
plates were then incubated at 37
o
C, 8% CO
2
 for 2-4 days. 
3.2.5 Western blot 
3.2.5.1 Cell lysis 
 
Once cells were confluent, medium was removed and culture plates washed in cold 
PBS, before adding cold radioimmunoprecipitation assay (RIPA) buffer (50mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1mM ethylenediaminetetraacetic acid (EDTA), 1% 
Igepal CA-630 (NP-40; Calbiochem, Millipore, Nottingham, UK), 0.1% sodium 
dodecyl sulphate (SDS)) mixed with a cocktail of protease inhibitors (Calbiochem) 
at 1:100. The plate was scrapped and the suspension was placed in a fresh eppendorf 
and incubated on ice for 20 minutes. The eppendorf was centrifuged at 10000 rpm, 
4
o
C for 5 minutes. The pellet was discarded and the supernatant was placed in a fresh 
eppendorf. The protein concentration was assessed with a Bio-Rad DC Protein 
Assay (Bio-Rad Laboratories, Hertfordshire, UK). Cell lysates and BSA standards 
(diluted in distilled water) were added at 5µl volumes to a 96-well plate in triplicate, 
before adding 25µl of solution A/S (1000µl reagent A and 20µl reagent S) per well 
followed by 200µl of reagent B per well. The reagents were left to incubate for 10 
minutes at room temperature before reading on a microplate reader (Labtech) at 620 
nm. An absorbance versus concentration curve was plotted using the BSA standards 
and this was used to estimate the sample protein concentration. The samples were 
stored at -20
o
C until needed. 
3.2.5.2 SDS Gel Electrophoresis 
 
An SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) gel was prepared, with 
component volumes adjusted depending on the molecular weight of the protein of 
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interest, for c-Met (~145kDa) a 6% gel was cast. The resolving gel solution (5.3 mls 
distilled water (dH2O), 2 mls 30% acrylamide mix (National Diagnostics, Hessle, 
UK), 2.5 mls 1.5M tris (pH 8.8), 100µl 10% SDS, 100µl 10% ammonium 
persulphate (APS; National Diagnostics) and 8 µl TEMED (National Diagnostics)) 
was dispensed into a 1mm thick gel cassette (Invitrogen) and 1ml of dH2O was 
overlain to allow sample diffusion. After the gel was set (approximately 10 minutes 
later), the dH2O was poured off. A 5% SDS-PAGE stacking gel solution (2.1 mls 
dH2O, 500 µl 30% acrylamide mix, 380 µl 1M tris (pH 6.8), 30 µl SDS, 30 µl 10% 
APS and 3µl TEMED) was added to the cassette, a 1mm 10-15 well comb was 
inserted and the gel was left to set for about 10 minutes. The comb was removed and 
the cassette placed in a gel tank containing 500mls of running buffer (50 mls tris-
glycine SDS in 450 mls dH2O).  
After thawing, 10µg of each protein sample was added to 4X sample buffer (5% 
SDS, 20% buffer (0.5M tris, 0.2M NaH2PO4 pH 7.8), 5% β-mercaptoethanol 
(Promega, Hampshire, UK), 50% glycerol, 0.01% bromophenol blue (Sigma-
Aldrich) and 20% dH2O) to give an end concentration of 1X. The samples were then 
boiled for 6 minutes at 98
o
C. The samples were loaded into the gel, along with 7.5µl 
of PageRuler pre-stained protein ladder (Fermentas, Loughborough, UK) and run for 
90 minutes at 125V, room temperature. Transfer buffer (50 mls tris-glycine buffer in 
450 mls 80% dH2O/20 % MeOH) was prepared, transfer sponges and a 
nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK) were 
soaked in transfer buffer while the cassette was removed from the gel tank and the 
stacking gel separated. A sandwich was created within the transfer apparatus, 
containing wet sponges, filter paper, the gel and pre-soaked nitrocellulose 
membrane, with the membrane immediately adjacent to the gel. Any bubbles were 
85 
 
removed by gently rolling a glass tube along the sandwich before sealing the lid and 
placing the apparatus into the inner chamber of the gel tank. Transfer buffer was 
added to the top of the inner chamber and dH2O added to the outer chamber before 
running at 30V for 90 minutes.  
After transfer, the membrane was removed and blocked in 3% BSA/TBST (0.1% 
Tween 20 (Applichem, Leicestershire, UK) in TBS) for 1 hour with gentle rocking. 
The membrane was inserted into a 50ml centrifuge tube containing 7mls of primary 
antibody (diluted in 3% BSA/TBST) and incubated overnight at 4
o
C on a roller 
mixer. The membrane was then washed in TBST three times for 15 minutes each 
time, after which the membrane was placed in a fresh 50ml centrifuge tube 
containing 7mls of secondary antibody (anti-rabbit/mouse IgG HRP, 1:1000; Dako, 
Cambridgeshire, UK) and incubated for 1 hour at room temperature on a roller 
mixer. The membrane was washed 3 times (15 minutes each) in TBST and the 
protein was visualised by developing in ECL detection (GE Healthcare, 
Hertfordshire, UK) reagent.      
3.2.6 Immunofluorescence (IF) 
 
Glass coverslips measuring 13mm in diameter were placed in a 24-well plate and 
MDA-MB-468 cells were seeded at a density of 30000 cells per well and incubated 
for 36 hours at 37
o
C/8% CO2. Cells were rinsed in warm PBS before fixing in ice-
cold methanol for 5 minutes. After rinsing in PBS, the cells were blocked and 
permeabilised in 0.1% Triton 100X (Alfa Aesar, Lancashire, UK)/2% BSA/ PBS for 
15 minutes. The primary antibody (CVD13) was diluted 1:100 in 2% BSA/PBS and 
a 23µl droplet per cover-slip was placed onto parafilm. The cover-slips were 
retrieved from the 24-well plate and placed ‘cell side down’ on the droplet for 20 
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minutes at room temperature. The coverslips were washed 3 times in PBS and 
incubated with the secondary antibody diluted in 2% BSA/PBS at 1:200 (donkey 
anti-rabbit Alexa 488 (Invitrogen, Paisley, UK)) on parafilm for 20 minutes at room 
temperature. The coverslips were rinsed 3 times in PBS and once in distilled water 
before mounting on glass slides in DAPI Prolong Gold anti-fade reagent 
(Invitrogen). The mounting media was then allowed to polymerise overnight at 37
o
C 
before visualising under fluorescence microscopy. 
3.2.7 Statistical analysis 
 
For the breast tissue samples, correlative statistics were performed using Spearman’s 
correlation coefficient (IBM SPSS Statistics 19).  
The Student’s t-test was used to compare c-Met expression in renal tumour cells and 
tumour-associated blood vessels in the pre and post-treatment RCC groups. 
Statistical analysis on the renal tissue samples was performed by KS using Prism 5.  
A p-value <0.05 was regarded as significant in all statistical analyses.    
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3.3 Results 
 
Of the four commercially available c-Met antibodies tested (Table 3.1), only the 
CVD13 and 8F11 antibodies showed clean and reproducible tumour staining, with 
minimal background reactivity. The staining pattern was predominantly cytoplasmic 
but also membranous.  
3.3.1 Correlation between CVD13 and 8F11 – breast tissue samples 
 
There was a positive correlation between CVD13 and 8F11 IHC scores on pre-
constructed ‘in-house’ TMA sections, comprising 181 samples (Spearman’s 
coefficient = 0.294, p = 0.002). However, in several tumours reactivity for the 
antibodies was notably different (Figure 3.2). 
An inverse correlation was seen when 8F11 FFPE scores on whole sections were 
compared with frozen sections from the same tumour (Figure 3.3), stained with 
either 8F11 or CVD13, although this wasn’t statistically significant (Table 3.2, p > 
0.05). In contrast, CVD13 FFPE scores showed a positive relationship with CVD13 
or 8F11 frozen section scores (Table 3.2, p > 0.05), suggesting sub-optimal antigen 
retrieval for the 8F11 antibody.      
 
 
Table 3.2: Correlation between anti-c-Met antibodies on FFPE and frozen sections. 
Spearman’s correlation coefficients between FFPE and frozen sections using CVD13 
anti-c-Met and 8F11 anti-c-Met antibodies (all p-values > 0.05). Abbreviations: 
FFPE = formalin-fixed, paraffin-embedded, n/a = not applicable.  
 
 
Antibody Processing method Correl. with CVD13 (FFPE) Correl. with 8F11 (FFPE) 
CVD13 FFPE n/a -0.194
CVD13 Frozen 0.146 -0.346
8F11 FFPE -0.194 n/a
8F11 Frozen 0.463 -0.418
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C                                                          D 
 
 
 
 
 
 
Figure 3.2: Variation in staining intensity of anti-c-Met antibodies. Photographs A 
and B are from the same tumour, stained with the mouse monoclonal antibody 8F11 
and rabbit polyclonal antibody CVD13 respectively. Photographs C and D are of a 
different tumour, stained with 8F11 and CVD13 respectively. All photographs were 
taken with a x40 objective lens (scale bar = 10µm).  
 
 
 
 
 
 
 
 
B 
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Figure 3.3: Anti-c-Met antibodies on FFPE and frozen sections. All photographs are 
of the same tumour. A and B are FFPE sections stained with 8F11 and CVD13 
respectively, C and D are of frozen sections stained with 8F11 and CVD13 
respectively. C-Met staining is considerably more intense in the 8F11 stained FFPE 
section compared with the other sections. All photographs were taken with a x40 
objective lens (scale bar = 10µm).  
 
 
 
 
 
 
 
B 
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3.3.2 Specificity of CVD13 – breast cancer cell line 
 
Knock-down of c-Met resulted in a reduction in intensity of the band detected by 
CVD13 at western blot (Figure 3.4A) and a loss of membranous staining at 
immunofluorescence (Figure 3.4B and C), suggesting this antibody was specific for 
c-Met.  
3.3.3 CVD13 in RCC – renal tissue samples 
 
C-Met was expressed in tumour cells and endothelial cells (Figure 3.5). C-Met 
scores in pre-treatment renal tumour cells (mean score = 80.5, 95% CI = 0-210.5) 
were not statistically different from those in the post-treatment group (mean score = 
77.5, 95% CI = 0-3.1, p > 0.05, Figure 3.6A). There were significantly more c-Met 
positive tumour-associated blood vessels in the post-treatment group (percentage of 
positive vessels = 1.9, 95% CI = 0-9.0) compared to the pre-treatment group 
(percentage of positive vessels = 0.4, 95% CI = 0-3.1, p = 0.04, Figure 3.6B). 
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B                                                          C 
 
 
 
 
 
 
 
Figure 3.4: C-Met knock-down in MDA-MB-468 cells. A shows a western blot with 
partial loss of c-Met when the membrane is probed with CVD13 at 2,3 and 4 days 
following siRNA knock-down (lanes are in duplicate). C-Met is seen here in both the 
precursor (p170 kDa) and mature forms (m145 kDa). HSC70 is the loading control. 
Abbreviations: KD = knock-down. B shows MDA-MB-468 cells stained with 
CVD13 (in green), showing a predominantly membranous pattern (see arrows). C 
shows CVD13 staining in the same cells following siRNA knock-down, with absent 
membrane staining (immunofluorescence; confocal microscope, x63 objective under 
oil immersion; scale bars represent 20µm).    
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Figure 3.5: C-Met staining in renal tissue samples. IHC showing positivity for c-
Met (CVD13) in pre and post-sunitinib tumour cells (A and B respectively, see 
arrows). IHC for CD31 in C and c-Met (CVD13) in D, showing c-Met negative 
vessels (see arrows) in a pre-sunitinib sample. IHC for CD31 in E and c-Met 
(CVD13) in F, showing a c-Met positive vessel in a post-sunitinib sample. A-D 
taken using a x40 objective, E and F taken with a x20 objective. All scale bars = 
10µm.  
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Figure 3.6: Quantification of c-Met expression in renal tissue. The scatter-plots 
show tumour cell c-Met scores (A) and percentage of vessels expressing c-Met 
(CVD13) (B) before and after treatment with a VEGFR inhibitor. Horizontal bars 
represent mean values. *: p=0.04. 
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3.4 Discussion 
 
3.4.1 Selection of the primary anti-c-Met antibody: CVD13 
 
The results of this validation study suggest the rabbit polyclonal antibody CVD13 is 
a reproducible and specific anti-c-Met antibody. Firstly, the staining pattern of 
CVD13 on FFPE (and frozen) sections of breast cancers – cytoplasmic and 
membranous decoration of tumour cells – is consistent with published studies that 
have evaluated c-Met expression using IHC on similar samples (Ghoussoub et al, 
1998; Kang et al, 2003; Lengyel et al, 2005, Lindemann et al, 2007). Secondly, the 
positive correlation between CVD13 scores on FFPE and frozen sections indicates 
that the epitope recognised by CVD13 can be effectively retrieved in processed 
tissue using heat-induced antigen retrieval. Lastly, using si-RNA technology, knock-
down of c-Met resulted in the loss of membrane staining and a less intense band 
when incubated with CVD13 at immunofluorescence and western blotting 
respectively. 
The lack of a strong correlation between CVD13 and the 8F11 antibody on TMA 
sections was not entirely surprising as others have commented on the poor agreement 
between different c-Met antibodies (Pozner-Moulis et al, 2007). In a study looking at 
five antibodies directed against the intracellular domain of c-Met (including 
CVD13), Pozner-Moulis et al found that only two showed a good correlation 
(MAB3729 from Chemicon and C28 from Santa Cruz)(Pozner-Moulis et al, 2007). 
Whilst tumour heterogeneity for c-Met may in part explain this finding (Pozner-
Moulis et al, 2007), other technical reasons may be responsible (Kang et al, 2003; 
Tolgay Ocal et al, 2003; Pozner-Moulis et al, 2007). Lot-to-lot variation has been 
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recognised by many workers, particularly with some polyclonal antibodies (Tolgay 
Ocal et al, 2003), but also with monoclonal ones, where staining the same spot of a 
tumour with different lots of the mouse monoclonal antibody 3D4 resulted in 
markedly different staining patterns (Pozner-Moulis et al, 2007). The binding 
characteristics of the antibody also seem to be a key consideration. In a study 
utilising antibodies raised against both the intracellular and extracellular regions of 
the c-Met receptor, Kang and co-workers found overall correlation but noted 
expression was dissimilar in many cases (Kang et al, 2003). Furthermore, they found 
that expression of the cytoplasmic tail and not the N-terminus had prognostic power 
at statistical analysis (Kang et al, 2003). This observation may in part explain the 
positive but not strong, correlation between 8F11 (which binds to the extracellular 
portion) and CVD13 (which recognises the cytoplasmic tail) in the TMA based 
component of this validation study and supports the decision to select CVD13 for 
further analysis.  
3.4.2 CVD13 expression in renal cell carcinoma  
 
Using renal tissue samples before and after patient treatment with the anti-VEGFR 
therapies sunitinib and pazopanib, it was possible to validate further the use of 
CVD13 in FFPE tissue. In this analysis, no difference was found between tumour 
cell c-Met expression before and after treatment, but there was a significant increase 
in c-Met positive tumour-associated blood vessels in post-treatment samples (Sharpe 
et al, 2013).  
Others have looked at the effect of anti-VEGFR therapy on c-Met expression in 
tumour models (Sennino et al, 2012; Sennino et al, 2013; Cooke et al, 2012). In 
mouse models of pancreatic neuroendocrine tumours, treatment with sunitinib results 
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in increased tumour invasiveness and number of metastatic deposits (Sennino et al, 
2012; Sennino et al, 2013). While these workers did identify vascular expression of 
c-Met after sunitinib treatment, it was only in the tumour cell compartment that 
higher levels of c-Met were identified (Sennino et al, 2012; Sennino et al, 2013). 
While the findings of this and the previous studies do differ, both would be 
consistent with the theory that targeting the endothelial/pericyte compartment with 
sunitinib results in vascular permeability leading to increased stromal pressure, 
reduced blood flow and hypoxia, and ultimately, induction of c-Met expression 
(Cooke et al, 2012). 
3.4.3 Conclusion 
 
In conclusion, CVD13 is a reproducible and specific anti-c-Met antibody. The 
staining characteristics of CVD13 on FFPE tissue from different organs are 
consistent with the published literature and taken together, these results validate this 
clone for use on the study cohort of breast cancer samples. 
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4.0 Validation of the Methods: Proximity Ligation Assay   
 
4.1 Introduction 
 
While phospho-specific antibodies may be used to assess receptor phosphorylation 
in fresh frozen samples using techniques such as western blotting, attempts to use 
these antibodies on FFPE samples have generally proven unreliable (Blokzijl et al, 
2010; Koos et al, 2009; Dua et al, 2011). The use of phospho-specific antibodies in 
IF and IHC is limited by poor sensitivity and specificity, often resulting in difficulty 
identifying the protein (Jarvius et al, 2007; Blokzijl et al, 2010; Dua et al, 2011). 
Hence, there is a need to develop alternative, more reliable methods for quantifying 
receptor phosphorylation. 
The proximity ligation assay (PLA) is a relatively novel assay that allows specific 
and sensitive detection of proteins, protein-protein interactions and post-translational 
modifications (including phosphorylation) in cells and tissues, with single molecule 
resolution (reviewed in Weibrecht et al, 2010). The PLA relies on the detection of a 
dual recognition event when both target molecules are in close proximity. Briefly, 
two primary antibodies raised in different species bind to their targets. Secondary 
antibodies with attached oligonucleotides (known as proximity probes) then bind to 
the primary antibodies. More oligonucleotides are then added, which are ligated into 
a circular DNA strand, creating a template for subsequent rolling circle amplification 
(RCA), forming 1000s of rolling circle products (RCPs) that can be visualised under 
fluorescence microscopy following the addition of fluorescently-labelled 
oligonucleotides (Figure 4.1).  
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Figure 4.1: Diagram of the proximity ligation assay (PLA). In the first step (A) the 
primary antibodies (in red and blue), raised in different species, bind to their 
respective epitopes. In the second step (B), the species-specific secondary antibodies 
(proximity probes; in green) bind to the primary antibodies. These proximity probes 
are conjugated to an oligonucleotide chain that forms a closed circle of DNA when 
ligase is added, if the proximity probes are close together (C). In the final, rolling 
circle amplification (RCA) step, polymerase catalyses the amplification of the DNA 
template 1000s of times (D). This rolling circle product (RCP) can then be visualised 
under fluorescence microscopy after the addition of fluorescently-labelled 
oligonucleotides (seen as a red circle) that are complementary to part of the 
amplified DNA (reviewed in Weibrecht et al, 2010).    
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The PLA resembles another technique used to analyse protein interactions and post-
translational modifications - Förster resonance energy transfer (FRET). FRET 
harnesses the energy transfer between two adjacent fluorophores acting as split 
reporter molecules: the donor (which has an emission spectrum with a longer 
wavelength than its excitation spectrum) and the acceptor (which has an excitation 
spectrum that overlaps with the emission spectrum of the donor (Weibrecht et al, 
2010). Detection of the acceptor emission spectrum (following donor excitation) at 
fluorescence microscopy indicates that the target proteins are in close proximity 
(usually 5-10nm) (Weibrecht et al, 2010). Unlike the PLA, FRET is hampered by 
photobleaching, high background autofluorescence (particularly in FFPE samples) 
and inadvertent simultaneous excitation of both the acceptor and donor fluorophores 
(Weibrecht et al, 2010).      
The PLA also has key advantages over conventional IHC and IF: 1) the requirement 
of dual binding makes the technique more specific, 2) the presence of an RCA step 
enhances sensitivity and 3) the fluorescent RCP allows for automated quantification 
and is easily distinguished from autofluorescence (Blokzijl et al, 2010). 
Before applying the PLA to the study cohort of patient samples, it is essential to first 
carry out a series of control experiments to validate the method and its key 
components. In particular, the antibodies used in the assay (both the primary 
antibodies and secondary proximity probes) should bind properly to the intended 
target (Leuchowius et al, 2011) and the method should be compatible with FFPE 
samples.  
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Since my intention was to use the CVD13 antibody to detect phosphorylated c-Met 
(in combination with the pan-phosphotyrosine antibody 4G10), the first aim of this 
validation study was to confirm that c-Met phosphorylation does not hinder the 
ability of CVD13 to bind the receptor. The other aims of this study were: to 
demonstrate the PLA signal using the CVD13/4G10 combination in fixed cells of 
known phosphorylation status and to evaluate the specificity of the proximity probes 
and PLA signal in FFPE samples. The effect of sample fixation and embedding on 
the PLA product will also be assessed.  
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4.2 Materials and Methods 
4.2.1 Tissue culture 
 
MDA-MB-468 cells were propagated, sub-cultured and preserved as in section 3.2.4. 
4.2.2 Tissue samples 
4.2.2.1 FFPE samples 
 
FFPE invasive breast carcinomas were retrieved from the Barts Cancer Institute 
Breast Tissue Bank for validation of the PLA. Whole tumour blocks from 25 patients 
with triple negative (TN) breast cancer were selected and placed onto a tissue 
microarray.  
4.2.2.2 Frozen samples 
 
Frozen samples, paired with selected cases in section 4.2.2.1 were retrieved from the 
Barts Cancer Institute Breast Tissue Bank. The criteria for selecting the cases are 
outlined in section 4.2.8. 
4.2.3 Tissue microarray (TMA) construction 
 
Sections were cut at 4µm thickness on each tumour block, placed onto a glass slide 
and stained with haematoxylin and eosin by George Elia (senior research technician). 
I then examined the slides and at least 2 regions of invasive carcinoma were 
highlighted. The highlighted slides were then placed over the paraffin block and the 
corresponding area was marked on the block. ‘Doner’ cores, 1mm in diameter were 
removed from the tumour block and placed into a new ‘recipient’ paraffin block, 
using Alphelys TMA machine and Minicore software package (Alphelys, Plaisir, 
France). Cores were placed in duplicate or triplicate depending on the volume of 
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tumour present within the block. Control cores (human spleen) were placed in 
triplicate at the start of the ‘recipient’ TMA block for orientation. Upon completion, 
4µm sections were cut from the TMA and placed onto glass slides (performed by 
George Elia). 
 4.2.4 Antibodies 
 
See Table 4.1 for details of the primary antibodies used in this study. 
 
 
 
 
Table 4.1: Primary antibodies used in the validation of the PLA. Abbreviations: Dil. 
= dilution, IF = immunofluorescence, IHC = immunohistochemistry, PLA = 
proximity ligation assay, WB = western blot, N/A = not applicable.  
4.2.5 Immunoprecipitation 
 
MDA-MB-468 cells were seeded in 10cm culture plates at a density of 1.8 million 
cells per plate. The cells were left for 36 hours to adhere and treated with SU11274 
(2µM; Calbiochem, Millipore, Nottingham, UK) for 10 minutes at 37
o
C followed by 
HGF (100ng/ml; R&D systems, Abingdon, UK) for 20 minutes at 37
o
C where 
appropriate. The plates were aspirated, washed in cold PBS and then cold RIPA 
buffer was added, containing protease and phosphate inhibitors (Calbiochem) at a 
dilution of 1:100. The plates were scraped and aspirated after which the aspirates 
were transferred into fresh eppendorfs and incubated on ice for 15 minutes. The 
eppendorfs were then placed on a rotating wheel (30rpm) for a further 15 minutes at 
Antibody Target Supplier Species Dil. (IF/IHC) Dil. (PLA) Dil. (WB)
CVD13 c-Met Invitrogen Rabbit 1:100 1:500 1:500
D24 Phospho-c-Met Cell Signalling Rabbit N/A N/A 1:1000
4G10 Phospho-tyrosine Millipore Mouse 1:100 1:500 N/A
24E10 E-Cadherin Cell Signalling Rabbit 1:100 1:100 N/A
NCH38 E-Cadherin Dako Mouse 1:100 1:100 N/A
MIB-1 Ki67 Dako Mouse 1:100 1:100 N/A
B-6 HSC70 Santa Cruz Mouse N/A N/A 1:10000
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4
o
C. The lysates were centrifuged at 10000rpm for 5 minutes and the supernatant 
transferred into a fresh eppendorf.  
Protein A sepharose beads (Invitrogen) and, for the positive control Agarose anti-
mouse IgG beads (Sigma-Aldrich) were prepared by centrifuging 400µl and 200µl 
respectively at 5000rpm for 1 minute at 4
o
C and then washing 3 times in 500µl of 
cold PBS. The lysate was pre-cleared by mixing 60µl of beads with 600µl of each 
lysate and incubating for 1 hour on a rotating wheel at 4
o
C. The lysate/bead mixture 
was centrifuged at 5000rpm for 2 minutes at 4
o
C; the supernatant was retrieved and a 
Bio-Rad DC Protein Assay was performed to estimate the post-clearing protein 
concentration. 
The beads were blocked by mixing 20µl per sample of beads with 500µl 3% 
BSA/PBS in a fresh eppendorf and then rotating for 1 hour at 4
o
C. At the same time, 
150µg of protein from each sample was incubated with 3µg of c-Met antibody on a 
rotating wheel for 1 hour at 4
o
C. The beads were centrifuged at 5000rpm for 2 
minutes, washed in cold RIPA buffer 3 times, mixed with the lysate/antibody 
solution and rotated for 1 hour at 4
o
C. After incubation, the eppendorfs were 
centrifuged and washed in cold RIPA buffer 3 times before re-suspending the beads 
in 4X sample buffer and heating to 98
o
C for 5 minutes. The entire sample (except the 
beads) was loaded into a 6% gel and a western blot was performed. The membrane 
was probed for phospho-c-Met (D26) and c-Met (CVD13). A lane containing beads, 
lysate and IgG served as a negative control.  
4.2.6 Western blot 
 
Western blotting was performed as outlined in section 3.2.5. 
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4.2.7 Immunofluorescence 
 
Immunofluorescence (IF) on glass cover-slips was performed as outlined in section 
3.2.6. Where appropriate, cells were treated with SU11274 (2µM for 10 minutes at 
37
o
C) and HGF (100ng/ml for 20 minutes at 37
o
C) 36 hours after seeding. 
4.2.8 Immunohistochemistry 
 
Immunohistochemistry (IHC) for E-Cadherin (24E10, NCH-38) and Ki67 (MIB-1) 
was performed on the TN TMAs as outlined in section 3.2.3. Stained sections were 
evaluated for expression of E-Cadherin and Ki67 and cases that showed strong 
expression of all three antibodies were selected for the PLA and paired with the 
corresponding frozen sections.     
4.2.9 Proximity ligation assay (PLA) 
 
4.2.9.1 Chamber slide preparation 
 
Chamber slides (Fisher Scientific) were prepared by seeding 20000 MDA-MB-468 
cells per well and allowing them to adhere for 36 hours. The chambers were treated 
with SU11274 (2µM for 10 minutes at 37
o
C) and HGF (100ng/ml for 20 minutes at 
37
o
C) as appropriate before rinsing in PBS and then fixing in ice-cold methanol for 5 
minutes. The wells rinsed again in PBS before removing the polystyrene walls. The 
slides were then used in the PLA or dried and stored at -20
o
C for later use. 
4.2.9.2 PLA 
 
The following method applies to the chamber slides, FFPE TMAs and frozen 
sections. TMAs were first de-waxed, hydrated through graded alcohols and subjected 
to heat-induced epitope retrieval as in section 3.2.3 (Immunohistochemistry). The 
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frozen sections were prepared as in section 3.2.3 with the exclusion of the 
endogenous peroxidase block. All incubation steps were conducted in a moisture 
chamber to prevent drying of the cells/tissue sections. The reagent quantities are 
based on a 30ul reaction volume (equivalent of about 1cm
2
). The slides were blocked 
with blocking solution (Olink Biosciences, Uppsala, Sweden) for 30 minutes at room 
temperature. Primary antibodies (CVD13, 4G10) were diluted at 1:500 or 1:100 
(24E10, NCH-38, MIB-1) in antibody diluents (Olink Biosciences) and incubated for 
1 hour at room temperature. The proximity probes (anti-mouse and anti-rabbit; Olink 
Biosciences) were prepared about 20 minutes before the end of the primary antibody 
incubation step: proximity probes were diluted in antibody diluents at a ratio of 1:5, 
vortexed and left to stand at room temperature. The slides were tapped on tissue 
paper to remove the reagents and washed in buffer A (0.01M tris, 0.15M NaCl, 
0.05% Tween 20) twice for 5 minutes each, with gentle agitation. The proximity 
probes were incubated for 1 hour at 37
o
C.  
The slides were tapped on tissue paper and washed for 5 minutes, twice, in buffer A 
with agitation. The ligation mixture was prepared by diluting the ligation stock 1:5 in 
distilled water. Immediately prior to adding the ligation mixture (Olink Biosciences) 
to the samples, ligase (Olink Biosciences) was added at a dilution of 1:40. The 
ligation mixture was incubated for 30 minutes at 37
o
C.  
The slides were washed twice in buffer A for 5 minutes each. During this time, the 
amplification and detection mixture was prepared by diluting the amplification stock 
(1:5; Olink Biosciences) in distilled water and adding polymerase (1:80; Olink 
Biosciences) just before adding to the samples. The amplification/detection mixture 
was incubated for 100 minutes at 37
o
C. The slides were then washed twice in buffer 
B (0.2M tris, 0.1M NaCl) for 10 minutes each and once in 0.01X buffer B for 1 
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minute. The slides were then left to dry in darkness before mounting in the PLA 
mounting media (Olink Biosciences) and stored at 4
o
C until visualisation under 
fluorescent microscopy. Negative controls consisted of MDA-MB-468 cells/breast 
cancers with omission of the primary antibodies.   
4.2.9.3 Quantification of the PLA product 
 
For each sample, at least 4 images were captured on an Axioplan epifluorescent 
microscope using a 63x objective under oil immersion. As PLA signals are identified 
at different planes of focus in the samples, consistency was obtained by selecting the 
plane that contained the most abundant signal. For each image, the nuclei were 
counted by eye, using the ImageJ software package and cell counter plug-in. The 
PLA product was quantified using the Duolink ImageTool (Olink Biosciences). The 
mean number of PLA signals per cell was then calculated by dividing the PLA 
product by the number of nuclei.    
4.2.10 Statistical analysis 
 
All statistical analyses were performed using SPSS 19.0. For comparisons of 
variance across multiple groups, the Kruskal Wallis test was performed. Subsequent 
post-hoc analyses were performed using the Mann-Whitney test. For paired cases, 
the Wilcoxon test was used. A two-sided p-value of less than 0.05 was considered 
significant; where multiple groups were present the p-value cut-off was lowered by 
dividing 0.05 by the number of comparisons (e.g for 4 groups there are 6 
comparisons so a p-value of 0.008 (0.05/6) was considered significant).  
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4.3 Results 
 
4.3.1 CVD13 binds to active (phosphorylated) c-Met 
 
To confirm that CVD13 binds to active c-Met, immunofluorescence (IF) was 
performed on MDA-MB-468 cells subjected to different treatment conditions: un-
stimulated cells, cell stimulated with HGF for 20 minutes, cells treated with 
SU11274 and cells treated with both HGF and SU11274. Trafficking of the receptor 
from a membranous location to the perinuclear compartment (Figure 4.2) was noted 
in the HGF stimulated cells only, suggesting that CVD13 recognises active c-Met.  
The IF findings were confirmed at immunoprecipitation (Figure 4.3). After MDA-
MB-468 cell lysates were immunoprecipitated with CVD13, subsequent western 
blotting with a phospho-c-Met antibody, resulted in a band in the immunoprecipitate 
from HGF stimulated cells but not the un-stimulated cells. 
4.3.2 PLA signals in breast cancer cells 
 
To establish if the PLA could be used as a measure of c-Met activity, the assay was 
performed (using the CVD13/4G10 primary antibody combination) on MDA-MB-
468 cells subjected to different treatment conditions. Under fluorescence 
microscopy, higher levels of the PLA product (sub-micrometer sized red fluorescent 
dots) were seen in the HGF stimulated cells (Figure 4.4).  
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Figure 4.2: C-Met trafficking in MDA-MB-468 cells following HGF-stimulation. A 
shows un-stimulated cells with a membranous (see arrows) and cytoplasmic staining 
pattern, B shows perinuclear accumulation (see arrows) of c-Met following 
stimulation with HGF. In C and D the membrane (see arrows) expression is present 
in SU and SU/HGF treated cells respectively (CVD13 is in green, nuclei are stained 
blue; immunofluorescence, confocal microscope with x63 objective under oil 
immersion; scale bars represent 20µm).   
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Figure 4.3: Immunoprecipitation (IP) of c-Met. The upper left panel shows a strong 
band in the HGF-stimulated sample for phospho-Met (D24), suggesting CVD13 
binds to active c-Met. The middle left panel confirms the successful 
immunoprecipitation of c-Met with the CVD13 antibody. The lower left panel shows 
the loading control (HSC70). Rabbit IgG (IgG(r)) served as a negative control. 
Another anti-c-Met antibody known to bind phosphorylated c-Met (25H2) was 
included as a positive control and since this is a mouse antibody, a mouse IgG 
control was also included. The right panels represent the lysate.  
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Figure 4.4: The PLA signals in breast cancer cells. Confocal microscope images of 
MDA-MB-468 cells that are A untreated, B treated with HGF, C treated with SU 
and D treated with HGF and SU. E is the negative control. The PLA product is 
markedly increased image B only (PLA, nuclei are stained with DAPI (blue) and the 
PLA product is in red; all images captured with a x63 objective; inset images are at 
200% magnification, scale bars represent 20µm). 
E 
C D 
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The mean number of PLA signals per nucleus showed significant variation across all 
treatment groups (Figure 4.5, p < 0.001). Mean signals were significantly higher in 
HGF stimulated cells (17.8, 95% confidence interval (CI): 16.0-19.6) compared to 
un-stimulated cells (8.8, 95% CI: 7.6-10.1; p < 0.001), SU treated cells (7.2, 95% CI: 
5.3-9.1; p < 0.001) and SU/HGF treated cells (7.8, 95% CI: 6.2-9.4; p < 0.001). 
There were no significant differences between the other groups. 
4.3.3 PLA signals in FFPE samples 
 
Since FFPE samples of known c-Met phosphorylation status were not available, the 
PLA was validated on FFPE samples, by performing the assay on serial sections 
using 2 different combinations of primary antibodies. The purpose of this experiment 
was to show a difference in PLA signal when antibodies against close epitopes (2 
different E-Cadherin antibodies) were used, compared with antibodies directed 
against distant epitopes (E-Cadherin and Ki67). The presence of more signals in the 
former would suggest that the proximity probes were specific for the primary 
antibodies and that the signal depended on the proximity of the epitopes (Figure 4.6).  
The mean number of PLA signals per nucleus was higher in the E-Cadherin/E-
Cadherin (24E10/NCH38) combination compared to the E-Cadherin/Ki67 
(24E10/MIB1) combination in all of the 4 cases tested, although this was of 
borderline significance (Figure 4.7; p = 0.068; n = 4). 
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Figure 4.5: C-Met phosphorylation status in breast cancer cells and quantification of 
the PLA signals. A is a Western blot showing phospho-c-Met (P-Met) and c-Met 
expression in MDA-MB-468 cells. Phospho-c-Met is only seen in HGF stimulated 
cells, in the absence of SU. Loading control: HSC70. B is a bar chart showing the 
mean PLA signals per nucleus in the 4 treatment groups. There is a significant 
increase in the HGF-treated cells compared to the other groups (** = p-value <0.001, 
Mann-Whitney test; error bars represent the 95% confidence interval; n=8). 
 
HGF                               -             +          -             + 
SU                                  -             -           +            + 
P-Met 
145 kDa 
C-Met 
145 kDa 
HSC70 
70 kDa 
170 kDa 
 145 kDa 
130 kDa 
70 kDa 
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Figure 4.6: The PLA in FFPE samples. All images are from the same tumour. A-C are brightfield images of A E-Cadherin (24E10) showing 
membrane staining (see arrows), B E-Cadherin (NCH38) also with membrane staining (see arrows) and C Ki67 (MIB1) with nuclear positivity 
(IHC, images acquired with a x20 objective; scale bars represent 10µm). D-E are confocal fluorescent images of D the 24E10/NCH38 
combination showing more PLA signal compared to the 24E10/Ki67 combination in E; F is the negative control (PLA, nuclei are stained with 
DAPI (blue) and the PLA product is in red; images acquired with a x63 objective; scale bars represent 10µm). 
A B C 
D E F 
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Figure 4.7: Mean PLA signals per nucleus in FFPE sections using E-Cadherin/Ki67 
antibodies. In each of the 4 cases, incubation with 2 primary E-Cadherin antibodies 
(24E10 and NCH38) produced more signals than incubation with primary antibodies 
against Ki67 (MIB1) and E-Cadherin (24E10), although this was of borderline 
significance (p=0.068, Wilcoxon test; n=4).   
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4.3.4 PLA signal in frozen versus FFPE samples 
 
To establish if the processes of fixation and embedding of breast tumour samples 
affects detectable c-Met phosphorylation using the PLA, the assay was performed on 
paired frozen and FFPE samples with the CVD13/4G10 combination of primary 
antibodies.  
The mean number of PLA signals per nucleus was higher in each of the frozen 
samples compared to FFPE samples, although this was of borderline significance 
(Figure 4.8; p = 0.068; n = 4). 
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Figure 4.8: Mean PLA signals per nucleus in matched frozen and FFPE samples. In 
each of the four cases, more signals are seen in the frozen sections, although this was 
of borderline significance (p=0.068, Wilcoxon test; n=4).   
 
 
  
117 
 
4.4 Discussion 
4.4.1 CVD13 recognises active c-Met 
 
In section 3.0, CVD13 was shown to be specific for the c-Met receptor. The current 
results show that the antibody still recognises the receptor after it has been activated: 
phospho-c-Met is detected following IP of c-Met in cells stimulated with HGF and 
immunofluorescent studies demonstrate trafficking of c-Met to the perinuclear 
compartment in HGF stimulated cells only. This finding demonstrated that the 
phosphorylation of c-Met did not impede CVD13 from binding to the receptor, thus 
the antibody was suitable for use in the PLA.  
The trans-cytosolic movement of c-Met following HGF-mediated activation has 
previously been demonstrated in HeLa cells (Kermorgant et al, 2003 and 2004). In 
resting (unstimulated) HeLa cells, c-Met is mostly expressed at the plasma 
membrane, with only scattered perinuclear positivity (Kermorgant et al, 2003). Upon 
incubation with HGF, the receptor is internalised and enclosed within cytosolic 
endosomes and traffics to the perinuclear compartment in a process that is regulated 
by protein kinase C (PKC) and facilitated by the microtubular network (Kermorgant 
et al, 2003). The resultant pattern of predominantly perinuclear vesicular positivity 
for c-Met, with minimal membranous expression contrasts with the pattern seen in 
the resting state (Kermorgant et al, 2003). This trafficking of c-Met within 
endosomes has subsequently been shown to be important in c-Met-induced 
migration, tumourigenesis and metastatsis (Kermorgant et al, 2004 and 2008; Joffre 
et al, 2011). 
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4.4.2 The PLA signal is increased in HGF-stimulated breast cancer cells 
 
Stimulation of MDA-MB-468 cells with HGF resulted in a significantly higher PLA 
signal compared to unstimulated cells or cells treated with the c-Met kinase-specific 
inhibitor SU11274 or combined HGF/SU11274 treatment. This result is corroborated 
by the findings at IF (showing receptor trafficking) and western blot (showing a band 
when probed with a phospho-c-Met antibody) in ligand-stimulated cells only. 
Importantly, this result supports the use of the CVD13/4G10 combination of primary 
antibodies in the PLA and demonstrates for the first time that this assay can be used 
for the relative quantification of c-Met activity. Others have conducted similar 
experiments to evaluate the PLA – most notably in assessing platelet-derived growth 
factor receptor (PDGFR) signalling (Jarvius et al, 2007; Koos et al, 2009). Using 
both human embryonic kidney 293 (HEK293) and choroid plexus epithelial cell 
lines, these workers visualised the RCPs of the PLA as sub-micrometer sized 
fluorescent objects (Jarvius et al, 2007; Koos et al, 2009), similar to those seen in the 
current study. As in the current study, cellular stimulation with the appropriate ligand 
(platelet-derived growth factor) generated increased PLA signals (Jarvius et al, 2007; 
Koos et al, 2009).  
4.4.3 The PLA in FFPE samples 
 
In common with IHC, tissue fixation and embedding can have a profound effect on 
the PLA result (Söderberg et al, 2008; Leuchowius et al, 2011). Although others 
have successfully applied the PLA to FFPE samples (Jarvius et al, 2007; Koos et al, 
2009), it remains necessary to validate the technique (especially the antibodies) on 
samples similar to the study cohort. In section 3.0, the suitability of CVD13 for use 
on FFPE samples following HIER was demonstrated. The secondary antibodies 
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(proximity probes) also require attention: poorly conjugated proximity probes and 
non-specific binding by the probes may cause reduced PLA signals and high 
background signal respectively. Furthermore, the process of antibody conjugation (to 
produce the proximity probes) can also adversely affect the antibody by interfering 
with the binding site, thus hindering their ability to recognise the target epitopes 
(Leuchowius et al, 2011).  
Since FFPE samples of known c-Met phosphorylation status were not available, I 
took an alternative approach to validate the proximity probes. Instead of using pan-c-
Met and pan-phosphotyrosine antibodies, I used primary antibodies directed against 
different cellular compartments: the membranous compartment (E-Cadherin) and the 
nuclear compartment (Ki67) (Cheuk and Chan, 2004). By incubating FFPE breast 
cancer samples with an E-Cadherin/E-Cadherin and E-Cadherin/Ki67 primary 
antibody combination, I was able to demonstrate a higher PLA signal with the 
former. Although the differences were of borderline significance, the analysis was 
performed on only four pairs of cases and, importantly in all pairs, the PLA product 
was higher in the E-Cadherin/E-Cadherin combination. The findings suggest that in 
FFPE samples the proximity probes show specificity for the primary antibodies, and 
that it is the proximity of the target proteins that dictates that quantity of the PLA 
signals.    
4.4.4 The PLA in frozen versus FFPE samples 
 
Comparison of frozen and FFPE samples from the same cases showed that the 
majority of the PLA signal is lost due to fixation/embedding. As above, the small 
sample size perhaps explains the borderline significance, but again, in all pairs it was 
the frozen sections that showed the more numerous PLA products. This finding is 
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not entirely surprising. Söderberg et al estimate that the requirement of a dual 
recognition event in the PLA may reduce the epitopes available for detection to just 
9% in FFPE tissue, assuming that fixation reduces the available fraction of any given 
epitope to 30% (30% x 30% = 9%) (Söderberg et al, 2008). Therefore, the efficiency 
of the PLA in detecting c-Met phosphorylation in FFPE samples would seem to be 
no worse than expected. 
4.4.5 Conclusion 
 
In conclusion, the results of this validation study confirm that CVD13 can bind to c-
Met after it has been phosphorylated, a pre-requisite for its use in the PLA. In cells 
of known c-Met phosphorylation status, more signals were seen in cells stimulated 
with HGF compared with un-stimulated cells and in FFPE samples, the PLA output 
was dependent on the proximity of the target epitopes/primary antibodies. Finally, 
although the PLA would seem better suited to frozen sections there is no reason to 
suggest that relevant data cannot be obtained from FFPE samples. Together, these 
findings validate the PLA and the selected antibodies for the analysis of c-Met 
phosphorylation in the study cohort of breast cancer samples.    
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5.0 Breast cancer cell line characterisation 
 
5.1 Introduction 
 
Breast cancer cell lines (BCLs) have contributed significantly to our current 
knowledge of breast cancer through in-vitro and in-vivo studies (Charafe-Jauffret et 
al, 2006). BCLs have several attributes that make them ideal for modelling the 
pathogenesis of breast cancer: they represent a pure population of cancer cells 
without stromal cell contamination, they are easy to handle, self-replicate and can be 
manipulated both genetically and pharmacologically, the effects of which can be 
studied in an array of functional assays (Charafe-Jauffret et al, 2006; Kao et al, 
2009).  
With over 50 different BCLs now available, including those originating from 
primary breast cancers as well as metastatic effusions (Neve et al, 2006) they clearly 
represent a diverse resource. The landmark paper that demonstrated the molecular 
heterogeneity of human breast cancer samples at gene expression profiling included 
an analysis of selected BCLs, illustrating that these cells lines could be clustered into 
the luminal or BL molecular sub-types (Perou et al, 2000). Since then, several 
studies have extended the characterisation of these cell lines to include proteomic, 
transcriptomic, genomic and epigenomic profiling (Neve et al, 2006; Charafe-
Jauffret et al, 2006; Grigoriadis et al, 2012). Investigators are now in the position of 
being able to select those specific BCLs that most closely resemble the tumour type 
they are studying. 
The aim of this validation study was to characterise the protein expression of a panel 
of BCLs that are considered representative of the BL phenotype. The protein 
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expression profile of these BCLs will be compared with the literature to select the 
most appropriate models of HGF/c-Met signalling in BL breast cancer.      
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5.2 Materials and Methods 
 
5.2.1 Tissue culture 
 
The 3 cell lines already established in the laboratory were: MDA-MB-468s, MDA-
MB-231s and SUM159s. The other cell lines (HCC1937s, BT-20s, HCC38s and 
Hs578ts) were purchased from ATCC/LGC Standards (Middlesex, UK). The MDA-
MB-468s were cultured as described in section 3.2.4. MDA-MB-231s were cultured 
in DMEM, supplemented with 10% FCS. Hs578ts were cultured in DMEM 
supplemented with 10% FCS and 0.01 mg/ml bovine insulin. The HCC38s and 
HCC1937s were cultured in Roswell Park Memorial Institute (RPMI) media (PAA), 
supplemented with 10% FCS. The BT-20s were cultured in Eagle’s Minimal 
Essential Medium (MEM; PAA), supplemented with 10% FCS and the SUM159s 
were cultured in Ham’s F12 (PAA), supplemented with 10% FCS.  
The cell lines were propagated, sub-cultured and preserved as set out in section 
3.2.4. 
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5.2.2 Antibodies 
 
See Table 5.1 for details of the primary antibodies used in this study. 
 
 
 
 
Table 5.1: Primary antibodies utilised in this cell characterisation study. 
 
5.2.3 Western blot 
 
Western blots were performed as set out in section 3.2.5. 
 
 
 
 
 
 
 
 
 
 
Antibody Target Supplier Species Dilution
CVD13 C-Met Invitrogen Rabbit 1:500
1005 EGFR Santa Cruz Goat 1:1000
G20 ER Santa Cruz Mouse 1:200
M45 Her2 Cell Signalling Rabbit 1:1000
D5/16 B4 CK 5/6 Dako Mouse 1:500
36/E-Cadherin E-Cadherin BD Transduction Labs Mouse 1:1000
B6 HSC70 Santa Cruz Mouse 1:10000
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5.3 Results 
 
All of BL cell lines were negative for ER and Her2, but showed EGFR expression. 
C-Met was also present in all cell lines. CK5/6 and E-Cadherin were present in the 
HCC1937s, MDA-MB-468s, HCC38s and BT-20s only (Figure 5.1 and Table 5.2). 
 
 
 
 
Table 5.2: Protein expression of BL cell lines, as determined by western blot.  
 
 
 
 
 
 
 
 
 
 
Cell line ER Her2 EGFR C-Met E-Cadherin CK 5/6
HCC1937 - - + + + +
Hs578t - - + + - -
468 - - + + + +
231 - - + + - -
SUM159 - - + + - -
HCC38 - - + + + +
BT-20 - - + + + +
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  A                                                                                                                     
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
Figure 5.1: Protein expression by different BL BCLs. Representative western blots 
from 3 experiments, showing no bands for ER and Her2 in each of the BL cell lines 
(positive controls: T47D (ER) and BT-474 (Her2) in A. B shows BL cell line 
expression of the basal markers EGFR and CK5/6, together with c-Met (seen here in 
both the precursor (p170 kDa) and mature (m145 kDa) forms) and E-Cadherin. 
Loading control: HSC70. 
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5.4 Discussion 
 
5.4.1 BL marker expression in breast cancer cell lines (BCLs) 
 
All seven BCLs were found to be negative for ER and Her2 and (variably) positive 
for EGFR. CK 5/6 expression was limited to the HCC1937s, HCC38s, MDA-MB-
468s and the BT-20s. The findings with regard to ER, Her2 and EGFR expression 
were largely in line with those of other studies that have assessed these markers in 
protein based and/or gene expression assays (Neve et al, 2006; Charafe-Jauffret et al, 
2006; Kao et al, 2009; Lehmann et al, 2011; Grigoriadis et al, 2012). Admittedly, 
Charafe-Jauffret et al found no expression of CK5/6 in BT-20s and HCC1937s 
(Charafe-Jauffret et al, 2006), a finding that contrasts with the western blot bands in 
the current study. This discrepancy may be due to the different detection methods 
used in the two studies, with the previous study utilising IHC on cell pellet paraffin 
blocks (Charafe-Jauffret et al, 2006). 
Although all seven BCLs profiled here could be considered BL based on the IHC 
profile proposed by Nielsen et al (ER and Her2 negative, CK5/6 and/or EGFR 
positive) (Nielsen et al, 2004), several groups have attempted to further divide the 
BL/TN BCLs into at least two distinct groups (Neve et al, 2006; Kao et al, 2009; 
Lehmann et al, 2011; Grigoriadis et al, 2012). The first group, referred to here as BL 
(also known as ‘Basal A’ elsewhere) are characterised by over-expression of the 
keratin (KRT) 5, 14 and 17 genes (Neve et al, 2006; Grigoriadis et al, 2012). The 
second group, the so-called mesenchymal-like cells (known as ‘Basal B’ elsewhere) 
lack KRT 5 and 17 expression; instead there is vimentin (VIM), caveolin (CAV1) and 
VEGFR over-expression (Neve et al, 2006; Lehmann et al, 2011; Grigoriadis et al, 
2012). The broad consensus from these studies was that the MDA-MB-468s and 
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HCC1937s clustered into the BL group and the Hs578ts, SUM159s and MDA-MB-
231s fell into the mesenchymal-like category (there was some disagreement as to 
whether the HCC38s and BT-20s could be classified as BL)(Neve et al, 2006; 
Lehmann et al, 2011; Grigoriadis et al, 2012). The CK5/6 western blot findings of 
the current study would correlate well with the BL designation given to the MDA-
MB-468s and HCC1937s and also with the mesenchymal-like BCLs by virtue of 
their lack of CK5/6 expression. 
According to Kao et al, the BL BCL gene expression cluster more closely resembled 
the profile of BL tumour samples than the mesenchymal-like cluster (Kao et al, 
2009), suggesting that the MDA-MB-468s and HCC1937s are the most appropriate 
choices for modelling BL cancer. 
5.4.2 C-Met expression in BCLs 
 
C-Met was expressed in all of the BCLs profiled. This finding is partly supported by 
the work of Charafe-Jauffret et al, who found positivity for c-Met in the BT-20s, 
HCC38s and MDA-MB-231s. However, they found no c-Met reactivity in the 
HCC1937s or Hs578ts (Charafe-Jauffret et al, 2006). Again, as with CK5/6 
expression, this difference may be explained by the different techniques used by this 
study and the previous one. 
Gene expression studies have identified MET over-expression in BCLs with a BL 
profile (Lehmann et al, 2011) and BL or mesenchymal-like profile (Grigoriadis et al, 
2012). Thus, c-Met/MET over-expression appears to be a consistent finding in 
BL/mesenchymal-like BCLs. 
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5.4.3 E-Cadherin expression in BCLs 
 
The results for E-Cadherin expression mirrored those for CK5/6, with a band present 
in the HCC1937s, MDA-MB-468s, HCC38s and BT-20s. This result is in keeping 
with the western blot analysis performed by Neve et al, who demonstrated E-
Cadherin in the BT-20 and HCC38 cell lines but not in the Hs578ts or MDA-MB-
231s (western blots were not presented for the other cell lines profiled in the current 
study)(Neve et al, 2006). Elsewhere, in an IHC analysis of different BCLs, Chekhun 
and co-workers found high E-Cadherin expression in the MDA-MB-468s and low 
expression of the protein in MDA-MB-231s (Chekhun et al, 2013).  
The fact that the Hs578t, MDA-MB-231 and SUM159 lysates show no band 
following E-Cadherin probing, lends credence to their designation as mesenchymal-
like cell lines. In the study by Lehmann and colleagues, the mesenchymal-like BCLs 
were partly defined by the expression of epithelial-mesenchymal transition (EMT) 
associated genes, with increased TWIST1 and SNAI2 and reduced expression of the 
E-Cadherin gene CDH1 (Lehmann et al, 2011). 
The question of whether the mesenchymal-like cluster corresponds to a specific sub-
type of breast cancer is one that several workers have pondered (Kao et al, 2009; 
Prat et al, 2010; Lehmann et al, 2011). Previously, it had been suggested that 
mesenchymal-like cells relate to a rare tumour sub-type not yet characterised or a 
sub-population of progenitor/stem cells preferentially selected in tissue culture or 
even that the existence of these cells was simply tissue culture artefact (Kao et al, 
2009). The first of these possibilities may be partly true – the Hs578t cell line for 
example was derived from a metaplastic carcinoma, a special histological sub-type 
that accounts for just 1% of breast cancers (Hackett et al, 1977; Harris et al, 2006). 
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Others have observed that these cell lines are reminiscent of the recently described 
claudin-low sub-type (Prat et al, 2010). Prat and colleagues identified nine cell lines 
(including the Hs578ts, MDA-MB-231s and SUM159s) with a claudin-low profile: 
low expression of genes important in cellular adhesion (CDH1, CLDNs (Claudins) 3, 
4 and 7), luminal differentiation and an mRNA expression signature characteristic of 
tumour initiating cells (CD24 low/CD44 high)(Prat et al, 2010). Interestingly, the 
authors went on to propose that the intrinsic molecular sub-types mirror the 
developmental stages in of mammary epithelium, in which the claudin-low 
cells/tumours occupy the least differentiated end of the spectrum, followed by the 
BL tumours and ending with both luminal sub-types (Prat et al, 2010).   
5.4.4 Conclusion 
 
The results from this validation study, together with those of previous studies, 
suggest that the MDA-MB-468 and HCC1937 BCLs are the most relevant cell lines 
for modelling BL breast cancer. Since they both express c-Met, they are ideal for 
analysing the functional significance of HGF/c-Met signalling in an in-vitro setting. 
Furthermore, as E-Cadherin is present in these cells, the possible role of this protein 
in c-Met signalling can be addressed.    
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6.0 Materials and Methods 
 
6.1 Tissue culture 
 
The MDA-MB-468s were cultured as described in section 3.2.4. The HCC1937s 
were cultured as described in section 5.2.1. Both cell lines were propagated, sub-
cultured and preserved as set out in section 3.2.4. 
6.2 Tissue samples 
6.2.1 UK Nottingham series 
 
Pre-constructed TMAs were made available to us by Professor Ian O Ellis and Dr 
Andrew Green at Nottingham University NHS Trust. These cases make up the 
Nottingham-Tenovus Primary Breast Carcinoma Series that includes samples from 
women presenting with invasive breast carcinoma between 1986 and 1998. In total, 
samples from 1896 patients were placed onto these TMAs, with a single 0.6 mm 
representative core taken from each tumour. Sections were cut at a thickness of 4µm 
and placed onto a glass slide. The samples were accompanied by clinical data 
including age at presentation, tumour size, tumour grade, histological sub-type, 
lymph node status, and presence of vascular invasion. Overall survival time was 
taken as the time (in months) between diagnosis and date of death/last known 
follow-up. The patients had been treated according to local guidelines (Rakha et al, 
2009). Biomarker data were also available and included ER, PR, Her2, CK5/6, CK 
14, E-Cadherin, p53, Ki67 and EGFR expression. These tissues had been acquired 
with ethical approval from the Nottingham Research Ethics Committee 2 (title: 
“Development of a Molecular Genetic Classification of Breast Cancer”).  
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6.2.2 Homerton series 
 
Cases of invasive breast cancer (181 in total) diagnosed between 1994 and 2009 at 
the Homerton hospital comprised the ‘in-house’ cohort. These tumours were in the 
form of FFPE blocks available for assembly into TMAs. The samples were 
accompanied by the same clinical and biomarker data as the UK Nottingham series, 
with the exception of E-Cadherin and p53. Self-reported ethnicity data were also 
available. These tissues were acquired with ethical approval from the Queen Mary’s 
Research Ethics Committee (06/Q0403/162).    
TMAs were constructed from these samples, as set out in section 4.2.3. 
6.3 Antibodies 
 
See Table 6.1 for details of the primary antibodies used in this study. 
 
 
 
 
Table 6.1: Antibodies used in this breast cancer study. Abbreviations: Dil. = 
dilution, IF = immunofluorescence, IHC = immunohistochemistry, PLA = proximity 
ligation assay, WB = western blot, N/A = not applicable.  
Antibody Target Supplier Species Dil. (IF/IHC) Dil. (PLA) Dil. (WB)
CVD13 c-Met Invitrogen Rabbit 1:100 1:500 1:500
D26 Phospho-c-Met Cell Signalling Rabbit N/A N/A 1:1000
4G10 Phospho-tyrosine Millipore Mouse 1:100 1:500 N/A
NCH-38 E-Cadherin Dako Mouse 1:100 N/A N/A
36/E-Cadherin E-Cadherin BD Trans Labs Mouse N/A N/A 1:1000
14/β-catenin β-catenin BD Trans Labs Mouse N/A N/A 1:1000
Vimentin (R28) Vimentin Cell Signalling Rabbit N/A N/A 1:1000
B6 HSC70 Santa Cruz Mouse N/A N/A 1:10000
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6.4 Immunohistochemistry  
 
IHC was performed for c-Met on both tissue sample cohorts (UK Nottingham series 
and Homerton series) as set out in section 3.2.3. IHC for E-Cadherin was also 
performed on the Homerton series. 
6.4.1 Scoring system 
 
All IHC was scored using the semi-quantitative approach outlined in section 3.2.3. In 
addition, for E-Cadherin staining, tumour reactivity was recorded as less than or 
equal to/greater than 10% for the purposes of cut-point selection (see Table 6.2). All 
cores were scored twice by me on separate occasions to ensure reproducibility. A 
proportion of TMA cores were also scored independently by a second observer 
(Louise Jones). 
6.4.2 Cut-point selection 
 
The cut-off values to determine tumour positivity for each biomarker (except c-Met) 
are displayed in Table 6.2. The cut-points selected were as previously described 
(Rakha et al, 2005; Rakha et al, 2009). Scores for p53 and Ki67 were kept as 
continuous variables (% of positive nuclei).   
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Table 6.2: Biomarker cut-points. Cut-points for each of the immunohistochemical 
biomarkers used for molecular sub-typing (
*
Strong complete membrane positivity or 
positive findings at fluorescent in-situ hybridisation (FISH) in cases showing only 
weak/moderate complete membrane staining). 
 
For the purpose of survival analysis, c-Met scores were dichotomised into c-Met 
‘high’ (total score ≥7) and c-Met ‘low’ (total score <7) using the X-Tile 
bioinformatics software package for optimal cut-point selection (Camp et al, 2004). 
The software works by randomly dividing the study population into ‘training’ and 
‘validation’ cohorts. X-Tile then finds the optimal cut-point in the ‘training’ set and 
applies this to the ‘validation’ set and vice-versa. The population is then randomly 
cut 1000 times and the process repeated to generate an average cut-point. Finally, X-
Tile performs survival analysis using Monte Carlo simulations to arrive at a 
corrected p-value for this cut-point. X-Tile has been validated in the literature, where 
the software arrived at cut-points for known prognostic factors in breast cancer 
(number of involved lymph nodes and tumour size) that were similar to those used in 
established staging protocols (Camp et al, 2004).    
 
 
 
Biomarker Cut-point indicating tumour positivity
ER Any tumour reactivity
PR Any tumour reactivity
Her2 >10%*
CK 5/6 ≥10%
CK 14 ≥10%
EGFR ≥10%
E-Cadherin ≥10%
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6.4.3 Immunoprofile for molecular sub-types 
 
The algorithm used to define the different molecular sub-types of breast cancer on 
IHC is displayed in Table 6.3. This algorithm is similar to those used in previous 
studies (Cheang et al, 2008; Blows et al, 2010; Carey et al, 2006). 
 
 
 
Table 6.3: Molecular sub-type immunoprofile. Immunoprofile used to classify 
invasive breast cancers into one of five main molecular sub-types (* = positive for at 
least one of these markers in luminal tumours, ^ = positive for at least one of these 
markers in BL tumours). Abbreviations: N/A = not applicable. 
 
6.5 Immunofluorescence  
 
IF was performed for c-Met and E-Cadherin on MDA-MB-468s and HCC1937s as 
outlined in section 3.2.6.  
6.5.1 Image capture and quantification 
 
Images were captured using a Zeiss Confocal Fluorescent LSM 710 microscope. E-
Cadherin staining was quantified by counting the number of cells with membranous 
reactivity and expressing this as the percentage of total cells, as identified by DAPI-
stained nuclei. Co-localisation analysis for E-Cadherin and c-Met was performed 
using the Zen 2009 software. For each antibody, the appropriate filter for that 
fluorophore was selected and the detection threshold adjusted so that only specific 
staining (membranous for both antibodies in un-stimulated cells) appeared as white 
Molecular sub-type ER PR Her2 CK 5/6 CK 14 EGFR
Luminal A +/-* +/-* - N/A N/A N/A
Luminal B +/-* +/-* + N/A N/A N/A
Her2 positive - - + N/A N/A N/A
Basal-like (BL) - - - +/-^ +/-^ +/-^
Unclassified - - - - - -
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pixels. The co-localised pixels were then expressed as a percentage of the total 
number of c-Met pixels. At least 50 cells were analysed for each treatment condition.     
6.6 Western blot  
 
Western blotting was performed on MDA-MB-468 and HCC1937 cells as outlined 
in section 3.2.5. Protein expression (band intensity at western blot) was quantified by 
performing densitometry analysis in ImageJ. For each antibody the untreated cells 
were regarded as the control and the density of this band was assigned a value of ‘1’. 
The densities of the bands from treated cell lysates were then given a value relative 
to the control band (sample relative density). The same process was repeated for the 
loading controls. Finally, the adjusted relative density (ARD) was computed by 
dividing the sample relative density by the loading control relative density.   
6.7 Proximity ligation assay 
 
The PLA was applied to the Homerton cohort using the CVD13/4G10 primary 
antibody combination and method outlined in section 4.2.9.  
6.7.1 Image capture and quantification 
 
Images were captured using a Zeiss Epifluorescent Axioplan microscope with a x63 
objective. For each TMA core, 2 images were captured. The PLA product was then 
quantified as set out in section 4.2.9.  
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6.7.2 Cut-point selection 
 
For the purpose of survival analysis, tumours were dichotomised into PLA ‘high’ 
(>3.19 PLA signals per nucleus) and PLA ‘low’ (0-3.19 signals per nucleus) using 
the X-Tile bioinformatics package, as set out in section 6.4.2.   
6.8 Cell Viability Assay (MTS assay) 
 
The MTS assay utilises the bioreduction of tetrazolium to formazan by nicotinamide 
adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide 
(NADH) in metabolically active cells to detect and quantify viable cells.  
Cells were serum-starved in 1% FCS/growth media (DMEM or RPMI depending on 
the cell type) for 24 hours, trypsinised and re-suspended in 1% FCS/growth media 
before counting. A standard curve was set up by seeding a range of cell densities into 
a 24-well plate (starting with 160000 cells, diluting 1:1 and ending with cell-free 
media) containing 400µl of media per well. MTS reagent (80µl; Promega, Madison, 
USA) was added to each well and the plate was incubated at 37
o
C. After 1 hour of 
incubation, 120µl aliquots from each well were dispensed in duplicate into a 96-well 
plate. Absorbance at 492nm was calculated for each cell density using a Tecan F50 
plate reader (Tecan UK, Reading, UK) and a standard curve was constructed using 
Microsoft Excel.     
A dose response was set up by seeding 40000 cells per well in a 24-well plate 
containing 500µl of 1% FCS/growth media and a range of HGF concentrations from 
0ng/ml to 100ng/ml. After 8 hours incubation at 37
o
C, the media was removed and 
replaced with 400µl of fresh 1% FCS/growth media and 80µl of MTS reagent. The 
plate was incubated for a further 1 hour at 37
o
C before aliquoting into a 96-well plate 
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and reading as outlined above. Finally, viable cell numbers at different HGF 
concentrations were calculated using the standard curve.      
6.9 Transwell migration assay 
 
The cells were serum-starved for 24 hours in 1% FCS/growth media. In order to 
provide a chemotactic stimulus, the transwell inserts (Appleton Woods, 
Birmingham, UK) were placed onto the lid of the 24 well-plate and the undersides 
coated with 100µl of fibronectin (10µg/ml; Sigma) diluted in sterile PBS and left to 
incubate for 1 hour at room temperature. The excess fibronectin was removed and 
the undersides of the transwells were rinsed in 100µl of sterile PBS. To each of the 
lower chambers in the 24 well-plate, 600µl of 1% FCS/growth media was added, 
along with HGF (100 ng/ml) where appropriate. The transwells were then transferred 
back into the 24 well-plate. 
The serum-starved cells were trypsinised, counted and re-suspended in 1% 
FCS/growth media so that there were 100000 cells/ml. At this point, SU11274 
(2µM) was added where appropriate and the cells were incubated for 10 minutes at 
37
o
C. The cell suspension was added to the upper chamber of the transwells in 
volumes of 200µl/well (containing 20000 cells) and left to incubate for 8 hours at 
37
o
C. 
The media was removed from both the upper and lower chambers and replaced with 
trypsin (200µl in the upper chamber, 500µl in the lower chamber) and left to 
incubate for a further hour at 37
o
C. For each chamber, the trypsin was removed and 
passed back over membrane twice, before being transferred to a counting tube 
containing sufficient filtered isoton for an end volume of 10mls per counting tube. 
Both the upper and lower chambers were counted using the Casy Cell Counter 
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(Schärfe system GmbH, Reutlingen, Germany) so that the percentage of migrated 
cells could be calculated. 
6.10 Statistical analysis 
 
Since the c-Met IHC/PLA scores did not show a normal distribution, the correlation 
between c-Met scores and continuous variables were analysed using the non-
parametric Spearman’s correlation co-efficient. Comparisons between c-Met scores 
and categorical variables were carried out using the Mann-Whitney test. Multivariate 
tests of association were carried out using binomial logistic regression with forward 
step-wise entry. 
Univariate survival analysis was carried out using Kaplan-Meier curves and the log-
rank test. For multivariate analysis, a Cox regression model was created, with 
forward step-wise entry. 
For in-vitro analyses, differences between multiple groups were assessed using the 
Kruskal-Wallis test, followed by a post-hoc Mann-Whitney test for comparisons 
between 2 groups. To correct for multiple group testing the significance level was 
reduced by dividing an α of 0.05 by the number of comparisons (for example, where 
6 comparisons are made, a p-value less than 8.3x10
-3
 (0.05/6) would be considered 
significant).     
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7.0 Results 
 
7.1 C-Met expression in invasive breast cancer 
 
7.1.1 Patient characteristics 
 
Of the 2077 cases of invasive breast cancer incorporated onto TMAs (1896 from the 
Nottingham cohort and 181 from the Homerton cohort), c-Met expression could be 
evaluated on 1455 cases (1274 from the Nottingham cohort and all of the Homerton 
cases, Figure 7.1). The most common reasons for not scoring c-Met expression on a 
tumour (missing case) were complete lack of a tissue core for that case or the 
presence of minimal tumour cells in the core.      
The key clinical/pathological characteristics of the entire cohort (‘All cases’) are 
compared with those of the patients on which c-Met scores were available (‘Cases 
with c-Met scores’) in Table 7.1. Compared with the entire cohort, the patients 
whose tumours could be scored for c-Met showed a similar mean age at presentation 
(both around 54 years old), mean tumour size (2.1 cm versus 2.2 cm respectively), 
degree of tumour differentiation (49% grade 3 versus 52% grade 3 respectively) and 
frequency of lymph node metastasis (40% versus 41% respectively; Table 7.1). 
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A                                                           B 
 
 
 
 
 
 
C                                                           D 
 
 
 
 
 
Figure 7.1: Immunohistochemistry for c-Met. A is the negative control (primary 
antibody omitted), B shows weak intensity cytoplasmic staining in most tumour cells 
with focal membrane staining (arrows), C shows moderate staining in most tumour 
cells with focal membrane positivity (arrows) and D shows strong cytoplasmic and 
membranous (arrows) staining (IHC; x40 objective, scale bars represent 10µm, all 
inset images are at 200% magnification). This figure is modified from Ho-Yen et al, 
2014.  
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Table 7.1: Characteristics of the study cohort, including missing cases. The table 
shows some of the key parameters of the entire cohort (n = 2077) compared with the 
patients whose tumours could be scored for c-Met expression (n = 1455). 
Abbreviations: CI = confidence interval.  
 
The clinical, pathological and molecular characteristics of the study cohort (minus 
the missing cases) are shown in greater detail in Table 7.2. The Nottingham and 
Homerton series, which together make up the study cohort, differed in several 
respects (Table 7.2). Compared to patients in the Nottingham series, Homerton 
patients presented at a later age (56.9 versus 54.1 years old) with larger tumours (2.6 
versus 2.1 cm) and with a higher frequency of lymph node metastasis (54% versus 
39%). The histological category of IDC-NST was more common in the Homerton 
series (82% of cases versus 59% in the Nottingham series) and a ‘Mixed’ diagnosis 
was less common (7% versus 27% in the Nottingham collection). Tumour recurrence 
was much less common in the Homerton patients (14% compared to 43% in the 
Nottingham series) although the follow-up time was considerably shorter (61.6 
months compared with 121.1 months follow-up for the Nottingham patients).     
 
 
Parameter Cases with c-Met scores All Cases 
Age (mean, 95% CI) 54.4 (37-69) years 54.5 (37-69) years
Tumour size (mean, 95% CI) 2.2 (0.9-4.0) cm 2.1 (0.9-4.0) cm
Tumour grade (% of cases)
1 15 17
2 33 34
3 52 49
Lymph node involvement (% of cases)
Yes 41 40
No 59 60
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Table 7.2: Clinical, pathological and molecular characteristics of the study cohort. 
The table shows the features of the whole cohort (WC, n = 1455), together with a 
breakdown of the Nottingham and Homerton components. Abbreviations: CI = 
confidence interval, LN = lymph node, IDC-NST = invasive ductal carcinoma, no 
special type, ILC = invasive lobular carcinoma.  
 
 
 
Parameter WC (n=1455) Nottingham (n=1274) Homerton (n=181)
Age (mean, 95% CI) 54.4 (37-69) years 54.1 (37-69) years 56.9 (37-82) years
Tumour size (mean, 95% CI) 2.2 (0.9-4.0) cm 2.1 (0.9-4.0) cm 2.6 (1.0-5.1) cm
Tumour grade (% of cases)
1 15 16 8
2 33 33 37
3 52 51 55
LN involvement (% of cases)
Yes 41 39 54
No 59 61 46
Histological sub-type  (% of cases)
IDC-NST 62 59 82
ILC 7 7 5
Tubular carcinoma 3 3 1
Mucinous carcinoma 1 1 3
Medullary/atypical medullary 2 2 2
Mixed 24 27 7
Other 1 1 0
Molecular sub-type (% of cases)
Luminal A 67 68 65
Luminal B 7 7 8
Her2 positive 7 7 6
Basal-like 14 13 17
Unclassified 5 5 4
Survival status (% of cases)
Alive 61 60 63
Dead 39 40 37
Recurrence (% of cases)
Yes 40 43 14
No 60 57 86
Follow-up (months (mean, 95% CI)) 114.1 (19.0-199.0) 121.1 (23-201) 61.6 (7.5-125.8) 
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7.1.2 Correlation between c-Met expression and prognostic factors 
 
7.1.2.1 Whole cohort 
 
The correlation between c-Met scores and continuous variables is shown in Table 7.3 
and the correlation with categorical variables is shown in Table 7.4. 
There was a significant inverse correlation between c-Met expression and increasing 
tumour size (r = -0.113, p <0.001). There were no significant correlations between c-
Met scores and age, p53 score or Ki67 score (Table 7.3).  
 
 
 
Table 7.3: Correlation between c-Met scores and prognostic factors in the whole 
cohort (continuous variables). Significant correlations are given in italics 
(Spearman’s correlation coefficient, n = 1455). 
 
C-Met expression was significantly higher in lymph node negative tumours (mean 
score = 7.4) compared with node positive tumours (mean score = 7.2, p = 0.045; 
Table 7.4). Invasive lobular carcinomas (ILCs) showed significantly lower c-Met 
scores compared with non-ILCs (mean score = 6.6 versus 7.5 respectively, p 
<0.001), whereas tubular carcinomas (TC) showed significantly higher c-Met 
expression (mean score = 8.7 versus 7.4 for non-TC tumours, p = 0.002; Table 7.4).  
Tumours classified as luminal A showed significantly lower c-Met scores (mean 
score = 7.4 versus 7.7 for non-luminal A tumours, p = 0.004) and BL tumours had 
higher levels of c-Met (mean score = 8.0 compared with 7.4 for all other molecular 
sub-types, p = 0.004; Table 7.4). Both EGFR and E-Cadherin positive tumours had 
Parameter Correlation Coefficient P-Value
Age 0.039 0.138
Tumour size -0.113 <0.001
p53 score 0.018 0.538
Ki67 score -0.046 0.114
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significantly higher c-Met scores. The mean c-Met score for EGFR positive tumours 
was 7.9 versus 7.4 for EGFR negative tumours, p = 0.003 and the mean score for E-
Cadherin positive tumours was 7.5 versus 7.0 for E-Cadherin negative tumours, p = 
0.003 (Table 7.4).  
There were no significant differences in c-Met expression between high and low 
grade tumours, tumours with and without vascular invasion, tumours from patients 
of different ethnicity (black versus white) or between Her2 positive and Her2 
negative tumours (Table 7.4).       
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Table 7.4: Correlation between c-Met scores and prognostic factors in the whole 
cohort (categorical variables). Significant findings are given in italics (Mann-
Whitney test, n = 1455). Abbreviations: CI = confidence interval, IDC-NST = 
invasive ductal carcinoma, no special type, ILC = invasive lobular carcinoma, TC = 
tubular carcinoma, MC = mucinous carcinoma. 
 
 
 
 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.5 (7.3-7.7)
3 7.4 (7.3-7.6) 0.878
Lymph node involvement
Yes 7.2 (7.0-7.4)
No 7.4 (7.2-7.6) 0.045
Vascular invasion
Yes 7.6 (7.3-7.4)
No 7.5 (7.2-7.8) 0.305
Histological sub-type
IDC-NST vs Non-IDC-NST 7.5 (7.3-7.6) vs 7.5 (7.3-7.7) 0.884
ILC vs Non-ILC 6.6 (6.0-7.2) vs 7.5 (7.4-7.7) <0.001
Tubular carcinoma (TC) vs Non-TC 8.7 (8.0-9.3) vs 7.4 (7.3-7.6) 0.002
Mucinous carcinoma (MC) vs Non-MC 6.6 (5.0-8.1) vs 7.5 (7.4-7.6) 0.269
Medullary/atypical vs Non-medullary/atypical 8.1 (7.0-9.1) vs 7.5 (7.3-7.6) 0.28
Molecular sub-type
Luminal A vs Non-Luminal A 7.4 (7.2-7.5) vs 7.7 (7.5-7.9) 0.004
Luminal B vs Non-Luminal B 7.3 (6.8-7.8) vs 7.5 (7.3-7.6) 0.586
Her2 positive vs Non-Her2 7.6 (7.2-8.0) vs 7.5 (7.3-7.6) 0.336
Basal-like (BL) vs Non-BL 8.0 (7.6-8.4) vs 7.4 (7.2-7.5) 0.004
Unclassified vs Non-Unclassified 7.6 (6.9-8.3) vs 7.5 (7.3-7.6) 0.212
Ethnicity
Black 7.0 (6.4-7.5) 
White 7.1 (6.7-7.5) 0.898
Her2 status
Positive 7.5 (7.1-7.8)
Negative 7.5 (7.3-7.6) 0.733
EGFR status
Positive 7.9 (7.6-8.2)
Negative 7.4 (7.3-7.6) 0.003
E-Cadherin status
Positive 7.5 (7.4-7.7)
Negative 7.0 (6.7-7.4) 0.003
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7.1.2.2 Nottingham cohort 
 
In the Nottingham cohort of patients, there was a significant negative correlation 
between c-Met expression and tumour size (p <0.001) and a borderline significant 
negative correlation between c-Met and Ki67 score (p = 0.050, Table 7.5). There was 
no significant correlation between c-Met scores and patient age and p53 score (Table 
7.5). 
 
 
 
Table 7.5: Correlation between c-Met scores and prognostic factors within the 
Nottingham cohort (continuous variables). Significant correlations are given in 
italics (Spearman’s correlation coefficient, n = 1274). 
 
Patients without lymph node involvement showed significantly higher tumour c-Met 
expression compared to those with involvement (mean c-Met score = 7.5 versus 7.2 
respectively, p = 0.033; Table 7.6). Tumours classified histologically as ILC had 
lower c-Met scores (mean score = 6.7 versus 7.6 for non-ILC tumours, p = 0.001) 
and those categorised as tubular carcinomas had higher c-Met scores (mean score = 
8.8 versus 7.5 for non-tubular carcinomas, p = 0.003; Table 7.6). BL tumours 
showed higher c-Met expression (mean c-Met score = 8.0 compared with 7.4 for 
non-BL tumours, p = 0.037) and luminal A tumours showed significantly lower 
expression of c-Met (mean score = 7.4 versus 7.7 for non-luminal A tumours, p = 
0.014; Table 7.6). There were no other significant differences in c-Met scores in the 
other parameters displayed in Table 7.6. 
Parameter Correlation Coefficient P-Value
Age 0.018 0.531
Tumour size -0.104 <0.001
p53 score 0.018 0.538
Ki67 score -0.061 0.050
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Table 7.6: Correlation between c-Met scores and prognostic factors within the 
Nottingham cohort (categorical variables). Significant findings are given in italics 
(Mann-Whitney test, n = 1274). Abbreviations: CI = confidence interval, IDC-NST 
= invasive ductal carcinoma, no special type, ILC = invasive lobular carcinoma, TC 
= tubular carcinoma, MC = mucinous carcinoma. 
 
 
 
 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.6 (7.3-7.8)
3 7.5 (7.3-7.7) 0.942
Lymph node involvement
Yes 7.2 (7.0-7.5)
No 7.5 (7.3-7.7) 0.033
Vascular invasion
Yes 7.5 (7.2-7.8)
No 7.6 (7.4-7.7) 0.305
Histological sub-type
IDC vs Non-IDC 7.5 (7.3-7.7) vs 7.6 (7.3-7.8) 0.873
ILC vs Non-ILC 6.7 (6.1-7.3) vs 7.6 (7.5-7.8) 0.001
Tubular carcinoma (TC) vs Non-TC 8.8 (8.1-9.4) vs 7.5 (7.4-7.7) 0.003
Mucinous carcinoma (MC) vs Non-MC 7.0 (4.9-9.2) vs 7.5 (7.4-7.7) 0.847
Medullary/atypical vs Non-medullary/atypical 8.0 (6.9-9.1) vs 7.5 (7.4-7.7) 0.451
Molecular sub-type
Luminal A vs Non-Luminal A 7.4 (7.2-7.6) vs 7.7 (7.5-8.0) 0.014
Luminal B vs Non-Luminal B 7.4 (6.9-7.9) vs 7.5 (7.4-7.7) 0.839
Her2 positive vs Non-Her2 7.6 (7.1-8.1) vs 7.5 (7.4-7.7) 0.447
Basal-like (BL) vs Non-BL 8.0 (7.6-8.5) vs 7.4 (7.3-7.6) 0.037
Unclassified vs Non-Unclassified 7.7 (6.9-8.5) vs 7.5 (7.4-7.7) 0.140
Her2 status
Positive 7.6 (7.2-7.9)
Negative 7.6 (7.4-7.7) 0.675
EGFR status
Positive 7.9 (7.5-8.2)
Negative 7.5 (7.3-7.7) 0.065
E-Cadherin status
Positive 7.6 (7.4-7.7)
Negative 7.2 (6.7-7.6) 0.104
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7.1.2.3 Homerton cohort 
 
In the Homerton group of patients, there was a significant positive correlation 
between c-Met expression and patient age (p = 0.009, Table 7.7). There were no 
significant correlations between c-Met and tumour size, p53 or Ki67 scores (Table 
7.7). 
 
 
 
Table 7.7: Correlation between c-Met scores and prognostic factors within the 
Homerton cohort (continuous variables). Significant correlations are given in italics 
(Spearman’s correlation coefficient, n = 181). 
 
Tumours in the IDC-NST histological category showed a significantly higher c-Met 
score (mean score = 7.2 versus 6.1 for non-IDC-NST tumours, p = 0.003; Table 7.8). 
Of the molecular sub-types, only BL tumours showed significantly higher c-Met 
expression (mean score = 8.0 compared with 6.8 for non-BL tumours, p = 0.003; 
Table 7.8). Both EGFR positive (mean c-Met score = 8.0 versus 6.7 for EGFR 
negative tumours, p = 0.001) and E-Cadherin positive (mean c-Met score = 7.3 
versus 6.7 for E-Cadherin negative tumours, p = 0.039; Table 7.8) tumours showed 
higher c-Met levels. There were no significant differences in c-Met expression in the 
other parameters displayed in Table 7.8. 
 
 
 
Parameter Correlation Coefficient P-Value
Age 0.193 0.009
Tumour size -0.105 0.163
p53 score -0.028 0.717
Ki67 score 0.022 0.781
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Table 7.8: Correlation between c-Met scores and prognostic factors within the 
Homerton cohort (categorical variables). Significant findings are given in italics 
(Mann-Whitney test, n = 181). Abbreviations: CI = confidence interval, IDC-NST = 
invasive ductal carcinoma, no special type, ILC = invasive lobular carcinoma, MC = 
mucinous carcinoma. 
 
 
 
 
 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.0 (6.5-7.4)
3 7.1 (6.7-7.5) 0.431
Lymph node involvement
Yes 7.1 (6.7-7.5)
No 6.9 (6.4-7.4) 0.369
Histological sub-type
IDC vs Non-IDC 7.2 (6.9-7.6) vs 6.1 (5.4-6.7) 0.003
ILC vs Non-ILC 5.9 (5.0-6.8) vs 7.1 (6.8-7.4) 0.065
Mucinous carcinoma (MC) vs Non-MC 5.6 (3.3-7.9) vs 7.1 (6.8-7.4) 0.126
Medullary/atypical vs Non-medullary/atypical 8.3 (3.9-12.7) vs 7.0 (6.7-7.3) 0.319
Molecular sub-type
Luminal A vs Non-Luminal A 6.9 (6.5-7.2) vs 7.4 (6.9-8.0) 0.077
Luminal B vs Non-Luminal B 6.4 (5.2-7.6) vs 7.1 (6.8-7.4) 0.356
Her2 positive vs Non-Her2 7.3 (6.6-8.1) vs 7.0 (6.7-7.4) 0.632
Basal-like (BL) vs Non-BL 8.0 (7.2-8.9) vs 6.8 (6.5-7.2) 0.003
Unclassified vs Non-Unclassified 6.6 (4.4-8.8) vs 7.1 (6.8-7.4) 0.444
Ethnicity
Black 7.0 (6.4-7.5) 
White 7.1 (6.7-7.5) 0.898
Her2 status
Positive 6.8 (6.1-7.6)
Negative 7.1 (6.7-7.4) 0.746
EGFR status
Positive 8.0 (7.3-8.7)
Negative 6.7 (6.4-7.1) 0.001
E-Cadherin status
Positive 7.3 (6.9-7.7)
Negative 6.7 (6.2-7.2) 0.039
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7.1.2.4 Molecular sub-type analysis – whole cohort 
 
7.1.2.4.1 Luminal A tumours  
 
Within the luminal A tumours, there was a significant positive correlation between c-
Met expression and age at presentation (p = 0.012, Table 7.9). There was a 
significant negative correlation between c-Met scores and tumour size (p <0.001) 
and Ki67 score (p = 0.004, Table 7.9). There was no correlation between c-Met and 
p53 scores. 
 
 
 
Table 7.9: Correlation between c-Met scores and prognostic factors within the 
luminal A sub-group (continuous variables). Significant correlations are given in 
italics (Spearman’s correlation coefficient, n = 928). 
 
Lymph node positive tumours showed lower c-Met levels (mean score = 6.9 
compared with 7.4 for node positive tumours, p = 0.011; Table 7.10). As with the 
whole cohort, luminal A ILCs had significantly lower c-Met scores (mean score = 
6.6 versus 7.5 for non-ILCs, p = 0.001; Table 7.10) and luminal A tubular 
carcinomas had higher c-Met expression (mean score = 8.6 versus 7.3 for all other 
histological sub-types, p = 0.003; Table 7.10). Medullary and atypical medullary 
carcinomas also had higher c-Met levels (mean score = 9.7 versus 7.4 for the other 
histological sub-types, p=0.034; Table 7.10). Luminal A tumours that were E-
Cadherin positive or EGFR positive showed significantly higher c-Met levels (p < 
0.001 and p = 0.002 respectively; Table 7.10). There were no significant differences 
in c-Met scores between high and low grade tumours, tumours with and without 
Parameter Correlation Coefficient P-Value
Age 0.082 0.012
Tumour size -0.142 <0.001
p53 score 0.011 0.763
Ki67 score -0.105 0.004
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vascular invasion and between tumours arising in black versus white women (Table 
7.10).  
 
 
 
 
 
 
 
 
 
 
Table 7.10: Correlation between c-Met scores and prognostic factors within the 
luminal A sub-group (categorical variables). Significant findings are given in italics 
(Mann-Whitney test, n = 928). Abbreviations: CI = confidence interval, IDC-NST = 
invasive ductal carcinoma, no special type, ILC = invasive lobular carcinoma, TC = 
tubular carcinoma, MC = mucinous carcinoma. 
 
7.1.2.4.2  Luminal B tumours 
 
There was a significant positive correlation between c-Met expression and p53 
scores in the luminal B sub-group (p = 0.016, Table 7.11). There were no significant 
correlations between c-Met scores and age, tumour size or Ki67 index (Table 7.11).  
 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.4 (7.2-7.6)
3 7.3 (7.0-7.5) 0.522
Lymph node involvement
Yes 6.9 (6.7-7.2)
No 7.4 (7.2-7.6) 0.011
Vascular invasion
Yes 7.3 (7.0-7.7)
No 7.5 (7.3-7.7) 0.400
Histological sub-type
IDC-NST vs Non-IDC-NST 7.3 (7.0-7.5) vs 7.5 (7.2-7.7) 0.300
ILC vs Non-ILC 6.6 (6.0-7.2) vs 7.5 (7.3-7.6) 0.001
Tubular carcinoma (TC) vs Non-TC 8.6 (7.9-9.2) vs 7.3 (7.1-7.5) 0.003
Mucinous carcinoma (MC) vs Non-MC 6.8 (5.0-8.7) vs 7.4 (7.2-7.5) 0.742
Medullary/atypical vs Non-medullary/atypical 9.7 (7.4-11.9) vs 7.4 (7.2-7.5) 0.034
Ethnicity
Black 6.9 (6.2-7.7) 
White 6.8 (6.4-7.3) 0.523
EGFR status
Positive 8.1 (7.6-8.5)
Negative 7.3 (7.1-7.5) 0.002
E-Cadherin status
Positive 7.5 (7.3-7.7)
Negative 6.7 (6.3-7.2) <0.001
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Table 7.11: Correlation between c-Met scores and prognostic factors within the 
luminal B sub-group (continuous variables). Significant correlations are given in 
italics (Spearman’s correlation coefficient, n = 100). 
 
Within the luminal B sub-group, there were no significant differences in c-Met 
scores between the categorical variables displayed in Table 7.12. 
 
 
 
 
 
 
 
 
 
Table 7.12: Correlation between c-Met scores and prognostic factors within the 
luminal B sub-group (categorical variables). Only the IDC-NST histological sub-
type is shown as the other sub-types contained too few cases (Mann-Whitney test, n 
= 100). Abbreviations: CI = confidence interval, IDC-NST = invasive ductal 
carcinoma, no special type. 
 
Parameter Correlation Coefficient P-Value
Age -0.089 0.376
Tumour size 0.024 0.815
p53 score 0.246 0.016
Ki67 score 0.051 0.662
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.1 (6.1-8.0)
3 7.3 (6.8-7.9) 0.514
Lymph node involvement
Yes 7.0 (6.3-7.7)
No 7.2 (6.5-8.0) 0.407
Vascular invasion
Yes 7.3 (6.5-8.1)
No 7.5 (6.7-8.2) 0.638
Histological sub-type
IDC-NST vs Non-IDC-NST 7.2 (6.7-7.8) vs 7.5 (6.0-9.0) 0.473
Ethnicity
Black 5.7 (3.7-7.8) 
White 7.2 (5.4-9.0) 0.116
EGFR status
Positive 7.7 (6.3-9.0)
Negative 7.4 (6.8-7.9) 0.536
E-Cadherin status
Positive 7.4 (6.9-7.9)
Negative 6.7 (5.0-8.5) 0.543
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7.1.2.4.3  Her2 positive tumours 
 
There was a borderline negative correlation between c-Met scores and tumour size in 
the Her2 positive sub-group (p = 0.063, Table 7.13). There were no significant 
correlations between c-Met expression and patient age, p53 or Ki67 scores (Table 
7.13).   
 
 
 
Table 7.13: Correlation between c-Met scores and prognostic factors within the 
Her2 positive sub-group (continuous variables). Spearman’s correlation coefficient 
(n = 95). 
 
Low grade (grades 1 or 2) tumours in the Her2 positive sub-group showed 
significantly higher c-Met scores compared to high grade (grade 3) tumours (mean 
score = 8.9 versus 7.4 respectively, p = 0.012; Table 7.14). There were no significant 
differences in c-Met scores in the other categorical variables displayed in Table 7.14.    
 
 
 
 
 
 
Parameter Correlation Coefficient P-Value
Age 0.023 0.825
Tumour size -0.191 0.063
p53 score 0.139 0.183
Ki67 score -0.111 0.342
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Table 7.14: Correlation between c-Met scores and prognostic factors within the 
Her2 positive sub-group (categorical variables). Significant findings are given in 
italics (Mann-Whitney test, n = 95). Only the IDC-NST and medullary/atypical 
medullary histological sub-types are shown as the other sub-types contained too few 
cases. Abbreviations: CI = confidence interval, IDC-NST = invasive ductal 
carcinoma, no special type. 
 
7.1.2.4.4  BL tumours 
 
There was a significant inverse correlation between c-Met scores and both p53 and 
Ki67 scores within the BL sub-group (r = -0.255, p = 0.002; r = -0.255, p = 0.005 
respectively; Table 7.15). There were no significant correlations between c-Met 
scores and patient age or tumour size (Table 7.15). 
 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 8.9 (8.0-9.8)
3 7.4 (7.0-7.9) 0.012
Lymph node involvement
Yes 7.6 (7.1-8.2)
No 7.3 (6.5-8.2) 0.917
Vascular invasion
Yes 7.5 (6.8-8.2)
No 7.8 (7.1-8.4) 0.148
Histological sub-type
IDC-NST vs Non-IDC-NST 7.6 (7.2-8.0) vs 8.2 (5.4-10.9) 0.851
Medullary/atypical vs Non-medullary/atypical 9.0 (1.6-14) vs 7.6 (7.2-8.0) 0.454
Ethnicity
Black 7.0 (5.4-8.6) 
White 7.7 (6.6-8.7) 0.451
EGFR status
Positive 7.6 (6.7-8.5)
Negative 7.6 (7.2-8.1) 0.991
E-Cadherin status
Positive 7.5 (7.0-7.9)
Negative 8.3 (7.1-9.6) 0.266
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Table 7.15: Correlation between c-Met scores and prognostic factors within the BL 
sub-group (continuous variables). Significant correlations are given in italics 
(Spearman’s correlation coefficient, n = 184). 
 
There were no significant differences in c-Met scores in the categorical variables 
displayed in Table 7.16. 
 
 
 
 
 
 
 
 
 
Table 7.16: Correlation between c-Met scores and prognostic factors within the BL 
sub-group (categorical variables). Only the IDC-NST and medullary/atypical 
medullary histological sub-types are shown as the other sub-types contained too few 
cases (Mann-Whitney test, n = 184). Abbreviations: CI = confidence interval, IDC-
NST = invasive ductal carcinoma, no special type. 
 
Parameter Correlation Coefficient P-Value
Age 0.057 0.440
Tumour size -0.005 0.950
p53 score -0.255 0.002
Ki67 score -0.255 0.005
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 9.1 (7.4-10.9)
3 7.9 (7.5-8.3) 0.112
Lymph node involvement
Yes 7.9 (7.4-8.4)
No 7.9 (7.3-8.4) 0.679
Vascular invasion
Yes 8.2 (7.6-8.9)
No 7.9 (7.3-8.6) 0.992
Histological sub-type
IDC-NST vs Non-IDC-NST 8.1 (7.7-8.5) vs 8.0 (7.0-9.0) 0.634
Medullary/atypical vs Non-medullary/atypical 7.4 (6.1-8.7) vs 8.1 (7.7-8.6) 0.180
Ethnicity
Black 8.0 (6.7-9.2) 
White 8.1 (7.1-9.2) 0.951
EGFR status
Positive 7.8 (7.3-8.3)
Negative 8.4 (7.6-9.1) 0.360
E-Cadherin status
Positive 8.0 (7.6-8.5)
Negative 7.9 (7.0-8.8) 0.897
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7.1.2.4.5  Unclassified tumours 
 
There was a significant inverse correlation between c-Met scores and tumour size (r 
= -0.328, p = 0.005; Table 7.17). There was a borderline significant inverse 
correlation between c-Met scores and patient age (r = -0.213, p = 0.071; Table 7.17). 
There were no significant correlations between c-Met scores and p53 or Ki67 scores 
(Table 7.17).  
 
 
 
Table 7.17: Correlation between c-Met scores and prognostic factors within the 
unclassified sub-group (continuous variables). Significant correlations are given in 
italics (Spearman’s correlation coefficient, n = 73). 
 
There were no significant differences in c-Met scores in the categorical variables 
displayed in Table 7.18. 
 
 
 
 
 
 
 
Parameter Correlation Coefficient P-Value
Age -0.213 0.071
Tumour size -0.328 0.005
p53 score -0.039 0.741
Ki67 score 0.104 0.417
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Table 7.18: Correlation between c-Met scores and prognostic factors within the 
unclassified sub-group (categorical variables). Only the IDC-NST and 
medullary/atypical medullary histological sub-types are shown as the other sub-types 
contained too few cases (Mann-Whitney test, n = 73). Abbreviations: CI = 
confidence interval, IDC-NST = invasive ductal carcinoma, no special type. 
 
7.1.3 Correlation between c-Met, other prognostic factors and the BL sub-type 
in the whole cohort 
 
In the whole cohort analysis, only tumours classified as BL by IHC showed 
significantly higher c-Met expression. In the next stage of the analysis, I established 
which other prognostic factors also associated with the BL sub-type. 
7.1.3.1 Univariate analysis 
 
Several factors were associated with BL tumours (Table 7.19). These included: 
increasing tumour size (p = 0.007), increasing p53 score (p < 0.001), increasing Ki67 
score (p < 0.001), grade 3 tumours (p < 0.001), the histological sub-types IDC-NST 
and medullary/atypical medullary (p < 0.001 for both) and being of black ethnicity 
Parameter Mean c-Met score (95%  CI) P-Value
Tumour Grade
1 or 2 7.4 (4.6-10.1)
3 7.6 (6.8-8.4) 0.936
Lymph node involvement
Yes 7.8 (6.8-8.5)
No 7.3 (6.2-8.4) 0.391
Vascular invasion
Yes 7.7 (6.2-9.2)
No 7.7 (6.7-8.7) 0.829
Histological sub-type
IDC-NST vs Non-IDC-NST 7.6 (6.8-8.4) vs 7.4 (5.6-9.3) 0.660
Medullary/atypical vs Non-medullary/atypical 8.9 (6.2-11.5) vs 7.4 (6.6-8.2) 0.678
Ethnicity
Black 5.5 (0.2-10.9) 
White 7.4 (3.5-11.3) 0.372
E-Cadherin status
Positive 7.9 (7.1-8.7)
Negative 6.5 (4.6-8.5) 0.133
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(p = 0.028). Increasing age was associated with a lower chance of having a BL 
tumour (p < 0.001). Increasing c-Met scores showed an odds ratio of 3.79 for having 
BL cancer (p = 0.002).    
   
 
 
 
 
 
 
 
 
 
Table 7.19: Association between c-Met, other prognostic factors and the BL sub-
type. Significant findings are given in italics (univariate logistic regression, n = 
1455). Abbreviations: CI = confidence interval, IDC-NST = invasive ductal 
carcinoma, no special type, LR = likelihood ratio, OR = odds ratio.   
 
 
7.1.3.2 Multivariate analysis 
 
To establish if c-Met was independently associated with the BL sub-group, I entered 
c-Met score together with the six other factors associated with BL tumours at 
univariate analysis (age at presentation, tumour size, p53 score, Ki67 score, tumour 
Parameter LR Chi-Square OR (95%  CI) P Value
Age 18.4 0.97 (0.95-0.98) <0.001
Tumour size 6.5 1.16 (1.04-1.30) 0.007
p53 score 125.5 9.80 (6.56-14.64) <0.001
Ki67 score 134.0 25.78 (14.40-46.17) <0.001
Tumour grade
1 or 2 1
3 154.3 12.54 (7.42-21.20) <0.001
Lymph node involvement
No 1
Yes 0.1 1.01 (0.72-1.41) 0.955
Vascular invasion
No 1
Yes 3.6 1.41 (0.99-2.0) 0.055
Histological sub-type
IDC-NST 55.3 4.28 (2.76-6.63) <0.001
Medullary/atypical medullary 23.8 6.83 (3.31-14.07) <0.001
Ethnicity
White 1
Black 5.0 2.45 (1.10-5.44) 0.028
E-Cadherin status
Negative 1
Positive 2.2 0.75 (0.51-1.08) 0.127
C-Met score 9.5 3.79 (1.60-8.97) 0.002
160 
 
grade and histological sub-type (IDC-NST and medullary/atypical medullary); 
ethnicity was excluded as an insufficient numbers of cases had this data) into the 
multivariate model.  
After forward stepwise entry (Table 7.20), the five factors that remained in the 
multivariate model were Ki67 score (p < 0.001), p53 score (p < 0.001), tumour grade 
(p < 0.001), c-Met score (p = 0.005) and age at presentation (p = 0.006).  
 
 
 
Table 7.20: Independent association between c-Met, other prognostic factors and the 
BL sub-type (multivariate logistic regression with forward stepwise entry, n = 945). 
Abbreviations: CI = confidence interval, LR = likelihood ratio, OR = odds ratio.   
 
7.1.4 C-Met expression and survival 
 
C-Met scores were dichotomised into ‘high’ (≥ 7) or ‘low’ (< 7) to create Kaplan 
Meier curves for survival analysis, as described in section 6.4.2. 
7.1.4.1 Whole cohort 
 
Within the whole cohort, overall mean survival time was significantly shorter for 
patients with c-Met high tumours (159.6 months, 95% confidence interval (CI) = 
153.8 – 165.5 versus 181.3 months, 95% CI = 170.1 – 192.5 for c-Met low tumours, 
p = 0.009, log-rank test, n = 1319, Figure 7.2A). After taking into account four other 
factors associated with poor prognosis in breast cancer (tumour grade, lymph node 
metastasis, tumour size and patient age), c-Met remained an independent poor 
Parameter Stepwise entry order LR Chi-Square OR (95% CI) P Value
Ki67 score 1 123.7 7.30 (3.24-16.44) <0.001
p53 score 2 46.2 4.47 (2.72-7.36) <0.001
Tumour grade 3 18.3 4.98 (2.23-11.13) <0.001
C-Met score 4 9.5 6.44 (1.74-23.78) 0.005
Age 5 7.6 0.97 (0.95-0.99) 0.006
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prognostic factor in the whole cohort (hazard ratio = 1.81, 95% confidence interval 
(CI) = 1.07 – 3.06, p = 0.026, Cox regression, n = 1153, Table 7.21).   
 
 
 
 
 
Table 7.21: Multivariate model for overall survival in the whole cohort. The table 
contains those parameters that are independently predictive of reduced survival (Cox 
regression with forward stepwise entry, n = 1153). Abbreviations: LR = likelihood 
ratio, HR = hazard ratio, CI = confidence interval.  
 
 
 
 
 
 
 
 
 
 
Parameter Stepwise entry order LR Chi-Square HR (95%  CI) P-Value
Tumour grade
1 or 2 1
3 1 67.9 2.22 (1.81-2.72) <0.001
Lymph node status
No 1
Yes 2 39.1 1.84 (1.52-2.24) <0.001
Age 3 36.7 1.03 (1.02-1.04) <0.001
Tumour size 4 14.6 1.20 (1.11-1.30) <0.001
C-Met score 5 5.1 1.81 (1.07-3.06) 0.026
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Figure 7.2: Kaplan-Meier survival curves for the whole cohort. A shows overall 
survival and B shows breast cancer specific survival (BCSS). For overall survival 
(A), patients with c-Met high tumours showed a worse outcome (p = 0.009, log-rank 
test, n = 1319; hazard ratio (HR) = 1.81, 95% confidence interval (CI) = 1.07 – 3.06, 
p = 0.026, Cox regression, n = 1153). For BCSS (B), patients with c-Met high 
tumours also showed reduced survival (p = 0.047, log-rank test, n = 1319; HR = 
1.96, 95% CI = 1.07 – 3.56, p = 0.028, Cox regression, n = 1153). 
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Similarly, patients with c-Met high tumours showed shorter breast cancer specific 
survival (BCSS) compared to those with c-Met low tumours (mean survival time = 
174.7 months, 95% CI = 168.8 – 180.5 versus 192.6 months, 95% CI = 182.2 – 
202.9 respectively, p = 0.047, log-rank test, n = 1319, Figure 7.2B). C-Met remained 
a poor prognostic marker for BCSS after taking into account established prognostic 
factors (HR = 1.96, 95% CI = 1.07 – 3.56, p = 0.028, Cox regression, n = 1153, 
Table 7.22).  
 
 
 
 
 
Table 7.22: Multivariate model for BCSS in the whole cohort. The table contains 
those parameters that are independently predictive of reduced survival (Cox 
regression with forward stepwise entry, n = 1153). Abbreviations: LR = likelihood 
ratio, HR = hazard ratio, CI = confidence interval.  
 
7.1.4.2 Nottingham cohort 
 
Patients with c-Met high tumours showed shorter overall survival time compared 
with those who had c-Met low tumours (mean survival time = 162.2 months, 95% CI 
= 156.5 – 168.6 versus 186.2 months, 95% CI = 174.4 – 197.9 respectively, p = 
0.005, log-rank test, n = 1154, Figure 7.3A). C-Met expression remained a poor 
prognostic factor at multivariate analysis (HR = 1.85, 95% CI = 1.07 – 3.19, p = 
0.027, Cox regression, n = 1002). 
Parameter Stepwise entry order LR Chi-Square HR (95%  CI) P-Value
Tumour grade
1 or 2 1
3 1 90.9 2.77 (2.17-3.53) <0.001
Lymph node status
No 1
Yes 2 63.5 2.34 (1.87-2.93) <0.001
Tumour size 3 14.8 1.22 (1.13-1.33) <0.001
Age 4 10.8 1.02 (1.01-1.03) 0.001
C-Met score 5 4.9 1.96 (1.07-3.56) 0.028
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Similar results were seen with BCSS, where c-Met high tumours were associated 
with reduced patient survival (mean survival time = 177.5 months, 95% CI = 171.5 – 
183.4 versus 198.6 months, 95% CI = 187.9 – 209.3 for patients with c-Met low 
tumours, p = 0.016, log-rank test, n = 1154, Figure 7.3B). C-Met was a poor 
prognostic factor for BCSS after taking into account other prognostic factors (HR = 
2.09, 95% CI = 1.11 – 3.94, p = 0.022, Cox regression, n = 1002.) 
7.1.4.3 Homerton cohort 
 
There were no significant differences in overall survival between patients with c-Met 
high or c-Met low tumours in the Homerton patients (mean survival time = 102.3, 
95% CI = 87.1 – 117.5 versus 103.8 months, 95% CI = 89.9 – 117.7 respectively, p 
= 0.215, log-rank test, n = 165, Figure 7.4A). C-Met was not an independent 
predictor of poor outcome (HR = 2.21, 95% CI = 0.29 – 17.10, p = 0.448, Cox 
regression, n =151). 
Regarding BCSS, c-Met expression was not significantly associated with survival at 
univariate (mean survival time for c-Met high tumours = 109.4 months, 95% CI = 
94.1 – 124.7 versus 103.8 months, 95% CI = 89.9 – 117.7 for c-Met low tumours, p 
= 0.440, log-rank test, n = 165, Figure 7.4B) or multivariate analysis (HR = 1.29, 
95% CI = 0.15 – 10.73, p = 0.817, Cox regression, n = 151).  
7.1.4.4 Luminal A tumours 
 
Within the luminal A sub-group, patients with c-Met high tumours showed a shorter 
overall survival compared with c-Met low tumours (mean survival time = 169.5 
months, 95% CI = 162.5 – 176.5 versus 188.2 months, 95% CI = 174.6 – 201.8 
respectively, p = 0.034, log-rank test, n = 842, Figure 7.5A). C-Met was not an  
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Figure 7.3: Kaplan-Meier survival curves for the Nottingham cohort. A shows 
overall survival and B shows breast cancer specific survival (BCSS). For overall 
survival (A), patients with c-Met high tumours showed a worse outcome (p = 0.005, 
log-rank test, n = 1154; hazard ratio (HR) = 1.85, 95% confidence interval (CI) = 
1.07 – 3.19, p = 0.027, Cox regression, n = 1002). For BCSS (B), patients with c-
Met high tumours also showed reduced survival (p = 0.016, log-rank test, n = 1154; 
HR = 2.09, 95% CI = 1.11 – 3.94, p = 0.022, Cox regression, n = 1002). 
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Figure 7.4: Kaplan-Meier survival curves for the Homerton cohort. A shows overall 
survival and B shows breast cancer specific survival (BCSS). For both overall 
survival (A) and BCSS (B), there was no significant difference between c-Met high 
and low tumours (p = 0.215 and p = 0.440 respectively, log-rank test, n = 165).  
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Figure 7.5: Kaplan-Meier survival curves for the luminal A tumours. A shows 
overall survival and B shows breast cancer specific survival (BCSS). For overall 
survival (A), patients with c-Met high tumours showed a worse outcome at 
univariate analysis (p = 0.034, log-rank test, n = 842) but not at multivariate analysis 
(hazard ratio (HR) = 1.71, 95% confidence interval (CI) = 0.86 – 3.41, p = 0.130, 
Cox regression, n = 741). For BCSS (B), patients with c-Met high tumours also 
showed a trend towards reduced survival, but this was not significant (p = 0.146, log-
rank test, n = 842). 
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independent poor prognostic factor for overall survival at multivariate analysis (HR 
= 1.71, 95% CI = 0.86 – 3.41, p = 0.130, Cox regression, n = 741).  
Patients with c-Met high tumours showed a trend towards shorter BCSS compared to 
patients with c-Met low tumours but this was not significant at univariate (mean 
survival time = 187.3 months, 95% CI = 180.5 – 194.0 versus 203.3 months, 95% CI 
= 192.1 – 214.5 respectively, p = 0.146, log-rank test, n = 842, Figure 7.5B) or 
multivariate analysis (HR = 2.05, 95% CI = 0.90 – 4.63, p = 0.087, Cox regression, n 
= 741).  
7.1.4.5 Luminal B tumours 
 
Patients with luminal B, c-Met high tumours showed a trend towards poorer overall 
survival compared to those with luminal B, c-Met low tumours but this was not 
significant (mean survival time = 124.2 months, 95% CI = 105.5 – 142.9 versus 
154.1 months, 95% CI = 108.4 – 199.7, p = 0.579, log-rank test, n = 93, Figure 7.6A; 
HR = 1.88, 95% CI = 0.22 – 16.00, p = 0.562, Cox regression, n = 76). 
BCSS within the luminal B sub-group showed a similar trend but no significant 
difference between c-Met high and low tumours (mean survival time = 130 months, 
95% CI = 110.8 – 149.1 versus 162.7 months, 95% CI = 116.5 – 208.9 respectively, 
p = 0.536, log-rank test, n = 93, Figure 7.6B; HR = 2.17, 95% CI = 0.21 – 22.52, p = 
0.515, Cox regression, n = 76).    
7.1.4.6 Her2 positive tumours 
 
There was no significant difference in overall survival between patients with c-Met 
high and c-Met low Her2 positive tumours (mean survival time = 130.3 months, 95% 
CI = 107.3 – 153.3 versus 115.2 months, 95% CI = 64.0 – 166.5 respectively, p =  
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Figure 7.6: Kaplan-Meier survival curves for the luminal B tumours. A shows 
overall survival and B shows breast cancer specific survival (BCSS). For both 
overall survival (A) and BCSS (B), in patients with c-Met high tumours there was a 
trend towards worse outcome but this was not significant (p = 0.579 and p = 0.536 
respectively, log-rank test, n = 93).  
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0.968, log-rank test, n = 84, Figure 7.7A). C-Met expression was not a poor 
prognostic factor at multivariate analysis (HR = 2.66, 95% CI = 0.28 – 25.17, p = 
0.395, Cox regression, n = 74). 
There was no significant difference in BCSS between those patients with Her2 
positive c-Met high tumours and those with c-Met low tumours (mean survival time 
= 136.8 months, 95% CI = 113.9 – 159.8 versus 115.2 months, 95% CI = 64.0 – 
166.5 respectively, p = 0.880, log-rank test, n = 84, Figure 7.7B). C-Met scores were 
not independently associated with poor BCSS (HR = 2.64, 95% CI = 0.24 – 28.56, p 
= 0.425, Cox regression, n = 74). 
7.1.4.7 BL tumours 
 
Patients with c-Met high BL tumours showed a trend towards shorter overall 
survival, but this was not significant (mean survival time = 141.7 months, 95% CI = 
125.4 – 158 compared with 164.3 months, 95% CI = 129.0 – 199.7 for patients with 
c-Met low tumours, p = 0.310, log-rank test, n = 167, Figure 7.8A). C-Met 
expression was not significantly associated with overall survival at regression 
analysis (HR = 2.26, 95% CI = 0.52 – 9.87, p = 0.280, Cox regression, n = 147).  
There were no significant differences in BCSS between the c-Met high and low 
groups, but again there was a trend towards reduced survival in patients with c-Met 
high tumours (mean survival time = 148.1 months, 95% CI = 131.6 – 164.5 versus 
170.2 months, 95% CI = 134.9 – 205.4 for patients with c-Met low tumours, p = 
0.315, log-rank test, n =167, Figure 7.8B). At multivariate analysis c-Met scores 
were not significantly associated with BCSS (HR = 3.16, 95% CI = 0.64 – 15.51, p = 
0.156, Cox regression, n = 147).  
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Figure 7.7: Kaplan-Meier survival curves for the Her2 positive tumours. A shows 
overall survival and B shows breast cancer specific survival (BCSS). For both 
overall survival (A) and BCSS (B), there were no significant differences between c-
Met high and c-Met low tumours (p = 0.968 and p = 0.880 respectively, log-rank 
test, n = 84).  
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Figure 7.8: Kaplan-Meier survival curves for the BL tumours. A shows overall 
survival and B shows breast cancer specific survival (BCSS). For both overall 
survival (A) and BCSS (B), there was a trend towards reduced survival in patients 
with c-Met high tumours but this was not significant (p = 0.310 and p = 0.315 
respectively, log-rank test, n = 167).  
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7.1.4.8 Unclassified tumours 
 
Overall survival for patients with unclassified tumours was longer in those with c-
Met high tumours compared to those with c-Met low tumours (mean survival time = 
149.5 months, 95% CI = 125.4 – 173.6 versus 86.6 months, 95% CI = 46.6 – 126.7 
respectively, p = 0.035, log-rank test, n = 66, Figure 7.9A). This association with 
survival did not persist at multivariate analysis (HR = 0.73, 95% CI = 0.15 – 3.61, p 
= 0.698, Cox regression, n = 62). 
As with overall survival, patients with c-Met high tumours had a significantly better 
BCSS than those with c-Met low tumours (mean survival time = 160.0 months, 95% 
CI = 136 – 184 versus 93.8 months, 95% CI = 51.2 – 136.5 respectively, p = 0.031, 
log-rank test, n = 66, Figure 7.9B), but this was not significant at multivariate 
analysis (HR = 0.76, 95% CI = 0.13 – 4.42, p = 0.756, Cox regression, n = 62).        
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Figure 7.9: Kaplan-Meier survival curves for the unclassified tumours. A shows 
overall survival and B shows breast cancer specific survival (BCSS). For both 
overall survival (A) and BCSS (B) univariate analysis showed a significantly worse 
outcome for patients with c-Met low tumours (p = 0.035 and p = 0.031 respectively, 
log-rank test, n = 66) but this was not significant at multivariate analysis (Hazard 
ratio (HR) = 0.73, 95% confidence interval (CI) = 0.15 – 3.61, p = 0.698 and HR = 
0.76, 95% CI = 0.13 – 4.42, p = 0.756 respectively, Cox regression, n = 62).  
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7.2 C-Met activity in invasive breast cancer 
 
7.2.1 Patient characteristics 
 
The clinical, pathological and molecular features of the Homerton cohort on which 
the PLA was performed are outlined in Table 7.2. Of the 181 cases that make up the 
Homerton cohort, the PLA signal could be evaluated in 155 cases. As with the IHC 
analysis, the most common reasons for not quantifying the PLA signal on a tumour 
(missing case) were complete lack of tissue cores or insufficient tumour within a 
core.  
The key clinical and pathological features of the entire Homerton cohort (‘All 
Cases’) are shown alongside the features of those cases on which the PLA could be 
evaluated (‘Cases with PLA scores’) in Table 7.23. Compared with the entire 
Homerton cohort, the cases on which the PLA could be evaluated had a similar mean 
age at presentation (both 56 years old), tumour size (2.6cm versus 2.7cm 
respectively), percentage of grade 3 tumours (55% versus 56% respectively) and 
frequency of lymph node involvement (54% compared with 56% respectively).  
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Table 7.23: Characteristics of the Homerton cohort, including missing cases. The 
table shows some of the key parameters of the entire Homerton cohort (n = 181) 
compared with those patients whose tumours could be evaluated for the PLA signal 
(n = 155). Abbreviations: CI = confidence interval.  
 
7.2.2 Reproducibility of the PLA signals 
 
To establish whether the PLA signal was reproducible, two separate comparisons 
were made. Firstly, since the Homerton TMAs were constructed in triplicate, 
correlation analysis between the PLA signals in each replicate was performed. 
Secondly, after performing the PLA on 2 adjacent serial sections from the same 
TMA on different days, the average PLA signal for each tumour was correlated with 
the corresponding signal on the other serial section.  
Each core showed a strong positive correlation with each of the replicates (p < 0.001 
for all comparisons, Table 7.24). There was also a strong positive correlation 
between the average PLA signal on 1 serial section and the signal on the adjacent 
serial section (p < 0.001, Table 7.24). 
 
 
 
Parameter Cases with PLA scores All Cases 
Age (mean, 95% CI) 56.7 (37-82) years 56.9 (37-82) years
Tumour size (mean, 95% CI) 2.7 (1.0-5.4) cm 2.6 (1.0-5.1) cm
Tumour grade (% of cases)
1 9 8
2 35 37
3 56 55
Lymph node involvement (% of cases)
Yes 56 54
No 44 46
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Table 7.24: Reproducibility of the PLA signals. Correlation between PLA signals on 
replicates on the same TMA section (for example, Core 1 vs Core 2) and between 
adjacent serial sections (TMA 1a vs TMA 1b) (Spearman’s correlation coefficient). 
 
7.2.3 Correlation between PLA signals and prognostic factors 
 
The PLA signals (Figure 7.10) showed a moderately strong and significant positive 
correlation with c-Met IHC scores (r = 0.419, p < 0.001, Figure 7.11) and a 
significant negative correlation with Ki67 scores (p = 0.033, Table 7.25). There were 
no significant correlations between PLA signals and patient age or tumour size 
(Table 7.25). 
 
 
Table 7.25: Correlation between PLA signals and prognostic factors (continuous 
variables). Significant correlations are given in italics (Spearman’s correlation 
coefficient, n = 155). 
 
PLA signals were significantly higher in low grade tumours compared to high grade 
tumours (mean PLA signals/nucleus = 3.8 versus 3.0 respectively, p = 0.022, Table 
7.26). There were no significant differences in PLA signals with any of the other 
parameters displayed in Table 7.26). 
 
Parameter Correlation Coefficient P-Value
Age 0.076 0.350
Tumour size -0.121 0.140
Ki67 score -0.178 0.033
Comparison Correlation Coefficient P-Value
Core 1 vs Core 2 0.742 <0.001
Core 1 vs Core 3 0.687 <0.001
Core 2 vs Core 3 0.825 <0.001
TMA 1a vs TMA 1b 0.863 <0.001
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Figure 7.10: Images of the PLA signals in tissue samples, with corresponding IHC 
images. A (IHC) and B (PLA) are from the same tumour showing low PLA signal in 
a tumour with weak c-Met immunopositivity. C (IHC) and D (PLA) are from 
another tumour, showing high PLA signal in a tumour that was strongly 
immunoreactive for c-Met. A and C are brightfield images (IHC; x40 objective), B 
and D are confocal immunofluorescent images (nuclei are in blue (DAPI), the PLA 
product is in red, x63 objective under oil immersion). All scale bars represent 20µm, 
inset images are at 200% magnification.    
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Figure 7.11: Scatter plot showing the correlation between PLA signals/nucleus and 
c-Met scores at IHC. There is a positive correlation between the 2 variables (r = 
0.419, p <0.001, Spearman’s correlation co-efficient).  
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Table 7.26: Correlation between PLA signals and prognostic factors (categorical 
variables). Significant findings are shown in italics (Mann-Whitney test, n = 155). 
Abbreviations: CI = confidence interval, IDC-NST = invasive ductal carcinoma, no 
special type, ILC = invasive lobular carcinoma, MC = mucinous carcinoma. 
 
7.2.4 PLA signals and survival 
 
Cases were dichotomised into ‘PLA high’ (mean signals/nucleus ˃3.19) or ‘PLA 
low’ (mean signals/nucleus ≤3.19) to create Kaplan-Meier curves for survival 
analysis, as described in section 6.7.2. 
Parameter Mean PLA score (95%  CI) P-Value
Tumour Grade
1 or 2 3.8 (3.2-4.4)
3 3.0 (2.6-3.5) 0.022
Lymph node involvement
Yes 3.5 (3.0-4.0)
No 3.2 (2.6-3.8) 0.269
Histological sub-type
IDC vs Non-IDC 3.4 (3.0-3.8) vs 3.2 (2.1-4.3) 0.308
ILC vs Non-ILC 2.9 (1.3-4.4) vs 3.4 (3.0-3.8) 0.675
Mucinous carcinoma (MC) vs Non-MC 4.4 (0-11.9) vs 3.4 (3.0-3.7) 0.855
Medullary/atypical vs Non-medullary/atypical 2.0 (0.5-3.5) vs 3.4 (3.0-3.8) 0.275
Molecular sub-type
Luminal A vs Non-Luminal A 3.4 (2.9-3.9) vs 3.3 (2.7-4.0) 0.937
Luminal B vs Non-Luminal B 4.5 (1.8-7.2) vs 3.3 (2.9-3.6) 0.514
Her2 positive vs Non-Her2 4.0 (2.4-5.7) vs 3.3 (2.9-3.7) 0.198
Basal-like (BL) vs Non-BL 3.0 (2.3-3.6) vs 3.5 (3.0-3.9) 0.535
Unclassified vs Non-Unclassified 2.5 (1.4-3.6) vs 3.4 (3.0-3.8) 0.430
Ethnicity
Black 3.3 (2.8-3.9) 
White 3.4 (2.9-3.9) 0.918
Her2 status
Positive 4.3 (2.8-5.8)
Negative 3.3 (2.9-3.6) 0.175
EGFR status
Positive 3.5 (2.8-4.2)
Negative 3.5 (3.0-4.0) 0.740
E-Cadherin status
Positive 3.5 (2.9-4.0)
Negative 3.2 (2.7-3.8) 0.560
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There was a trend towards increased survival time in patients with PLA high 
tumours compared to those with PLA low tumours, although this was not significant 
(mean survival time = 122.8 months, 95% CI = 105.2 – 140.3 versus 89.4 months, 
95% CI = 76.2 – 102.6 respectively, p = 0.098, log-rank test, n = 139, Figure 7.12A). 
Tumour PLA signals were not significantly associated with outcome at multivariate 
analysis (HR = 0.98, 95% CI = 0.85 – 1.14, p = 0.807, Cox regression, n = 129).  
A similar trend was seen for BCSS, with longer survival time in PLA high tumours 
(mean survival time = 129.2 months, 95% CI = 112.6 – 145.9 versus 93.0 months, 
95% CI = 79.8 – 106.2 for PLA low tumours, p = 0.064, log-rank test, n = 139, 
Figure 7.12B), although this was of borderline significance. At multivariate analysis, 
tumour PLA signals were not an independent predictor of outcome (HR = 0.93, 95% 
CI = 0.78 – 1.10, p = 0.390, Cox regression, n = 129).  
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Figure 7.12: Kaplan-Meier survival curves for PLA high and PLA low tumours. A 
shows overall survival and B shows breast cancer specific survival (BCSS). For both 
overall survival (A) and BCSS (B), univariate analysis showed a trend towards 
longer survival in PLA high tumours that was of borderline significance in BCSS (p 
= 0.098 and p = 0.064 respectively, log-rank test, n = 139) but PLA signals were not 
significant at multivariate analysis (HR = 0.98, 95% CI = 0.85 – 1.14, p = 0.807 and 
HR = 0.93, 95% CI = 0.78 – 1.10, p = 0.390 respectively, Cox regression, n = 129).  
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7.3 The effect of HGF in in-vitro models of BL cancer 
 
7.3.1 The effect of HGF on migration 
 
To establish whether HGF-mediated c-Met phosphorylation may contribute to the 
migratory phenotype in BL breast cancer, transwell migration assays (n = 4) were 
performed on the MDA-MB-468 and HCC1937 breast cancer cell lines.  
After 8 hours, there was a significant difference in cell migration in the MDA-MB-
468s under the 4 treatment conditions (un-stimulated, HGF stimulation, SU 
inhibition and combined SU/HGF treatment) (p = 0.003, Figure 7.13A). Between 
group comparisons showed a significantly higher percentage of cells migrated after 
HGF stimulation (mean migration = 46.9%) compared to un-stimulated cells (36.4%, 
p = 0.004), SU treated cells (38.8%, p = 0.004) and SU/HGF treated cells (38.7%, p 
= 0.006). There were no significant differences between the other conditions. 
Similarly, the HCC1937 cells showed significant differences in migration under the 
different conditions (p = 0.001, Figure 7.13B). Again, the HGF stimulated cells 
showed a higher mean percentage migration (60%) compared to un-stimulated cells 
(46.4%, p = 0.006) and SU treated cells (49.6%, p = 0.004). The SU/HGF treated 
cells also showed lower mean migration, but this was of borderline significance after 
correcting for multiple group testing (52.2%, p = 0.011). There were no significant 
differences between the other conditions. 
7.3.2 The effect of HGF on cell viability 
 
To assess whether the increased migration in HGF stimulated cells was due to 
increased proliferation, MTS cell viability assays (n = 3) were performed, comparing 
un-stimulated cells with cells exposed to increasing doses of HGF (up to 100ng/ml).  
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Figure 7.13: Transwell migration assays. The bar charts show the mean migration 
(expressed as a percentage of total cells seeded) over an 8 hour time period in the A 
MDA-MB-468s and B HCC1937s with and without treatment with HGF and SU. 
There was a significant increase in migration after HGF stimulation in both cell lines 
but this was abrogated when the cells were treated with SU. The results are derived 
from pooled data from 4 experiments (** = p<0.01).     
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A standard curve was used to estimate the number of viable cells (Figure 7.14). After 
8 hours, there was no significant difference in the mean number of viable cells (both 
the MDA-MB-468 cells and HCC1937 cells, p = 0.502 and 0.812 respectively, 
Figure 7.15A and B). There were no significant differences noted in between group 
comparisons.   
7.3.3 The effect of HGF on protein expression 
 
To address whether the effect of HGF on migration may be due to the acquisition of 
an EMT phenotype and an alteration in the E-Cadherin/β-Catenin complex, western 
blot analysis were performed on lysates from MDA-MB-468 and HCC1937 cells 
exposed to different treatment conditions and probed for E-Cadherin, β-Catenin and 
vimentin, as well as phospho-c-Met and c-Met. 
7.3.3.1 MDA-MB-468 breast cancer cells 
 
There was no significant difference in E-Cadherin expression at 20 minutes of HGF 
stimulation (mean adjusted relative density (mARD) = 0.87) or 120 minutes (mARD 
= 0.98), relative to un-stimulated cells (mARD = 1, p = 0.191, Figure 7.16A and B).  
There was no significant change in β-Catenin expression under these treatment 
conditions (mARD after 20 minutes HGF = 1.06, mARD after 120 minutes = 0.98) 
relative to un-stimulated cells (mARD = 1, p = 0.832, Figure 7.16A and C). There 
was no expression of vimentin (Figure 7.16A). 
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Figure 7.14: Representative standard curves used to calculate cell viability in the 
MTS assay. The graph in A shows the MDA-MB-468s, the graph in B shows the 
HCC1937s. Both graphs show increasing optical densities correlating with 
increasing cell numbers. The R
2
 Linear figure represents the Pearson coefficient of 
determination. Abbreviations: A.U = arbitrary units.    
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Figure 7.15: MTS cell viability assays. The bar charts show the number of viable 
cells (MDA-MB-468s in A and HCC1937s in B) after an 8 hour time point. There is 
no statistically significant change in the number of viable cells in either cell line after 
stimulation with 1-100 ng/ml of HGF. The results represent the pooled data from 3 
experiments.    
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Figure 7.16: Protein expression in MDA-MB-468s by western blot. In A only the 
unopposed HGF lanes show c-Met phosphorylation. There is no change in E-
Cadherin or β-Catenin expression with HGF treatment, which is quantified in B and 
C. There is no expression of vimentin in any treatment condition; the positive 
control is a lysate from the MDA-MB-231 cell line. Abbreviations: ARD = adjusted 
relative density. 
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7.3.3.2 HCC1937 breast cancer cells  
 
As with the MDA-MB-468s, there were no significant differences in E-Cadherin 
expression at 20 or 120 minutes relative to un-stimulated cells (mARD = 1.04, 1.19 
and 1 respectively, p = 0.550, Figure 7.17A and B) or in β-Catenin expression at 20 
and 120 minutes (mARD = 1.03 and 0.97 respectively, relative to 1 for un-treated 
cells, p = 0.832, Figure 7.17A and C). There was no expression of vimentin (Figure 
7.17A). 
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Figure 7.17: Protein expression in HCC1937s by western blot. In A only the 
unopposed HGF lanes show c-Met phosphorylation. There is no change in E-
Cadherin or β-Catenin expression with HGF treatment, which is quantified in B and 
C. There is no expression of vimentin in any treatment condition; the positive 
control is a lysate from the MDA-MB-231 cell line. Abbreviations: ARD = adjusted 
relative density. 
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7.3.4 The effect of HGF on E-Cadherin localisation and co-localisation 
 
After finding no effect on the amount of protein expression, I sought to establish if 
HGF could be having an effect on migration by altering the location of E-Cadherin 
within the cell and whether the protein trafficked to the cytosol in a similar way to c-
Met following ligand binding. Therefore, immunofluorescence for E-Cadherin and c-
Met was performed on the MDA-MB-468 and HCC1937 cells after 20, 60 and 120 
minutes of HGF treatment. 
7.3.4.1 MDA-MB-468 breast cancer cells 
 
In untreated MDA-MB-468 cells, the majority of cells showed membranous E-
Cadherin expression (84.4%, Figure 7.18 and 7.19A). There was a reduction in 
membrane expression at 20 minutes (76.6%) followed by an increase to 83.4% at 60 
minutes and 93% at 120 minutes, resulting in a borderline significant difference 
across the four groups (p = 0.062). However, there were no significant differences in 
the between group comparisons, after correcting for multiple group testing.   
Co-localisation analysis showed a reduction in E-Cadherin/c-Met co-localisation 
with increasing duration of HGF stimulation (Figure 7.18 and 7.19B) and this was 
significant across the four groups (p = 0.001). Between group analysis showed 
significant differences between a) un-stimulated cells (mean co-localisation = 
41.8%) and cells stimulated for 60 min (mean co-localisation = 13.6%, p = 0.009), b) 
un-stimulated cells and cells exposed to 120 minutes of HGF (mean co-localisation = 
11%, p = 0.009), c) cells stimulated with 20 minutes of HGF (29.6%) and the 60 
minute group (p = 0.009) and d) the 20 minute group versus cells exposed to 120 
minutes of the ligand (p = 0.009). There were no significant differences between the 
other groups. 
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Figure 7.18: Immunofluorescence for c-Met and E-Cadherin in MDA-MB-468s. Images A – C are untreated cells and D – F are of cells 
stimulated for 20 minutes with HGF; C-Met (A and D) is in green, E-Cadherin (B and E) is in red; C and F are the merged images, where yellow 
represents c-Met/E-Cadherin co-localisation. There is trafficking of c-Met from the membrane to the perinuclear compartment after HGF 
stimulation but E-Cadherin remains at the membrane. Consequently, co-localisation is reduced in the treated cells (confocal immunofluorescent 
microscopy, x63 objective under oil immersion, nuclei are in blue (DAPI stain); scale bars represent 20µm). 
A B C 
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Figure 7.19: Membranous expression of E-Cadherin and c-Met/E-Cadherin co-
localisation in MDA-MB-468 cells. A shows the percentage of cells that express E-
Cadherin at the membrane in unstimulated cells and at different time points of HGF 
treatment. There were no statistically significant differences. B shows the percentage 
of total E-Cadherin pixels that co-localised with c-Met. Overall, co-localisation 
decreased with HGF treatment (p = 0.001, Kruskal-Wallis test) and this was 
significant at pair-wise analysis after 60 and 120 minutes compared to untreated cells 
and cells treated for 20 minutes (p = 0.009 for all, Mann-Whitney test). Error bars 
represent the 95% CI, ** = p<0.01.    
A 
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7.3.4.2 HCC1937 breast cancer cells 
 
HCC1937 cells in the different treatment conditions showed similar amounts of 
mean membranous E-Cadherin: 94.4% in un-stimulated cells, 94% after 20 minutes 
HGF, 96.2% after 60 minutes and 93.2% after 120 minutes (Figure 7.20 and 7.21A). 
Correspondingly, there was no statistically significant difference across the groups (p 
= 0.768) and no significant between group differences. 
As with the MDA-MB-468s, mean co-localisation showed a downward trend with 
increasing duration of HGF treatment, albeit with a small increase between 60 and 
120 minutes (Figure 7.20 and 7.21B). The mean co-localisation at baseline was 
21.8%, falling to 10.8% after 20 minutes of HGF treatment, 6.8% after 60 minutes 
and 7.8% after 2 hours. Statistically, there was a significant difference across the 
groups (p = 0.016) but between group analysis showed only a borderline difference 
between baseline and 60 minutes treatment and baseline and 120 minutes of HGF (p 
= 0.014 for both). The other groups showed no significant differences after 
correcting for multiple group testing.  
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Figure 7.20: Immunofluorescence for c-Met and E-Cadherin in HCC1937s. Images A – C are untreated cells and D – F are of cells stimulated 
for 20 minutes with HGF; C-Met (A and D) is in green, E-Cadherin (B and E) is in red; C and F are the merged images, where yellow represents 
c-Met/E-Cadherin co-localisation. There is trafficking of c-Met from the membrane to the perinuclear compartment after HGF stimulation but E-
Cadherin remains at the membrane. Consequently, co-localisation is reduced in the treated cells (confocal immunofluorescent microscopy, x63 
objective under oil immersion, nuclei are in blue (DAPI stain); scale bars represent 20µm).   
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Figure 7.21: Membranous expression of E-Cadherin and c-Met/E-Cadherin co-
localisation in HCC1937 cells. A shows the percentage of cells that express E-
Cadherin at the membrane in unstimulated cells and at different time points of HGF 
treatment. There were no statistically significant differences. B shows the percentage 
of total E-Cadherin pixels that co-localised with c-Met. Overall, co-localisation was 
reduced with HGF treatment (p = 0.016, Kruskal-Wallis test) and this was of 
borderline significance at pair-wise analysis at the 60 and 120 minutes versus 
untreated cells (p = 0.014 for both). Error bars represent the 95% CI.    
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8.0 Discussion 
 
8.1 C-Met expression in invasive breast cancer 
 
8.1.1 C-Met expression and molecular sub-type 
 
The results from this study of over 1450 samples show that significantly higher 
levels of c-Met are present in the BL sub-type compared to other molecular sub-
types of breast cancer. In contrast, the luminal A tumours showed significantly lower 
c-Met expression. Those triple negative (TN) tumours that lacked basal 
cytokeratin/EGFR expression – the unclassified tumours – did not show higher 
levels of c-Met. (Ho-Yen et al, 2013; Ho-Yen et al, 2014). This finding reinforces 
the argument for distinguishing BL tumours from the wider TN group and raises the 
possibility that c-Met may contribute to the poorer outlook associated with BL TN 
tumours compared to non-BL TN cancers (Cheang et al, 2008). Importantly, this is 
the first study to demonstrate an association between c-Met and BL tumours that is 
independent of other relevant clinical, pathological and immunohistochemical 
parameters (Ho-Yen et al, 2014). 
Previously, smaller studies have described higher levels of c-Met in human BL 
tumours (Charafe-Jauffret et al, 2006; Garcia et al, 2007a; Graveel et al, 2009). 
Charafe-Jauffret and co-workers used a set of 388 genes (including MET) to perform 
hierarchical clustering on 122 breast tissue samples (comprising 115 cancers and 7 
non-malignant samples)(Charafe-Jauffret et al, 2006). It was shown that this gene set 
correctly separated the luminal A tumours from the BL tumours, with MET over-
expression forming part of the BL cluster (Charafe-Jauffret et al, 2006). In an 
immunohistochemical analysis of 137 invasive breast carcinomas, Graveel et al 
198 
 
identified significantly higher levels of c-Met in BL tumours at univariate analysis 
(Graveel et al, 2009). Another IHC-based study used TMAs (constructed from over 
900 samples) to look at the relationship between c-Met, a variety of other BL 
markers (including CK5/6, p63 and c-Kit) and outcome (Garcia et al, 2007a). The 
authors noted a worse outcome for c-Met high tumours, but no direct relationship 
between c-Met and the BL phenotype was presented (Garcia et al, 2007a).  
My findings are further supported by the fact that the association between c-Met and 
BL status was present in both the Nottingham and Homerton cohorts, two quite 
different and independent collections of invasive breast cancers. Furthermore, the 
characteristics of the BL tumours in the current study are similar to those previously 
described in the literature. These include: younger age at presentation (Cheang et al, 
2008), larger tumour size (Kuroda et al, 2008), predominance of the histological 
category of IDC-NST (Carey et al, 2006), high proliferation rate and high nuclear 
grade (Fulford et al, 2006) and high levels of p53 expression (Manié et al, 2009). 
Thus, the current cohort would appear to be an accurate representation of the BL 
category and as such, my findings (with respect to c-Met expression) could be 
extrapolated to the wider population.  
The current findings are supported further by in-vivo work using different mouse 
models of mutated MET (Ponzo et al, 2009; Graveel et al, 2009). A knock-in mouse 
model with mutationally activated MET developed mammary carcinomas with 
varying histological appearances, but showed a high frequency (65% of tumours) of 
squamous metaplasia, a feature more commonly seen in human BL tumours (Graveel 
et al, 2009; Fulford et al, 2006). Moreover, the basal cytokeratin CK5 was detected 
in the majority of tumours arising in these mice (Graveel et al, 2009). Similarly, 
Ponzo and colleagues generated a transgenic mouse model in which c-Met was 
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expressed in the mammary epithelium (Ponzo et al, 2009). The tumours that 
subsequently developed could be placed into one of two morphological categories: 
1) tumours with a solid nodular architecture or, 2) those with papillary, scirrhous, 
adenosquamous or spindle-cell appearances (referred to as ‘mixed pathology’ 
tumours)(Ponzo et al, 2009). As well as squamous and spindle-cell differentiation, 
the ‘mixed pathology’ tumours showed other BL characteristics such as high nuclear 
grade, necrosis and lymphocytic infiltration (Ponzo et al, 2009; Livasy et al, 2006). 
In addition, these tumours clustered with human BL cancers at gene expression 
profiling and expressed cytokeratins 5, 6 and 14 on IHC (Ponzo et al, 2009).  
Of note, the ‘solid’ tumours more closely resembled luminal tumours on gene 
expression and IHC analysis, prompting the authors to speculate that multi-potent 
stem cells with the potential to differentiate into either luminal or basal cells may be 
a key target of c-Met (Ponzo et al, 2009). The fact that neither of these mouse 
models develops BL mammary tumours exclusively is consistent with the current 
analysis, where c-Met was expressed in each of the five molecular sub-types. 
Clearly, c-Met should not be regarded as a specific marker of the BL sub-type. 
Rather, the main message from this sub-type analysis is that patients with BL 
tumours should be included in future clinical trials of c-Met inhibitors, given the 
high level of c-Met expression in this sub-type and the lack of alternative targeted 
therapy. 
It is also emerging that anti-c-Met therapy may have a role in the treatment of 
patients who have already received systemic molecular treatment (Minuti et al, 
2012). In an analysis of 130 patients with Her2 positive metastatic breast cancer, 
Minuti and colleagues found that tumours with high gene copy numbers of HGF or 
MET (as assessed by FISH) were associated with a higher risk of trastuzumab-based 
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treatment failure (Minuti et al, 2012). This study is supported by other work showing 
that HGF-mediated c-Met activation abolished the growth inhibitory response of 
Her2 expressing SKBR3 breast cancer cells to trastuzumab (Shattuck et al, 2008). 
Both the SKBR3 cell line and another Her2 positive cell line – BT474 – significantly 
up-regulated c-Met expression after less than 2 days of trastuzumab treatment 
(Shattuck et al, 2008). These workers also observed that trastuzumab-dependent p27 
(a cyclin-dependent kinase inhibitor) expression was reduced when either cell line 
was treated with HGF, suggesting a possible mechanism for HGF/c-Met mediated 
protection from the inhibitory effect of trastuzumab (Shattuck et al, 2008).  
Although c-Met expression in the current study was not significantly increased in the 
Her2 positive sub-type (or associated with positivity for the Her2 receptor), one 
should bear in mind that many of the samples in the Homerton cohort and all of the 
Nottingham cohort pre-date the widespread use of trastuzumab in the UK.    
8.1.2 C-Met expression and other prognostic factors 
 
8.1.2.1 Tumour size 
 
This study demonstrated an inverse correlation between c-Met expression and 
tumour size. This relationship was significant in the cohort as a whole, the 
Nottingham cohort and within the luminal A and unclassified sub-types. This finding 
was unexpected given the fact that BL tumours have a larger mean size at 
presentation (Kuroda et al, 2008). This is true also in the current analysis, where 
increasing tumour size was significantly associated with BL status at univariate 
analysis.  
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Others have found no association between c-Met expression and tumour size (Jin et 
al, 1997; Camp et al, 1999; Nakopoulou et al, 2000; Lengyel et al, 2005; Lindemann 
et al, 2007; Zagouri et al, 2013). Previously, it has been shown that tumour size is 
not a good predictor of outcome in BL cancer, possibly due to the relatively early 
occurrence of blood-borne metastasis in this molecular sub-type (Foulkes et al, 
2009). Hence, one could speculate that c-Met plays an important part in the 
aggressive behaviour of some smaller tumours. Interestingly, in a previous analysis 
of the Homerton cohort, black women with smaller breast cancers (≤ 2 cm) had a 
poorer prognosis than white women matched for tumour size (Bowen et al, 2008). It 
is possible that c-Met contributed to the poorer outlook for these black patients.   
8.1.2.2 Lymph node involvement 
 
The propensity for BL cancers to metastasize via the haematogenous route rather 
than through the lymphatics to the lymph nodes (Rakha et al, 2009), also explains 
the finding of higher c-Met scores in lymph node negative tumours in the current 
analysis. 
8.1.2.3 Patient age 
 
As is the case with previous studies, this study found no significant association 
between c-Met and patient age at presentation in the whole cohort analysis (Camp et 
al, 1999; Nakopoulou et al, 2000; Lengyel et al, 2005; Lindemann et al, 2007; 
Zagouri et al, 2013). Interestingly, there was a significant positive association 
between these variables when only the Homerton cohort was considered. It could be 
argued that this reflects the differences in demographics between the two collections 
of patient samples (the mean age at presentation was nearly three years older in the 
Homerton series compared to the Nottingham collection). However, the finding that 
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the luminal A tumours alone (most of which come from the Nottingham set) show 
the same correlation suggests that this is not the case.  
8.1.2.4 Tumour grade 
 
Regarding tumour grade, there was no association with c-Met in the wider cohort, or 
in the sub-type analysis, with the exception of the Her2 positive sub-type, where c-
Met scores were significantly lower in high grade tumours. Other groups have made 
conflicting observations when considering c-Met and tumour differentiation (Jin et 
al, 1997; Camp et al, 1999; Nakopoulou et al, 2000; Zagouri et al, 2013). Some 
found no association between tumour grade and c-Met (Jin et al, 1997; Lengyel et al, 
2005; Chen et al, 2007), while others noted higher expression of the receptor in high 
grade tumours, although the study by Zagouri et al focused only on TN tumours 
(Camp et al, 1999; Zagouri et al, 2013). In contrast, Nakopoulou and colleagues 
identified more frequent c-Met staining in grade 1 carcinomas, where 75% of 
tumours were positive compared to 43.8% of grade 3 tumours (Nakopoulou et al, 
2000). The study by Nakopoulou et al emerged before the widespread acceptance of 
the molecular classification proposed by Perou et al (Perou et al, 2000) and therefore 
no sub-type analysis is presented, but since only 10% of tumours were immuno-
reactive for Her2 it is unlikely that the Her2 positive sub-type was over-represented 
in their study (Nakopoulou et al, 2000).   
8.1.2.5 Histological sub-type 
 
Tubular carcinomas had the highest c-Met scores in the whole and Nottingham 
cohorts, but only one case of tubular carcinoma was present in the Homerton series 
(precluding further statistical analysis). Unlike the Nottingham cohort, the Homerton 
tumours classified as IDC showed significantly higher c-Met expression compared to 
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non-IDC tumours. In all probability, these differences are due to the different 
reporting practices employed at the two centres. The striking difference in the 
percentage of tumours classified as IDC (82% in the Homerton cohort versus 59% in 
the Nottingham cohort) strongly suggests a higher threshold for diagnosing tubular 
(and mixed histology) carcinomas in our ‘in-house’ series. It is not possible to say 
whether there were too many IDCs classified as tubular carcinomas in the 
Nottingham cohort or too few in the Homerton cohort, although data from the 
Surveillance, Epidemiology and End Results (SEER) registry does quote a tubular 
carcinoma frequency of 0.7% (Berg and Hutter, 1995). Either way, if the proportions 
of each of the histological sub-types were more similar then it would seem plausible 
that the statistical trends of both cohorts, with regard to c-Met, would match up more 
closely. 
C-Met expression in ILC was more consistent across the cohorts, with lower levels 
in the cohort as a whole and both the Nottingham and Homerton components 
(although the association was only of borderline significance in the Homerton 
series). Few clinical studies have specifically addressed the relationship between c-
Met and histological sub-type. Tubular carcinomas are a well differentiated form of 
breast cancer, characterised by angulated tubules that frequently demonstrate ‘apical 
snouting’ (Harris et al, 2006). It seems paradoxical that these tumours that are 
generally associated with a favourable outcome compared to controls (Harris et al, 
2006) should express higher levels of c-Met. However, some have stated that the role 
of HGF (and c-Met) may vary depending on the degree of tumour differentiation, 
such that HGF/c-Met contributes to the invasive profile of poorly differentiated 
tumours whilst driving gland formation in those tumours with functioning adhesion 
complexes (Rosen et al, 1994). With reference to c-Met expression in ILC, other 
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studies have shown mixed results (Nakopoulou et al, 2000; Chen et al, 2007; 
Carracedo et al, 2009; Zagouri et al, 2013). Carracedo et al found a significantly 
higher number of c-Met positive cases in IDCs compared to ILCs (Carracedo et al, 
2009) whereas Nakopoulou and co-workers noted the opposite: 22.2% of ILCs 
showed strong staining in more than 50% of tumour cells compared to 3.9% of 
tumours classified as IDC (Nakopoulou et al, 2000). Two other studies found no 
statistical difference in c-Met expression when comparing histological sub-types 
(Chen et al, 2007; Zagouri et al, 2013).  
Classical ILCs have a distinct histological appearance in which relatively bland 
discohesive tumour cells infiltrate the breast stroma, accompanied by absent or 
reduced expression of E-Cadherin on IHC (Harris et al, 2006).  
8.1.2.6 E-Cadherin status 
 
My findings regarding c-Met and ILC are mirrored and supported by the analysis of 
the correlation between c-Met score and E-Cadherin status, where c-Met was 
consistently over-expressed in E-Cadherin positive tumours (significantly so in the 
whole cohort and the Homerton component). Given the relative scarcity of ILCs (this 
sub-type accounted for only 7% of the whole cohort), it should be appreciated that 
the analysis of E-Cadherin status in this study is mostly based on non-ILCs. 
Other workers have considered the relationship between c-Met and E-Cadherin in 
non-ILCs, but a clear consensus has not yet been established. Götte and colleagues 
looked at IHC expression of these proteins in pure DCIS and where DCIS co-existed 
with invasive carcinoma (though only the DCIS component was analysed in the 
latter)(Götte et al, 2007). They found a significant positive correlation between c-
Met and E-Cadherin in the pure DCIS cases, but noted a significant reduction in c-
205 
 
Met levels in co-existent DCIS samples (Götte et al, 2007), suggesting that co-
expression is lost with disease progression. Another study looked at 55 IDCs and 95 
cases of DCIS, performing IHC for a variety of markers associated with EMT 
(Logullo et al, 2010). There was no significant correlation between c-Met and E-
Cadherin in either the invasive or in-situ carcinomas (Logullo et al, 2010). In an 
analysis of 41 cases of inflammatory breast carcinomas (IBCs) – an uncommon form 
of breast cancer linked with an aggressive clinical course – Garcia et al found that all 
of the IBCs showed immunopositivity for E-Cadherin and c-Met (Garcia et al, 
2007b).  
These studies illustrate how the E-Cadherin/c-Met relationship varies across 
different groups and in different types of samples. Yet it is tempting to find the 
results of the current study puzzling since HGF/c-Met signalling is thought to drive 
epithelial dissociation by negatively regulating cadherins (Rosen et al, 1994). Some 
have suggested that c-Met may influence adhesion and migration despite the 
presence of E-Cadherin (Garcia et al, 2007b). It is possible that in such cases E-
Cadherin is ineffective or that an intact cell-cell adhesion apparatus is actually 
necessary for the formation and dissemination of compact tumour emboli consisting 
of several tumour cells (Garcia et al, 2007b). 
8.1.2.7 EGFR status 
 
Another biomarker that demonstrated a relatively consistent positive association with 
c-Met expression was EGFR. This is not surprising, since EGFR was one of the 
basal markers used to identify BL tumours in this study and it has already been 
shown that c-Met is independently predictive of this sub-type. In lung cancer cells, 
EGFR activation due to EGF stimulation or an activating mutation has been shown 
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to increase both the gene and protein levels of c-Met, via the hypoxia-inducible 
factor (HIF)-1α pathway (Xu et al, 2010). Also in non-small cell lung carcinoma 
cells (NSCLCs), amplification of the MET gene has been linked with resistance to 
the EGFR inhibitor gefitinib by stimulating ErbB3 (Her3) signalling and PI3K 
activation (Engelman et al, 2007). A similar compensatory relationship has been 
described in SUM229 breast cancer cells (Mueller et al, 2008). These cells were able 
to maintain EGFR phosphorylation in the presence of gefitinib, when c-Met and c-
Src were also phosphorylated (Mueller et al, 2008). The authors went on to 
demonstrate that inhibition of c-Met reduced c-Src phosphorylation, EGFR 
phosphorylation and cell growth during treatment with EGFR inhibitors (Mueller et 
al, 2008). Taken together with the results of the current study, these findings re-
iterate the point that co-expression of EGFR and c-Met may have implications in the 
treatment of BL breast cancer.  
8.1.2.8 Ki67 scores 
 
The HGF/c-Met signalling axis is thought to drive cellular proliferation through 
several down-stream signalling cascades (Trusolino et al, 2010). Therefore, a 
significant inverse correlation between c-Met and Ki67 scores in the sub-type 
analysis in luminal A and BL tumours was unexpected. It is very likely that this 
inverse correlation partly explains why c-Met expression was included in the 
multivariate model predictive of BL status. If c-Met had positively correlated with 
Ki67 (a strong predictor of BL status), c-Met scores may not have provided any 
additional predictive power to the model, potentially leading to its exclusion. 
Other immunohistochemical studies have correlated c-Met expression with Ki67 
scores in in-situ and invasive breast carcinoma (Edakuni et al, 2001; Tolgay Ocal et 
207 
 
al, 2003; Lindemann et al, 2007). Tolgay Ocal et al found a positive correlation 
between c-Met and Ki67 (Tolgay Ocal et al, 2003) and Edakuni and colleagues 
showed a higher Ki67 index in those cases where HGF and c-Met were co-expressed 
(c-Met in the tumour cells and HGF in the tumour cells and/or stromal cells) 
(Edakuni et al, 2001). In their analysis of DCIS samples, Lindemann et al found no 
association between c-Met and Ki67 expression, but they did see a significant 
correlation between HGF and Ki67 (Lindemann et al, 2007). These last two studies 
suggest that HGF-mediated c-Met activation rather than c-Met expression per se 
may be a more accurate marker of tumour proliferation.  
8.1.2.9 p53 scores 
 
Expression of p53, like Ki67, showed no significant correlation with c-Met in the 
whole cohort, but did show a significant inverse correlation in the BL tumours. A 
couple of recent studies have sought to examine the role of c-Met and p53 in pre-
clinical models of mammary tumourigenesis (Smolen et al, 2006; Knight et al, 
2013). Mammary tumours generated by combining a heterogeneous TP53 mutation 
with a BRCA1 deletion were analysed by oligonucleotide arrays (Smolen et al, 
2006). Out of the 15 mice included in the study, 11 (73%) showed amplification of 
the MET gene (Smolen et al, 2006). In contrast, these workers found no high level 
amplification of MET when they analysed 100 sporadic human breast cancers, 
prompting the authors to suggest that MET amplification may not be a crucial event 
in human breast tumours (Smolen et al, 2006).  
To further investigate the events leading to TN breast cancer, another study 
combined a transgenic mouse model expressing oncogenic MET with a conditional 
deletion of TP53 (Knight et al, 2013). The vast majority (80%) of tumours from 
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these mice showed a spindle-cell morphological appearance and this contrasted with 
the varied histology observed in mice harbouring only the oncogenic MET (Knight et 
al 2013; Ponzo et al, 2009). Moreover, these spindle-cell tumours showed weak or 
sporadic expression of the cytokeratins, but strong vimentin and c-Met 
immunoreactivity (Knight et al, 2013). Gene expression profiling showed that these 
spindle-cell tumours clustered with the claudin-low sub-group of human breast 
cancers. The authors concluded that MET and TP53 synergise to promote the 
formation of claudin-low tumours (Knight et al, 2013).  
Claudin-low tumours are usually TN and show similar gene expression profiles to 
BL cancers (Perou, 2011). As there is currently no established immunohistochemical 
marker for claudin-low tumours, one would expect these tumours to fall into the BL 
or non-BL TN (unclassified in my cohort) groups of tumours (Knight et al, 2013). 
Perhaps the inverse correlation between c-Met and p53 in the BL tumours in the 
current analysis reflects a paucity of claudin-low tumours.      
8.1.3 C-Met expression and survival 
 
This study confirmed that overall, patients with c-Met high tumours had a poorer 
prognosis than those whose tumours had lower levels of c-Met expression: this was 
true even after accounting for other prognostic factors. This observation is consistent 
with previous studies identifying c-Met as a poor prognostic factor in lymph node 
negative and positive breast carcinoma (Ghoussoub et al, 1998; Camp et al, 1999; 
Tolgay Ocal et al, 2003; Kang et al, 2003; Lengyel et al, 2005; Chen et al, 2007; 
Zagouri et al, 2013). Only one study has found c-Met expression to be a favourable 
prognostic factor in breast cancer (Nakopoulou et al, 2000). Unlike the above 
studies, which used arbitrary cut-points to divide the study population into ‘positive’ 
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or ‘negative’ for c-Met, or selected the cut-point based on the distribution of c-Met 
scores, I used the X-Tile bioinformatics tool to select an appropriate c-Met score to 
divide the cohort. Cut-point selection can have a profound effect on the outcome of a 
study and when different cut-points are used between studies, valid comparisons may 
be impossible (Altman et al, 1994). Using the S-phase fraction (SPF) in breast 
cancer by way of example, Altman et al showed that 19 studies published between 
1988 and 1993 used cut-points for SPF between 2.6 and 15 (Altman et al, 1994). 
These workers questioned whether any of these cut-points could be regarded as 
‘optimal’ and added that the use of multiple cut-points may lead to a false positive 
rate in excess of 40% (Altman et al, 1994). 
X-Tile offers several advantages in biomarker statistical analysis (Camp et al, 2004). 
Firstly, by basing the cut-point on survival, the population is divided in a clinically 
relevant way. Secondly, by randomly separating the study population into training 
and validation cohorts and applying the optimal cut-point in the training set to the 
validation set and vice versa, the software insures that each time the analysis is 
performed, the same p-value and cut-point is obtained. Thirdly, the software 
performs cross-validation to give a corrected p-value, thus making allowance for 
multiple cut-point selection (Camp et al, 2004). 
Survival analysis in the Homerton cohort alone showed no statistical differences 
between c-Met high and low cases. It is possible that this is due to the relatively 
small number of patients. The characteristics of the cohort may also have a bearing 
on the analysis: these patients presented with larger tumours and more frequent 
lymph node metastasis than their Nottingham counterparts. Whether c-Met 
expression has more prognostic power in early or late stage disease has not been 
established. 
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In my analysis of the different molecular sub-types, the lack of statistically 
significant findings may again be related to the fact that smaller groups of patients 
are being assessed. The trend of the survival curve for the c-Met high BL tumours is 
reminiscent of the BL group in general, where the first five years are associated with 
a particularly poor survival, followed by a plateau in the curve (Cheang et al, 2008). 
It would be of particular interest to extend the survival analysis to a larger group of 
BL cancer patients. Notably, the unclassified tumours with high c-Met expression 
did better than those with low c-Met expression and this was significant (albeit at 
univariate analysis only) in a group of just 66 patients. This finding further 
emphasizes the importance of sub-dividing the wider TN group in biomarker 
analysis and for stratifying patients for novel therapy. In a study of 170 TN breast 
cancer patients, Zagouri et al found that patients with c-Met high tumours had a 
significantly increased risk of tumour recurrence and death (HR = 3.43 and 3.74 
respectively) than those with c-Met low tumours (Zagouri et al, 2013). These 
workers did not stain for basal markers, but my findings would suggest that the bulk 
of their c-Met high tumours had a BL phenotype.  
8.1.4 Conclusion 
 
In summary, the results from this large retrospective study confirm that 
immunohistochemical expression of c-Met is an independant poor prognostic factor 
in invasive breast cancer. My analysis of the relationship between c-Met expression 
and several established prognostic factors and biomarkers generated mixed results, 
some of which were predictable, others were unexpected. This perhaps reflects the 
numerous cellular processes influenced by c-Met and the complexity of the HGF/c-
Met pathway. Importantly, this study has demonstrated that c-Met expression is 
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independently predictive of the BL sub-type. This novel finding indicates that 
patients with these tumours should be included in future studies looking at the 
therapeutic benefit of c-Met inhibition in breast cancer.  
Such clinical studies would be more informative if they stratify patients based not 
only on tumour c-Met expression, but also on the level of activation of the receptor. 
The PLA is one assay that offers the potential to quantify levels of c-Met activation 
on FFPE samples with more sensitivity and specificity than conventional IHC with 
anti-phospho-c-Met antibodies.    
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8.2 The PLA and invasive breast carcinoma 
 
8.2.1 The PLA signal and clinical, pathological and molecular parameters 
 
In this study, I have shown for the first time that the PLA can be used to generate a 
quantifiable signal in FFPE breast cancer samples, using a pan-c-Met antibody and a 
pan-phospho-tyrosine antibody. The results showed a significant positive correlation 
between the PLA signal and c-Met expression, as detected by conventional IHC. 
However, there were key differences between the two variables when they were 
correlated with relevant prognostic factors and outcome. 
Unlike the c-Met scores from the Homerton cohort, the PLA signal (also based on 
the Homerton cohort) showed no relationship with molecular sub-type of breast 
cancer. Further, the PLA signals inversely correlated with Ki67 score and worsening 
tumour grade, two associations not seen in the Homerton c-Met scores. Finally, 
patients with PLA ‘high’ tumours showed a trend towards better survival, a trend 
that reached borderline significance (at univariate analysis only) for BCSS. 
To date, there have been no studies specifically designed to look at c-Met 
phosphorylation/activation in FFPE breast cancer samples so it is difficult to make 
direct comparisons with the literature. Several other groups have used IHC to 
phospho-c-Met in other types of cancer with inconsistent results (Nakamura et al, 
2007; Miyata et al, 2009; Lahat et al, 2011; Arriola et al, 2011; Tsuta et al, 2012), 
perhaps reflecting the lack of robustness of conventional techniques in detecting 
phospho-proteins in archival material (Dua et al, 2011). In bladder cancer, 
phosphorylation of the Y1349 (pY1349) residue was associated with reduced 
survival at univariate and multivariate analysis (Miyata et al, 2009) and 
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phosphorylation of the Y1234/5 residue has been linked with a poor outcome at 
univariate analysis in unclassified pleomorphic sarcoma/malignant fibrous 
histiocytoma (Lahat et al, 2011). In lung cancer, Arriola et al found phospho-c-Met 
(pY1349) expression to be associated with advanced tumour stage and poor survival 
(Arriola et al, 2011).  On the other hand, Tsuta and colleagues found higher 
pY1234/5 expression in smaller lung carcinomas and no correlation with survival 
(Tsuta et al, 2012). In an analysis of 130 primary lung adenocarcinomas, Nakamura 
et al observed that pY1234/5 expression associated with the absence of vascular 
invasion and well-differentiated tumours (Nakamura et al, 2007). This last finding 
has some similarities to the findings in this study and it prompted the authors to 
postulate whether abnormalities other than c-Met activation drive progression in 
poorly-differentiated carcinomas (Nakamura et al, 2007). 
With reference to breast cancer, a study by Hochgräfe and co-workers failed to 
identify phospho-c-Met (pY1234/5) on IHC in their cohort of FFPE breast cancer 
samples, but they could identify the protein using reverse phase protein analysis 
(RPPA), noting higher pY1234/5 expression in TN breast cancers (Hochgräfe et al, 
2010). A more recent study analysed 257 snap-frozen breast cancers, quantifying the 
c-Met and phospho-c-Met (pY1235), again using RPPA (Raghav et al, 2012). The 
authors found no relationship with molecular sub-type, but both c-Met and pY1235 
expression were found to be poor prognostic factors at multivariate analysis (Raghav 
et al, 2012). While the study by Raghav et al supports the findings in the current 
study regarding molecular sub-type, the survival analysis contrasts with my own 
results. Clearly, these workers used a different technique to assess phospho-c-Met 
expression, but the use of frozen tissue is also an important distinction. Indeed, how 
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tissue is prepared and processed are relevant factors that may have influenced the 
PLA result and merit further discussion.  
8.2.2 Confounding factors that may have impacted upon the PLA result 
 
During the validation study of the PLA (section 4.0), a reduction in the number of 
PLA signals in FFPE samples compared with frozen section from the same tumour 
was demonstrated. This was not unexpected, given estimates about the efficiency of 
the PLA in FFPE tissue (approximately 9%, Söderberg et al, 2008), but it is apparent 
that only a small proportion of the signal is being analysed in these samples. It also 
suggests that the PLA may give more reliable results if its use was restricted to 
frozen material. 
The time that it takes to fix or freeze tissue once it is removed from the body 
influences the phosphorylation of proteins (Baker et al, 2005; Jones et al, 2008). 
After realising that phospho-Akt (p-Akt) was detectable only in biopsy samples from 
patients with gastro-oesophageal junction adenocarcinomas and not surgical 
resections, Baker and colleagues investigated the stability of this protein in xenograft 
samples generated from HT-29 human colon cancer cells (Baker et al, 2005). They 
established that p-Akt was present in those tumour samples that were fixed 
immediately following resection, but no p-Akt staining was detected in samples that 
had been left at room temperature for 30-60 minutes prior to fixation. They went on 
to show that, at western blotting p-Akt had a half-life of just 20 minutes compared to 
180 minutes for total Akt (Baker et al, 2005). Morphological evidence of a 
prolonged delay before fixation (as manifest by tumour autolysis) was not a common 
feature in the Homerton samples. Clearly though, there would have been a degree of 
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variation in the time to fixation across the cohort and this may have impacted upon 
the quantity of PLA signals.  
Another valid consideration is the identity of phosphotyrosine being detected, since 
the PLA in the current study used a pan-phosphotyrosine antibody (4G10) as 
opposed to a more specific phospho-c-Met antibody. Previously, two studies 
compared the expression of different phospho-c-Met residues (pY1003, 
pY1230/1234/1235 and pY1349) in frozen and FFPE samples from a variety of 
tumours (Ma et al, 2005; Dua et al, 2011). In FFPE non-small cell lung carcinomas 
(NSCLCs) pY1003 was detected more often than pY1230/1234/1235 and in 
squamous carcinomas and carcinoid tumours in particular, the difference was 
marked with 71% and 40% expressing pY1003 respectively versus no expression of 
pY1230/1234/1235 (Ma et al, 2005). Dua et al performed western blots on lysates 
from frozen NSCLCs and gastric tumours (Dua et al, 2011). They identified pY1003 
in 9/15 NSCLCs and 2/6 gastric tumours, but could not detect either pY1234/1235 or 
pY1349, prompting the authors to suggest that the pY1003 site may be more stable 
than pY1234/1235/1349 (Dua et al, 2011).           
This suggestion may have important implications for the current study because 
pY1003 has been shown to interact with the tyrosine kinase binding domain of c-Cbl 
(Peschard et al, 2001). C-Cbl is regarded as a negative regulator of many RTKs due 
to its role in the polyubiquitination of these proteins. The negative regulatory role of 
c-Cbl also extends to c-Met, where c-Cbl recruitment and subsequent ubiquitination 
of c-Met is dependent on the juxtamembrane tyrosine Y1003. In cells where Y1003 
is substituted for a phenylalanine residue, the mutated receptor (Met Y1003F) 
becomes oncogenic, promoting morphological changes and cell scattering in the 
absence of HGF (Peschard et al, 2001). Moreover, breast cancer cells (T47Ds) 
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expressing Met Y1003F demonstrated sustained Ras-MAPK pathway activation 
compared to cells with wild-type c-Met (Abella et al, 2005). These in-vitro findings 
are supported by in-vivo models, where subcutaneous injections of NIH3T3 cells 
expressing Met Y1003F into nude mice resulted in the formation of larger tumours 
in a shorter time period than those in mice injected with cells containing the wild-
type receptor (Abella et al, 2005). Thus, it is possible that the PLA signal in the 
current study reflects the binding of 4G10 to pY1003, an arguably more stable 
epitope than other phosphorylation sites, which has an important role in the negative 
regulation of c-Met. This would perhaps explain why patients with ‘PLA high’ 
tumours showed a more favourable outcome than those with ‘PLA low’ tumours at 
univariate survival analysis.    
8.2.3 Conclusion 
 
In summary, I have shown that the PLA can be used to quantify c-Met activation in 
FFPE breast cancer samples. Correlating the PLA signal with prognostic factors and 
survival yielded unexpected results, not least a borderline association between high 
signal and improved survival. However, it is apparent that issues relating to the 
detection of phospho-proteins in archival material limit the conclusions that can be 
drawn from these PLA findings. Despite efforts to validate the PLA in cells and 
tissues, it is clear that 1) the time taken to fix the tissue samples, 2) formaldehyde 
cross-linking of epitopes and 3) variations in the stability of functionally distinct 
phospho-epitopes may have had a profound effect on the PLA signal. While these 
factors do not preclude the use of the PLA in quantifying c-Met activation, they do 
suggest that the PLA may be better suited to a more controlled setting, such as on 
rapidly frozen tissue, perhaps utilising different antibodies. 
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An alternative approach to evaluating the significance of c-Met activation in breast 
cancer is through in-vitro studies. The use of appropriate cell lines permits both 
functional and mechanistic analysis of the HGF/c-Met pathway in an environment 
lacking some of the confounding factors present in tissue samples.   
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8.3 HGF/c-Met in in-vitro models of BL cancer 
 
8.3.1 The effect of HGF on BL cancer cell migration 
 
The results from the in-vitro experiments show that the presence of HGF in the lower 
chamber of a transwell leads to a significant increase in migration over an eight hour 
time period in both BL cancer cell lines. This increase is abrogated by pre-incubating 
the cells with the c-Met specific kinase inhibitor SU11274 (significantly so in the 
case of the MDA-MB-468s). Given the well described mitogenic properties of HGF 
(Gastaldi et al, 2010; Nakamura et al, 2011) it was necessary to demonstrate that this 
result was not simply due to increased proliferation of the cells on the underside of 
the transwell in the HGF-treated chambers. My MTS cell viability assay findings 
suggest this is not the case, as there were no significant changes in viable cells over 
eight hours across a range of HGF concentrations, including the concentration used 
for the migration assay (100ng/ml). 
The current findings are supported by previous studies that have investigated HGF-
induced cell migration in non-BL and mesenchymal-like (section 5.0) BCLs (Castro 
and Lange, 2010; Hung et al, 2011; Ayoub et al, 2013). Castro and Lange showed 
significantly increased migration by the luminal T47Ds and the mesenchymal-like 
MDA-MB-231s over a six hour time period when 50ng/ml of HGF was used as a 
chemo-attractant (Castro and Lange, 2010). Using a wound healing assay to evaluate 
cell migration by luminal MCF7s, Hung and colleagues demonstrated a significant 
increase in wound closure over 24 hours when cells were incubated with HGF (Hung 
et al, 2011). Interestingly, these workers also noted that osthole, a fatty acid synthase 
inhibitor reduced HGF-induced migration and c-Met levels, perhaps by disrupting 
the lipid rafts utilised by receptors such as c-Met for optimal signalling (Hung et al, 
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2011). Also using a wound healing assay, Ayoub et al quantified wound closure after 
a 24 hour period in MDA-MB-231s and +SA cells (a highly malignant murine 
mammary cancer cell line) treated with SU11274, with HGF present as a chemo-
attractant (Ayoub et al, 2013). In both cell lines, cells treated with SU11274 showed 
a significant reduction in wound closure compared to vehicle treated controls 
(Ayoub et al, 2013). Taken together with the results from the current study, these 
observations suggest that the HGF/c-Met pathway contributes to the migratory 
phenotype of different models of breast cancer, including BL breast cancer. 
8.3.2 The effect of HGF on BL cancer cell protein expression 
 
To investigate whether the migratory effects of HGF on BL cell lines are 
accompanied by the acquisition of an EMT-like phenotype, protein expression was 
quantified using western blotting and protein localisation was assessed using IF-
based studies. 
After 20 and 120 minutes of HGF treatment, no detectable change in total expression 
of the EMT markers E-Cadherin, β-Catenin or vimentin was found, as assessed by 
western blotting. This result was not entirely surprising, since 120 minutes is perhaps 
not long enough for a change in protein expression to develop. A similar study also 
found no change in E-Cadherin and β-Catenin levels in MCF10 and MCF7 cells after 
30 and 60 minutes of HGF stimulation (Matteucci et al, 2006). Elsewhere, others 
have been able to demonstrate changes in EMT marker levels using lysates from 
cells exposed to HGF for a longer time period (Hung et al, 2011; Ayoub et al, 2013). 
After 18 hours of HGF stimulation, Hung et al noted a reduction in E-Cadherin 
expression, along with increased vimentin levels in MCF7 cells (Hung et al, 2011). 
When the mammary +SA tumour cells were treated with HGF and SU11274 over 
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three days, levels of E-Cadherin and β-Catenin were elevated and vimentin levels 
were lower, compared to those cells exposed to HGF alone (Ayoub et al, 2013). This 
finding suggests that c-Met inhibition reverses HGF-induced EMT features.  
The results from these cell line based studies are supported by work utilising cell 
lines from upper aero-digestive cancers (Anderson et al, 2006; Kim et al, 2007; Xie 
et al, 2010). Using varying HGF concentrations (10 – 100 ng/ml), hypopharyngeal 
cancer FaDu cells, oesophageal adenocarcinoma OE33 cells and nasopharyngeal 
carcinoma CNE-1/2 cells all showed a reduction in total E-Cadherin at western 
blotting after 24-48 hours of treatment (Anderson et al, 2006; Kim et al, 2007; Xie et 
al, 2010). Hence, it seems that 18-24 hours of HGF stimulation may be necessary 
before total levels of E-Cadherin expression show a detectable decrease. 
Nevertheless, it could be reasoned that a shorter period of HGF stimulation may still 
be sufficient to observe a change in E-Cadherin localisation. This reasoning is based 
on growing evidence of co-localisation and a direct interaction between E-Cadherin 
and c-Met and the fact that I (and others) have already demonstrated intracellular 
trafficking of c-Met after just 20 minutes of HGF treatment (section 4.0; Kermorgant 
et al, 2003; Kermorgant et al, 2004; Reshetnikova, 2007; Reshetnikova et al, 2007; 
Hiscox and Jiang, 1999). 
Using IF, it was shown that while c-Met trafficked from the membrane to a 
perinuclear compartment, E-Cadherin staining remained at the membrane even after 
120 minutes. This resulted in a marked reduction in c-Met/E-Cadherin co-
localisation (although this only reached statistical significance in the MDA-MB-
468s). This finding contrasts with a previous study looking at E-Cadherin 
localisation in MCF7 cells (Matteucci et al, 2006). These workers noted that E-
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Cadherin and c-Met accumulated asymmetrically following 30 minutes of HGF 
treatment, culminating in complete internalisation (and co-localisation) of the 
proteins by 120 minutes (Matteucci et al, 2006). Of course, one cannot compare 
directly the luminal MCF7 cells with the BL cells used in the current study and, as 
with my western blot findings it may be that 120 minutes is simply too early to see 
reproducible alterations in E-Cadherin localisation. Indeed, work on Madin-Darby 
canine kidney (MDCK) cells demonstrated membrane co-localisation of c-Met and 
E-Cadherin in resting cells but both c-Met and E-cadherin were shown to partially 
disappear from the membrane at four hours and accumulate in the perinuclear region 
at 18 hours post-HGF stimulation (Kamei et al, 1999). 
Much of the current literature focuses on the tumour suppressor role of E-Cadherin 
in cancer (Rodriguez et al, 2012). E-Cadherin is regarded as a key component of 
adherens junctions (specialised intraepithelial cell-cell junctions) and an important 
regulator of β-Catenin activity along with other transcriptional factors implicated in 
the acquisition of a mesenchymal phenotype (Thiery, 2002; Logullo et al, 2010). As 
such, E-Cadherin has been referred to as one of the ‘caretakers of the epithelial 
phenotype’ and its loss may be pivotal to the EMT process in cancer (Thiery, 2002).  
However, recent studies have also demonstrated a potential tumour promoter role for 
E-Cadherin (Rodriguez et al, 2012). For example, in oral squamous cell carcinoma 
(SCC) cell lines, E-Cadherin and EGFR have been found to be co-localised at points 
of cell-cell adhesion (Shen and Kramer, 2004). This co-localisation leads to ligand 
independent phosphorylation of EGFR and subsequent activation of the downstream 
Erk/MAPK pathway resulting in an accumulation of the anti-apoptotic protein Bcl-2 
(Shen and Kramer, 2004).  
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In addition to promoting tumour cell survival, intact E-Cadherin may also contribute 
to cellular migration (Rodriguez et al, 2012). Knockdown of p120-catenin in a vulval 
SCC cell line (A431) results in the loss of E-Cadherin expression and a reduction in 
tumour cell invasion (as assessed by an in-vitro invasion assay) (Macpherson et al, 
2007). The authors of this study suggested that p120 contributed to A431 cell 
invasion by maintaining the E-Cadherin associated junctions that are necessary for 
the characteristic invasion pattern of groups of cells as opposed to single cells 
(Macpherson et al, 2007). This concept of ‘collective cell migration’ (the movement 
of groups of cells that maintain cell-cell junctions throughout their migration) is 
thought to be particularly important in wound repair and cancer (Friedl et al, 2004). 
In this model, the front edge of the invasive group of cancer cells generate traction 
with the substrate via the actin cytoskeleton and the rest of the group is effectively 
pulled along behind due to the presence of intact cell-cell junctions (to which the 
Cadherin family are central)(Friedl et al, 2004). The invasion/migration of groups of 
cells rather than individual cells may favour tumour progression by not only 
increasing the quantity of invasive cells, but also facilitating the movement of a 
heterogeneous group composed of cells with different characteristics. A diverse 
cluster of cells that are able to interact with each other may be more successful at 
embolising into the bloodstream and surviving at sites of metastasis (Friedl et al, 
2004). It is possible that the BL cell lines used in the current study utilise collective 
cell migration, however more sophisticated models such as those incorporating 3D 
collagen lattices or in-vivo models (Friedl et al, 2004) would perhaps be required to 
test this hypothesis. 
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8.3.3 Conclusion 
 
In summary, the results of this in-vitro study show that the HGF/c-Met pathway 
contributes to the migration of two different BL cancer cell lines, suggesting that 
HGF-mediated c-Met phosphorylation may contribute to the progression of BL 
cancer. After stimulating these cell lines with HGF, there was no significant change 
in the expression of EMT-associated markers or change in E-Cadherin localisation. 
These results do not in themselves question whether EMT and/or E-Cadherin 
trafficking contribute to the migration of these cell lines, but they do indicate that if 
such processes are occurring, they may only be detectable at a later time point. It is 
also possible the HGF can contribute to migration despite a functional E-Cadherin 
network, perhaps by collective cell migration.     
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9.0 General Discussion 
 
The main goals of this study were: 1) to establish the clinical significance of c-Met 
expression in a large, well-characterised cohort of breast cancers (in particular the 
correlation with molecular sub-type), 2) to quantify c-Met activity in a selection of 
these tumours and 3) to address the functional and phenotypic effects of HGF/c-Met 
signalling in BL cancer cells.  
The first part of this study was dedicated to validating the techniques and materials 
that would subsequently be used on the breast cancer samples and selecting 
appropriate cell lines for the in-vitro analysis. During the initial evaluation of various 
c-Met antibodies, a recognised problem in quantifying protein expression of the 
receptor was encountered – poor reproducibility between commercially available 
antibodies on FFPE tissue (Pozner-Moulis et al, 2007; Cecchi et al, 2010). 
Fortunately, the polyclonal rabbit antibody CVD13 demonstrated specificity for c-
Met and a reproducible staining pattern on breast cancer cells and a variety of FFPE 
tissues. The ability of CVD13 to recognise the active form of c-Met made it a 
suitable candidate for quantifying phospho-c-Met using the PLA. The PLA probes 
also appeared specific, with the number of detectable signals being related to the 
proximity of the target proteins. Characterisation of several ‘BL’ cell lines identified 
two (the MDA-MB-468s and HCC1937s) which had a protein expression profile 
similar to human BL cancers, suggesting they would be plausible models for 
investigating c-Met signalling in BL cancer in an in-vitro environment. 
The IHC analysis of c-Met expression confirmed that a high level of the receptor in 
breast cancer is a poor prognostic factor and perhaps, more importantly, 
demonstrated an independent association with BL cancer. Crucially, c-Met appeared 
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to distinguish BL cancer from other TN cancers in terms of absolute levels and 
survival outcomes, stressing the need to distinguish these two over-lapping sub-
groups. Although expression of c-Met is often cited as a cause of c-Met activation 
(Nakamura et al, 2007; Sierra and Tsao, 2011), IHC for total c-Met expression is not 
a direct measure of activity. 
For a more specific measure of c-Met phosphorylation, the PLA was applied to a 
proportion of the invasive breast cancer cohort. Although the PLA offered clear 
advantages over conventional IHC in the assessment of protein phosphorylation 
(Blokzijl et al, 2010), when the PLA results were correlated with clinico-
pathological factors and survival, it was evident that the PLA was of limited 
prognostic value. In section 8.2 the limitations, not just of the PLA, but of detecting 
phospho-proteins in general were discussed and these suggested caution should be 
applied when interpreting the PLA results. The key questions that remain therefore 
include 1) is c-Met activation important in breast cancer progression? 2) Does c-Met 
activity vary amongst the molecular sub-types (as expression does)? 3) Finally, is c-
Met activity more relevant than c-Met expression? 
The only other study to specifically address these questions did identify phospho-c-
Met as a poor prognostic factor (using an anti-phospho-c-Met antibody), but 
phospho-c-Met levels did not offer more prognostic information (in terms of overall 
and relapse-free survival) than total c-Met levels (Raghav et al, 2012). Moreover, 
phospho-c-Met expression did not vary significantly between the molecular sub-
types (Raghav et al, 2012). The findings on cell lines in this study, together with 
those of previous studies, suggest that HGF/c-Met signalling may contribute to the 
migratory phenotype of different sub-types of breast cancer, including BL breast 
cancer (Castro and Lange, 2010; Hung et al, 2011; Ayoub et al, 2013).  
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Comparing the relative merits of expression versus phosphorylation of c-Met is not 
straightforward, due in part to the issues outlined in section 8.2 and also the fact that 
protein/RTK phosphorylation may be a transient event, triggered by dynamic 
changes in the microenvironment such as hypoxia (Baker et al, 2005; Wang and 
Schneider, 2010; Halle et al, 2011). These changes may not be consistently 
represented in archival material, where one gets a ‘snap-shot’ of a tumour at a 
particular time. As such, it could be argued that expression of the receptor is a more 
reliable measure than activation. In addition, another RTK (EGFR) has been shown 
to exhibit oncogenic effects that are independent of its kinase activity (Weihua et al, 
2008).     
Another study, looking at recurrent glioblastomas, also questioned the benefits of 
measuring receptor phosphorylation over expression. Paulsson et al assessed 
PDGFRα expression and activity (using the PLA) finding that both parameters 
correlated with each other and higher levels of each were associated with reduced 
survival (Paulsson et al, 2011). However, the authors concluded that measuring 
PDGFRα phosphorylation offered no additional prognostic information (Paulsson et 
al, 2011). Notably, this study also considered the predictive role of PDGFRα 
expression/activation by correlating these markers with the response to treatment 
(hydroxyurea monotherapy versus combined treatment with hydroxyurea and 
imatinib, the RTK inhibitor). They observed that neither PDGFRα expression nor 
activation levels identified patients likely to respond to the combined treatment 
(Paulsson et al, 2011).  
This study highlights another potential application for c-Met IHC/phospho-c-Met 
PLA – predicting the response to anti-c-Met therapy. The predictive role of these 
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assays is beyond the scope of this thesis, but represents an area of intended future 
work and would complement well the prognostic data contained herein. 
The relationship between c-Met and E-Cadherin is one explored in some depth in the 
IHC analysis (section 8.1) and the in-vitro part of this study (section 8.3). The 
decision to investigate these proteins was largely based on the increasing body of 
literature suggesting a relationship between c-Met and E-Cadherin, in particular their 
possible involvement in EMT (Hiscox and Jiang, 1999; Reshetnikova, 2007; 
Reshetnikova et al, 2007). In the tissue-based analysis, co-expression of c-Met and 
E-Cadherin was seen across the whole cohort and in-vitro IF studies demonstrated 
co-localisation of these proteins in resting (un-stimulated) BL cell lines. These 
findings support the notion that E-Cadherin may occupy a facilitatory role, 
maintaining c-Met at the membrane to optimise ligand/receptor binding 
(Reshetnikova et al, 2007). The methodology used in the current study may explain 
why no trafficking of E-Cadherin was observed and why there was no reduction in 
total protein levels following HGF-stimulation, given the results of similar studies 
(Matteucci et al, 2006; Hung et al, 2011; Ayoub et al, 2013).  
Evidently, the role of E-Cadherin in cancer progression is complex: on the one hand 
loss of the protein favours EMT, on the other hand over-expression favours 
collective cell migration and tumour emboli formation (as in inflammatory breast 
cancer)(Rodriguez et al, 2012). Investigating the significance of EMT is further 
complicated by the knowledge that this event is frequently incomplete and sensitive 
to culture conditions in-vitro and difficult to identify in human tumours (Thiery, 
2002). Further work is necessary to elucidate the relationship between E-Cadherin 
and c-Met, and the nature of this relationship in BL breast cancer. 
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In conclusion, c-Met expression is a poor prognostic factor in breast cancer, 
independently associated with the aggressive BL sub-type (TN tumours with 
expression of one or more basal markers). The PLA can be used to detect c-Met 
phosphorylation in cells and tissues, but more work is needed to refine the technique 
and establish its prognostic utility in breast cancer. HGF stimulation results in 
increased migration in BL cell lines, but EMT-like phenotypic changes were not 
seen in the relatively short time period studied. The results from this study advocate 
the continued investigation of anti-c-Met therapy as a novel treatment for BL breast 
cancer.  
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